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Abstract
The thesis is divided into six chapters:
Chapter one introduces an oveiview of deuterium and tritium propeities, 
vaiious labelling procedures as well as analytical methods for hydrogen isotopically 
labelled compounds.
Chapter two describes the preparation of polymer supported transition 
metal catalysts, particularly rhodium trichloride catalyst, and their applications in 
the deuteriation and tritiation of aromatic compounds and selected drugs. ^H-NMR 
spectroscopy showed some aromatic compounds and drugs were labelled with 
1 0 0 % regiospecificity. The regiospecificity was improved when rhodium trichloride 
was supported on PVP polymer.
Chapter three presents a new procedure for the specific incorporation of 
three tritium atoms into organic confounds.
Chapter fbiu describes the apphcations of a mild Lewis acid catalyst - 
boron trifluoride etherate in the deuteriation and tritiation of some aromatic 
compounds and drugs. and ^H-NMR spectroscopy analysis of the labelled 
compounds and drugs confirmed the exchange reaction was electrophilic.
Chapter five describes a procedure for the synthesis of a deuteriated 
biocompatible polymer, ^H-PmMlz. When the procedure was adopted for the 
synthesis of the tritiated version, the polymer was labelled with very low specific 
activity. A microwave assisted procedure was investigated to see whether the 
deuteriation of the monomer, HEMA-PC could be achieved by this method.
hr chapter six NMR spectroscopy is employed to study méthylation kinetics 
using methyl triflate as methylating reagent.
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1.1 History of Deuterium and Tritium. Their 
Properties and Uses
There are tliree isotopes of hydrogen, deuterium (^H) and tritium (^H). 
Deuterium (^H or D) is stable with a natural abundance of ~ 0.015%\ Molecular 
deuterium, D ,^ was first isolated by Urey at Columbia University in 1931 and 
D2O was prepared by Lewis shortly thereafiier by electrolysis'*. Urey won the Nobel 
prize in 1934.
Being stable, there are no radiation problems associated with the synthesis, 
storage, and application of deuterium labelled compounds. This is a great 
advantage, particularly in clinical studies, as well as in some environmental 
applications. In addition, there are some properties of deuterium which enable 
information to be obtained which would not be available through the use of tritium. 
For example, the study of drug metabolism in humans will offer invaluable 
information to assist in the safety evaluation and clinical development of drugs. 
Normally there are very limited use of tritium labelled compounds in the human 
body. When a drug has a long half-life, or becomes localised in a particular tissue, 
it is inadvisable to carry out any tritium tracer studies in the human body.
Shortly after the discovery of deuterium, the possibility of observiag 
deuterium isotope effects was appreciated^. The first reported experiment using 
deuterium labelled compounds was performed by Schoenheimer and Rittenberg .^ 
They used a deuteriated fatty acid for the study of fat and fatty acid metabolism
Since then deuteriated confounds have been widely used in the detection 
and identification of metabolites, in mechanistic studies of metabolic pathways, 
and, indirectly, in the development of sensitive and specific methods for the 
analysis of drugs and metabolites in biological fluids  ^'
Unlike deuterium, tritium is radioactive. It decays through the emission of 
low energy (3 radiation in the following manner:
" t  ^ 2 He + _? B
Tritium was first prepared in 1934 by Rutherford whist working in the 
Cavendish Laboratory* \  This was achieved by bombardment of deuterophosphoric 
acid with fast deuterons. Tritium was produced through the reaction:
iH + + energy
The chemical and physical properties of the two isotopes of hydrogen are 
very similar, but because the ratios of their masses are the largest for any set of 
isotopes in the Periodic Table, the differences are larger than those encountered for 
other isotopes.
Some important properties of tritium are summarised in Table 1. 1 
Table 1.1 A Summary of the Properties of Tritium*^
Atomic w ei^t 3.01605 (ref 1)
Production 'TU(n,a)='H
Radiation p- (1 0 0 %)
Natural abundance < 10'*® (ref. 13)
Half-life 12.3 years
Decay constant 1 .8 x 1 0 '^  s'*
Maximum p energy 18.6 KeV
Mean p energy 5.7 KeV
Maximum specific activity (per site) 29.1 Ci/mmole
Volume of 1 Ci of tritium gas under standard 
conditions
0.385 ml
The main properties which make tritium such a useful isotope, and its 
compounds so widely used in many fields of basic and applied research, are:
1 . Tritium is one of the less expensive radioisotopes, much less than *^*0. In 
1995, the price for 1 Ci of tritium gas was £140, whereas for 1 mCi of *'*C carbon 
dioxdde, the price was £1 2 0 .
2. Tritium has a half-life of 12.3 years. It is conveniently long enough to 
make preparation, use and storage much easier than with shorter-lived isotopes, 
such as **C, *^ *I or
3. Tritium labelled compounds, compared to other nuclei, can easily be 
prepared by a wide range of procedures requiring very little time
4. Tritium labelled compounds can be synthesised with high specific 
activities (the maxdmum specific activity is 29.2 Ci/mmole per site). In contrast *'*C 
compounds can only be prepared with maxdmum specific activities of 
62 mCi/mmole per site. So the high specific activities achievable means that 
tritiated compounds can be widely used in drug metaboUsm and receptor bhiding 
studies*'*’ *^ . Althou^ carbon-14 labelled compounds still dominate the study of 
drug metabolism, the use of tritiated compounds is necessary when the 
concentrations of such metabolites are exrtremely low.
5. The radioactivity of tritium labelled compounds can be measured by 
liquid scintillation counting and the position(s) of labelling in a tritiated compound 
can be determined by tritium NMR spectroscopy.
6 . The maxdmum energy of 18.6 KeV of tritium gives tritium labelled 
compounds good autoradiographic properties, which allows the compounds to be 
located in various organs and tissues.
7. Tritium is a pure emitter with low energy so that the hazard of 
external radiation is small.
Tritium labelled compounds have been widely used in many diverse 
fields. There are many books summarising the applications of tritium 
compounds
1.2 Specific Features of the Procedures for 
Preparing Tritium Labelled Compounds
Unlike the preparation of ordinary organic compounds, tritium labelling 
procedures normally use very small amounts of starting materials (1  - 1 0 0  mg). 
Almost all the preparations start from tritiated water or tritium gas. Although the 
operations are on a small scale, large amounts of radioactivity can be employed if 
necessary. The skills of microquantity techniques are essential. Standard 
purification procedures for organic compounds such as distillation, precipitation 
and crystaUisation are not normally used in the labelling of tritiated compounds. 
Techniques such as radio-GC, radio-HPLC etc. are preferred. In order to maximise 
the yields, the tritium source should be introduced at the last stage of the 
preparation.
1.3 Procedures for the Preparation of 
Deuterium and Tritium Labelled Compounds
Because all the procedures used for preparing tritium labelled compounds 
can be adapted for deuterium labelled compounds, it is not necessary to distinguish 
between them in this chapter.
As mentioned before, one of the main reasons for tritium labelled 
compounds bemg widely used is that there are a range of methods to meet the 
different needs. Generally speaking, the labelling procedures can be grouped into 
two main categories: the first one is direct chemical synthesis, the other is 
hydrogen isotope exchange reactions.
1.3.1 Direct Chemical Synthesis
Almost all of the organic reactions involving hydrogen atom(s) at stable 
positions can be adapted for the preparation of tritium labelled conpounds. Tritium 
gas, tritiated water, tritiated reducing agents (such as NaBT^), or tritiated 
compounds (such as CT3I) are used as the tritium source from which tritium 
labelled compounds can be synthesised by one of the four procedures illustrated 
below.
1.3.1.1 Reduction of Unsaturated Compounds
The addition of tritium gas to an unsaturated organic conpound in the 
presence of a catalyst is one of the sinplest and most convenient methods of 
preparing tritium labelled compounds with high pecific activities. The following 
reactions can be used to obtain tritiated compounds
Tor C H ==C H X  ----- ^  R— CHT— CHT— X
T, T,RC = C X  --------- ► R—C T = C T  X  ^  R—CT^— CT^— X
(1 )T 2
(2) MeOH '  R - G T - N H ,
\  (1) \  \C = o  ----------------► CTOH/  (2) MeOH /K R'/
Fig, 1,1 Some Reactions Used for Labelling Tritiated Compounds
A large number of tritium labelled compounds have been synthesised using 
catalysts such as Pd/C, Pt, Pd/BaSO^. Not only simple organic molecules but also 
complex compounds can be prepared by a simple one-step reduction. For example, 
[15,16-^H]buprenoiphine was prepared from 15,16-didehydrobuprenorphine using 
the following reaction* :^
c  -C (C H J TgfdO/BaSOj3/3 DMF. 2 h
OH
Ç -C (C H ,1
OCH,
1.3.1.2 Halogen-Tritium Replacement Reactions
The replacement of a halogen atom in an organic molecule by a tritium 
atom under catalytic conditions is another method for preparing tritiated 
coEcpounds. It can be illustrated as follows:
RX + T2 ^  RT + TX
where X = halogen.
In practice, it is necessary to add a small amount of a basic compound to 
neutralise the tritium halide, XX, produced in the reaction and thereby prevent 
catalyst poisoning. If the reaction is slow, the build-up of tritiated water in solution 
may produce some non-specific labelling caused by metal-catalysed hydrogen 
isotope exchange^ ®. Another drawback to this procedure is that only half of the 
tritium can be incorporated into the tritiated confound. Before dehalogenation, 
much time and skill may be needed to synthesise the suitable precursor. This is the 
main disadvantage of the procedure.
The preparation of [4,6-^H]-2-pyridone is an exaicple of halogen-tritium 
replacement^ :^
Br
Bi
T2 .Pd/C I
H O
1.3.1.3 Reduction with Tritiated Metal Hydrides
Confounds containing unsaturated groups other than carbon-carbon 
bonds, such as carboxylic acids, esters, aldehydes, ketones and nitriles can be 
readily reduced by tritiated metal hydrides to form tritium labelled compounds. 
These are then specifically labelled on the carbon atom forming the unsaturated 
group. The following reaction is an exauple of reduction using NaBT4
cio;
NaBT.
EtOH
NMe.
+ HCIO.
1,3.1.4 Méthylation Reactions
This is a method in which three tritium atoms can be incorporated into an 
organic confound so that compounds with very high specific activities can be 
prepared. Such compounds have been widely used in pharmaceutical studies^ ’^ 
Tritiated methyl iodide, CT3I, is normally used as the methylating reagent, e.g.^ :^
1. t-BuO' Ktt-BuOH  
2 .CT3I '
1.3.2 Hydrogen Isotope Exchange Reactions
One of the drawbacks to the procedures using direct chemical methods is 
that for some compounds it can be very time-consuming. Sometimes it is 
impossible to synthesise the desired tritiated compounds, as in the areas of 
biopolymers and natural products. These disadvantages can be overcome by using 
hydrogen exchange reactions.
Hydrogen isotope exchange can be illustrated in the following manner:
AT + BH a H + BT
The reaction is a reversible process in which tritium and hydrogen exchange places.
Usually, the hydrogen exchange reactions are divided into two groups:
( 1) Hydrogen isotope exchange reactions with tritium gas; (2) Hydrogen isotope 
exchange reactions with tritiated solvents.
1.3.2.1 Hydrogen Isotope Exchange Reactions with Tritium
Gas
This procedure was first reported by Wilzbach in 1956 Exposure of an 
organic compound to tritium gas leads to the formation of tritiated compounds. 
Two serious limitations of this simple route to labelled compounds are: (1) 
radioimpurities are produced because of the radiation, thus making it very difficult 
to obtain radiochemically pure products; (2 ) the specific activities of the labelled 
compounds and the labelling rate are very low.
Considerable effort has been made to improve the Wilzbach labelling 
method. Several modified versions have been reported e.g. the recoil method^ ,^ in 
which the labelling of organic compounds is obtained by hot tritium atoms formed 
in nuclear reactions ^ i  (n, a) ^H or ^He (n, p) ^H the electric discharge 
method^^’ the tritium ion beam method^ and the microwave discharge 
activation method^ .^ Because of the difficulties in purifying tritiated compounds
and the relatively low specific activities normally achieved, these modified labelling 
procedures have very limited use.
A more useful exchange method using tritium gas was developed by Evans 
et al^ '^ . This method uses the ability of hydrogen in certain confounds to exchange 
with tritium gas when in the presence of a metal catalyst such as Pt or Pd. A wide 
range of tritiated organic compounds have been prepared using this method. 
Sometimes, compounds can be labelled with high specific activities and 
radiochemical purities, and sometimes specifically labelled compounds can be 
obtained^ .^
1.3.2.2 Hydrogen Isotope Exchange Reactions with Tritiated
Solvents
Labelling organic compounds with tritium by catalytic exchange using 
tritiated solvents such as tritiated water or acetic acid, is the most usefiil general 
method. This category consists of a number of procedures which are described 
below according to the catalysts used in the reaction.
1.3.2.2.1 Acid Catalysed Method
When an organic conpound is in contact with a strong acid it can be 
protonated. In the presence of a tritiated solvent, the deprotonation of the 
intermediate can lead to the formation of a tritiated conpound. This is the basis of 
the acid catalysed method.
As early as 1934, Ingold observed acid catalysed hydrogen isotope 
exchange^ :^
ArH + DA ArP + HA
Since then, a variety of acids from mineral acids to polymer supported acids 
have been used to prepare a range of electron rich aromatic compounds. As the 
concentration of acid increases so does the exchange rate. Frequently, a linear
10
relationship can be obtained between the logarithm of the rate constant and the 
acidity of the acid^ .^
1.3.2.2.2 Base Catalysed Method
Nearly aU organic conoponnds can be considered as carbon acids, so that in 
a sufficiently strong basic environment we have:
C '  + THO ► ---- C — T + OH
The carbanion, an intermediate, can remove a triton from a tritiated solvent to yield 
the tritiated conpound.
It can be seen from the equation that two factors deteimine the degree to 
which exchange takes place: ( 1) the acidity of the conpound to be labelled; (2 ) the 
basicity of the medium Compounds that exhibit relatively high acidity, such as 13- 
diketones, can be labelled under mild conditions, whereas those with low acidity, 
such as aromatic hydrocarbons, need stronger bases. The base catalysed method 
produces a complementary route to the use of acid catalysts in the preparation of 
tritium labelled conpounds.
1.3.2.2 3 Homogeneous Metal Catalysed Method
Garnett et al reported in 1967 that both platinum (II) and palladium (II) 
salts can induce hydrogen isotope exchange under homogeneous conditions. They 
found that the reaction is very sensitive to the acidity of the medium If it is too 
high the catalyst will be poisoned; if the acidity is too low the catalyst will be 
reduced and precipitation of the metal occurs.
The method has been found to be most suitable m the labelling of aromatic 
conpounds, but it gives lower radiochemical yield, lower labelling regiopecificity, 
and lower pecific activity than a number of other methods.
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In the life sciences, it is very important to know the labelled position(s) of a 
tritiated conpound. Unfortunately, many exchange reactions yield generally or 
randomly labelled products. However, by caiefiiUy selecting the catalyst and the 
reaction conditions, it is possible to direct the labelling to a pecific part of a 
molecule, and sometimes even to a pecific position within the molecule.
For exanple, regiopecifically deuteriated a, (3-unsaturated and aromatic 
carbo^Qhc acids C-arylamides and benzylamines and N-arylamides are 
obtained using rhodium trichloride catalyst. The same catalyst has been used to 
label a wide range of deuterated and tritiated aromatic conpounds, including 
aromatic acids, amides, aralkylamines, heterocyclic conpounds, and some drugs. 
^H-NMR pectroscopy has been used to show the high regiopecficity of labelling 
ortho to carboxyl, carboxamide and methamide groups'*^ ’
When tristriphenylphophineruthenium (ü) chloride is used as a 
homogeneous catalyst, pecificaUy labelled alcohols and amines (in the a- 
methylene position) can be obtained. The reaction conditions that give best results 
are 100°C, 0.5 to 3 hours"^ .^
1.3.2.2 4 Heterogeneous Metal Catalysed Method
The procedure is similar to that of the homogeneous metal catalysed 
method. Most catalysts used are transition metal catalysts, particularly those in 
Group Vm, either in supported or unsupported forms. Palladium and platinum are 
the most widely used catalysts, althou^ rhodium, iridium, nickel and ruthenium 
are also effective‘s^ . The method has been widely enployed for preparing generally 
labelled compounds. Amino acids, compounds with heteroatoms, purines, aromatic 
conpounds and steroids are amongst the compounds that have been labelled using 
this method
Two mechanisms have been used to explain the heterogeneous metal 
catalysed reactions, one called the classical and the other Tc-conplex mechanism 
Both are shown in Fig. 1. 2 and Fig. 1 . 3 ; benzene is used as the substrate and 
platinum as the catalyst.
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Dg + 2P t 2 P t— D
DgO + 2 P i < = ^  P t— D + Pt— OD 
Adsorption of deuterium on the catalyst
(v ^ P t  + P t— H
D + 2Pt
Classical dissociative
\\ / /  H-^ i— i^H
Pt Pt
+ P t— DH^l—  
Pt Pt
H-4— j^H 
Pt D
+ R — H
D
Classical associative
Fig. 1.2 Classical Mechanism of Heterogeneous Metal Catalysed 
Hydrogen Isotope Exchange
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Dj + 2 R  <---- »■ 2 R — D
D p  + 2 R  3 = ±  Pt— D + Pt— OD 
Adsorption of deuterium on the catalyst
Pt
+ P t— D
H
Pt
■D
Pt
Pt
+ Pt — H
%/
Pt
/ /  \ \  
Pt
+ Pt— D
Ti-Complex Dissociative
Pt
71-Complex Associative
Fig. 1.3 7i-Complex Mechanism of Heterogeneous Metal Catalysed
Hydrogen Isotope Exchange 16
The disadvantages of this method are that generally labelled compounds are 
produced and that the specific activity of the labelled conçiound can not be 
predicted and can vary fi*om sample to sample. In addition when a compound 
contains iodine or nitro groups the catalyst will be poisoned.
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1.4 Analytical Methods
Many isotopes are used in the life sciences (see Table 1. 2) of which and 
are amongst the most inq)ortant. In the case of the former the most important 
techniques for analytical purposes are spectroscopy and mass
spectrometry, whilst for it is ^H-NMR spectroscopy, MS and liquid scintillation 
counting These techniques take advantage of the fundamental properties of the 
isotopes.
1.4.1 Deuterium NMR Spectroscopy
Pioneering work in this area was earned out by Diehl and colleagues as 
early as 1964 but it was only m the 1970’s, with the development of modem 
NMR ^ectrometers that the technique found a wider audience.
The nuclear properties of some isotopes widely used in the life sciences are 
listed in Table 1. 2.
Table 1.2 Nuclear Properties of Isotopes Used in the Life Sciences
Isotope Natural
abundance
(%)
Nuclear
spin
Magnetic
moment
( u /U n )
Magnetogyric 
ratio (y/1 0  ^
radians
Resonance
frequency
(Mhzat7.1T)
Relative 
sensitivity ®
H 99.984 1 /2 4.8371 26.7519 300.13 1 .0
H 0.0156 1 1.2125 4.1064 46.07 9.65x10“^
3h < 1 0 '^ ® 1 /2 5.1594 28.5336 320.13 1 .2 1
1 3 c 1 .1 1 1 /2 1.2162 6.7263 75.46 1.59x10'^
99.63 1 0.5706 1.9324 6.50 " 1 .0 1 x1 0 '^
0.37 1 /2 -0.4902 -2.7107 9.12'’ 1.04x10'^
" o 0.037 5/2 -2.2398 -3.6266 1 2 .2 0  *■ 2.91x10'^
31p 1 .0 0 1 /2 1.9581 10.8290 36.43 " 6.63x10'^
32p 0 1 -0.3568 -1.2084 4.06'’ 2.46x10"^
* a - sensitivity given for equal numbers of nuclei in the same field 
b - at 2.114 Tesla
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The disadvantages of ^H-NMR are a consequence of the magnetic 
properties of the deuteron. Because it is a quadiupole nucleus, and thus very 
efficiently relaxed when irradiated, the spectral lines are broad, and this, when 
combined with the low magnetogyric constant and the small chemical shift, often 
results in poorly resolved spectra. The low sensitivity of ^ H-NMR means that 10“^ 
accumulations are needed to give a ^H-NMR signal of similar intensity to that 
obtained for ^H-NMR from a single pulse spectrum (assuming a similar number of 
and nuclei). Because of the rapid relaxation of the deuteron and absence of 
nuclear Overhauser effects ^H-NMR spectra can be readily integrated so that the 
relative enrichment at different sites in a molecule can be accurately assessed. 
has virtually identical chemical shifts to Another major advantage of ^ H-NMR 
spectroscopy is that as a consequence of the low natural abundance (0.0156%) of 
^H, much greater dilutions are tolerable than hr the case of carbon-13 labelUng. 
This is the reason why deuterium labelling is particularly suitable m the study of the 
incorporation of intermediates hi a biosynthetic pathway^ ®.
An important advantage of ^H-NMR spectroscopy comes from the 
quadrupolar properties of deuterium The dominant pathway for deuteron 
relaxation is through an intramolecular quadrupolar mechanism^\ Inteimolecular 
mteractions, or interactions with paramagnetic ions, which complicate the 
interpretation of ^H-NMR spectra, have no effect on relaxation times^ .^ 
Consequently spectroscopy can be used in studies of the relaxation times
of deuteriated water e.g. where water mteracts with solutes such as with 
biopolymers^ '^
^H-NMR spectroscopy has found applications not only m the analysis of 
deuteriated confounds, but also in other areas e.g. m the study of biochemical 
reductions'^ and the mechanisms of biosynthesis^ ,^
1.4.2 Tritium NMR Spectroscopy
After Tiers reported the first ^H-NMR work in 1964 a collaborative 
project was initiated in 1968 between the Chemistry Department (Professors 
Etvidge and Jones) at the University of Surrey and Amersham International (The
16
Radiochemical Centre) to develop tritium NMR spectroscopy. This was done in 
order to be able to i^ecify the degree and pattern of labelling obtained in a range of 
tritiation procedures
Some important magnetic properties of tritium are presented in Table 1. 2. 
bas two in^ortant properties which make ^H-NMR spectroscopy a powerM 
technique in the analysis of tritium labelled compounds. One is that has a high 
nuclear magnetic moment so that it has the highest value of the magnetogyric ratio 
among all the nuclei in the Periodic Table. Consequently is the most readily detected 
NMR nuclei. This, plus its very low natural abundance, makes it possible to 
obtain a ^H-NMR spectrum even when a compound is labelled at very low specific 
activity, e.g. 10^- 1 0 "^  % per site, corresponding to 3 mCi - 30 pCi per site when 
using a modem Fourier transform NMR spectrometer.
The second important magnetic property of tritium is that the chemical 
shifts and coupling constants of are almost the same as those of in 
corresponding environments^ .^ This means that a large amount of chemical shift 
data and coupling constants for can be directly used to assign the peak(s) m a 
^H-NMR spectrum
Normally the tritium abundance in a tritiated compound is very low, so that 
the ^H-NMR signals are very weak and need to be strengthened by accumulation.
In addition, proton decoupling is often used to remove couplings between adjacent 
magnetic nuclei in order to clearly illustrate the positions of the tritium atoms and 
interpret the NMR spectrum correctly. However, by decoupling the protons, 
nuclear Overbauser effects may arise.
Unlike ^H-NMR spectra, ^H-NMR ^ectra can not be accurately integrated 
because of the nuclear Overbauser effect (n O.e.). When a tritiated sample is 
analysed, the population of the upper spin state is larger than the lower because of 
the irradiation of the protons. A corresponding redistribution of triton spins occurs 
to give a biÿier population in their lower spin state in order to maintain an overall 
Boltzmann distribution between lower and upper spin states for the whole of the 
system of interacting nuclei (tritons and protons). Then more energy is absorbed 
and the triton signal strength increases. The theoretical maximum nuclear
17
Overbauser effect for tritium is 47%(Tp/2yt)^ ®. Tbe integration errors in ^H-NMR 
spectra caused by n.G.e’s. will never be higher and at the very worst would be 
within 1 0 %, but generally much less^\
^H-NMR spectroscopy has not only been used in assigning labelling 
patterns, which is tbe most important appbcation, but also in other fields such as 
examination of tbe decomposition products formed by radiolysis of tritium 
compounds^ ,^ investigation of tbe biosynthesis of natural products^^, study of 
organic reaction mechanisms investigation of the kinetics of detritiation 
reactions '^ ,^ study of protein-ligand interactions^ ,^ examination of protein structure 
and dynamics®^ , and labelling of biocompatible polymers^’.
1.5 Proposed Research
There were several objectives to the research project. These can be 
summarised as follows;
(1) to improve and labelling procedures by preparing polymer 
supported transition metal catalysts which were then used to label a range of 
compounds;
(2 ) to synthesise hthium aluminium deuteride and tiitide and explore the 
possibihty of incorporating these deuterium or tritium atoms into selected 
precursors;
(3) to investigate the opportunities offered by the use of weak Lewis acids 
such as boron trifluoride in labelling reactions;
(4) to synthesise and ^H-labelled biocompatible polymers;
(5) to study the kinetics of méthylation reactions as a prelude to 
optimisation of tritiation procedures using CF3SO3CT3
18
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2.1 Introduction
2.1.1 Homogeneous and Heterogeneous Catalysts
A catalyst is a substance which changes the rate of a chemical reaction, but at 
the end of the reaction the catalyst is still present and has not undergone any 
permanent chemical change. There are two kinds of catalysts: homogeneous catalysts 
and heterogeneous catalysts.
A catalyst that is in the same phase as the reactant(s) is called a homogeneous 
catalyst, whereas a catalyst that is in a different phase from the reactants is said to be a 
heterogeneous catalyst. Heterogeneous catalysts are materials with the ability of 
adsorbing gases or Hquids onto their surfaces. The actual catalytic reaction then takes 
place at the surface of the solid where it makes contact with the Kquid or gas. We may 
say that the reaction occurs at an interface. An exarnple of heterogeneous catalysis is 
the use of finely divided platinum to catalyse the reaction of carbon monoxide with 
oxygen to form carbon dioxide. This reaction is used in catalytic converters fitted in 
automobiles to eliminate carbon monoxide from the exhaust gases.
Catalysts are of major importance in today’s industrial world. It has been 
estimated that about 20% of the U.S. gross national product is generated throu^ the 
use of catalytic processes.
2.1.2 Polymer Supported Catalysts
Soluble metal complexes that are active homogeneous catalysts have a metal 
centre which fimctions as the “active site” for catalysis. The metal centre of a
homogeneous catalyst bound to coordinating ligands exerts a profound influence on
the catalytic activity of the metal centre. A typical metal conplex, which is an active 
hydroformylation catalyst  ^ is the square-planar complex [(C6H5)3P]2Rh(CO)Cl. This 
complex has the same structure in solution as in the solid state.
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R? ^ P (C s%  
'Rh.
Each of the foiu* groups bonded to the rhodium centre is referred to as a Hgand. 
Not only are temperature and mixing better controlled than in heterogeneous systems, 
but also the nature of the active catalytic species is regulated more effectively. Control 
of catalyst and ligand concentration is better than that attainable on the sur&ce of a 
sohd.
Homogeneous catalysts often have the advantage of giving high selectivity 
under relatively mild operating conditions In addition, their activity and selectivity 
can be tailored by varying the ligands attached to the metal and by varying the solvent. 
Furthermore, every molecule of the catalytic conplex is available to participate in 
catalysing the reaction in question, unlike the situation found with heterogeneous 
catalyst where only surface atoms or molecules may participate. Heterogeneous 
catalysts, such as metal or metal oxide surfaces, are often less active and less selective, 
but they are often very durable and readily separated from the reactants and products. 
They may be used in fixed beds in gas-solid and liquid-solid contact reactors. It would 
be ideal to combine the advantages, and simultaneously avoid the disadvantages of 
each class of catalysts. One approach to this is to attach homogeneous catalysts to 
organic polymers or inorganic supports.
Today, a clean chemical reaction is a ‘^ u s t”, not only for industrial chemists 
but also for laboratory investigators. Saving energy and material can be accomplished 
by utihsing new highly active, selective catalysts. To meet these requirements, 
homogeneous catalysis has aheady been given sufficient credit.
The term 'heterogenismg” refers to the process whereby a homogeneous 
catalyst, such as a transition metal complex, is supported on or anchored to an inert 
polymer or inorganic support.
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The single most important factor in favour of supported catalysts is 
environmental. The growing awareness of the unacceptahility of many conventional 
catalysts and resulting legislation have given a major impetus to the search for 
“cleaner technology”.
The support of catalysts on inorganic sohds or organic polymers can offer 
great advantages in synthetic organic chemistry. The use of a polymeric support 
can facüitate reaction workup because supported catalysts can easily be removed 
from the reaction medium (soluble reactants, products and/or solvents) simply by 
filtration. Supported catalysts make it possible to recycle and reuse the expensive 
catalysts many times. This relative ease of workup may permit the use of an excess 
of reagent, in order to drive a reaction to or near to completion, a situation which 
is often avoided in solution because of subsequent separation difficulties. 
Supported catalysts are easily handled and can be used in flow reactors in 
automated processes. Finally, but importantly, many polymer supported catalysts 
offer greater selectivity than the corresponding homogeneous catalysts. Extensive 
reviews are available.
Two major classes of polymer supports have been used in making 
supported catalysts: (1) H i^ y  cross-linked resin beads of large surface area called 
macroreticular or macroporous resin Common ion-exchange resins and styrene- 
divinylbenzene resins with divinylbenzene (DVB) contents of 20, 40 and 60 % are 
examples of this class; (2) Swellable, lightly cross-hnked, microporous (gel-type) 
resins, for example, styrene resins cross-linked with 1 or 2 % DVB.
2,1.3 Synthesis of Supported Catalysts
2.1.3.1 Modification of Preformed Polymers
The polymer most commonly chosen as a support is polystyrene and many 
reactions have been used to chemically modify it^ .^ Those shown in Fig. 2.1 involve 
the reaction of electrophhic reagents directly with polystyrene.
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CH2CI
ÇH-CH,-
I
Br
CICH2OCH3
Lewis Acid
A
NO.
CISO3H cB
E
ROOOl 
Lewis acidTKOOCCH))^  I
-CH-CH2- -ÇH-CH.
Hg
OOCCF,
Fig. 2.1 Reactions of polystyrene with electrophhic reagents. A, Ref. 14; B, 
Ref. 15; C, Ref. 16; D, Ref. 17; E, Ref. 18; F, Ref. 19.
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If the polystyrene is first lithiated, less reactive electrophhic reagents can be 
incorporated as ^own in Fig. 2. 2.
-ÇH-CHg-
I  I ] Br.TI(OOCCH.l
n-C^HgLi 
TMEDA
(1) MgBr^(2) n-C^ HgSnCIg
H-CHz-
n-C^Hg S n  Cl
Cl
-CH-CH.- CH-CH.-
P(C«HJ
n-C.H.U (GgHg)2PCI
-CH-CH.-
(1) Sg(2) UAIH^
-CH-CH.- CH-CH
COOH
Fig, 2 ,2  Preparation and reactions of lithiated polystyrene. From Ref. 23, 
unless otherwise noted. A, Ref 20; B, Ref. 21; C, Ref. 17.
This can be achieved directly, in which case only about 25 % of the phenyl 
residues may be methylated or indirectly by first brominating the polystyrene, then 
carrying out a halide-metal exchange. The latter method can lead to essentially 
quantitative lithiation.
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The reactions i^own in Fig. 2. 3 involve the introduction of functional groups 
by nucleophilic reagents reacting with chloromethylated polystyrenes.
-CH-CHg- CH-CHg- -ÇH-CH2
CH.NRX1 C H X O C RCICH-OCH,CH-CH.-
RCOOK . c H-CH,-
LiP(C,Hg)2 
C -CH-CHg-
CKPfC^ H,)
H-CH.-
CHgCI
CHgSR
H (1) (NH^ lgC^ S 
(2) NaOH
CI-yCN -CH-CH.-
NaHCO.
DMSO
-CH-CHg-
CHgCH— Y
X
CHO
-CH-CH.-
CH.SH
Fig. 2 .3  Preparation and reaction of chloromethylated polystyrene. A, Kef.
22; B, Ref. 23; C, Ref. 24; D, Ref. 25; E, Ref. 26; F, X and Y = CN, 
COCH3, Ref. 27; G, Ref. 28; H, Ref. 29.
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A single method of making polymer supported catalysts is illustrated as below 30.
H28O,
SO3H
lu this reaction, sulphonic acid groups are incorporated by direct sulphonation 
of cross-linked polystyrene. Then, this macroporous strong acid ion exchange resin can 
be further used to react with several bifunctional phosphines to support some 
multidentate ligands. The resulting resins can then be treated with Rh, Co and Pt 
complexes to give a series of supported catalyst systems These syntheses are
illustrated in Fig. 2. 4.
(M%N)aP
(2 ) SOgH (MejNCHjCHjO)^? (7)— SÔ3H P(OCH2CH2NMei)3
S03HP(CeH.,NMej)3(MCjNCeH^aP
PtH(SnCla)(PPh3) C%(CO)g
( 7 )  SO3H P(CgH.,NMe)3ptH(8nCl3)
OgH^ jNMe^
(7)— S03HP(CeH^NMe,),
CgH.NMe2->Co(CO)JcO).
Fig. 2. 4 Macroporous strong acid ion exchange resin as catalysts support
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Polymers containing groups similar to the phosphiue ligands used iu transition 
metal complex catalysts are prepared by routes known from organometallic synthesis. 
For exançle, phosphine-functionalised poly(styrene-divinylbenzene).
PPh,
is an often-used polymer support since, when it is brought in contact with metal 
conq)lexes like Rli(PPh3)Cl, it undergoes phosphine-phosphine ligand exchange and 
forms metal-containing polymers, such as
-CH-CH.-
PPh,
Ph_P R h  Cl
PPh
These polymers have chemical and catalytic properties similar to those of their 
soluble analogues. Many acidic, basic, and metal-containing polymers have been 
prepared, some of them are shown in Fig. 2. 5.
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p PPhg RhCKPhgP),
P PPhg RhH(C0 )(Ph3P),
PPhg RuCyC0)2(Ph3P)
(Ph3P)^ ir(C0 )CI  ^ ^PPh, P P h j )g lr(CO)CI
y ■PPhg Ru^(CO) 2^ ( X = 1 ,3, Or 4)
Pd(PhCN)2CI,
Fig. 2. 5 Metal-containing polymers prepared by ligand exchange of metal 
complexes and clusters with poly(styrene-divinylbenzene) 
incorporating phosphine groups^°
A number of organic polymers have been used as catalyst supports; some of 
these polymers are shown in Table 2. 1 with functional groups or ligands offered for 
attachment of catalytic groups.
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Table 2.1 Organic Polymers Used as Catalyst Supports
Polymer Ligand Metals bounded 
to ligand
Ref
Polybutadiene K Fe 34
Polyvinylferrocene Fe 35
Poly(vinyl alcohol) —OPR2 Co, Rh, Re 36
Polyvinylpyriditie Fe, Co, Ni 37
Polyvinylimidazole
Na Co 38
Polyacrylonitrile -C=N Pd 39
Polymethacrylate 0"
c-
— 0 
---- NH
Pd 40
Polyamides “ r0
—  NH Cu, Rh, Pt, Pd 41
Polynaphthoquinone = 0 Ti, V, Fe,Mo 42
The following reaction of M(CO)6 (M = Or, Mo, W) with polystyrene or 
polyarenes shows that polymers do not always require functional modification to 
provide ligands to bind metal complex
G> // M(CO)e
M(C0)3
+ 3C0
Non-aromatic as well as aromatic polymers can be used as supports, although 
the former have not been used as widely as aromatic polymers. Phosphate-rhodhim 
complexes derived jfrom poly(methallyl alcohol) have been employed as hydrogenation 
catalysts
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ÇHj ÇH3 CH3 CH3
PPh^CI Rh(C0 )2Cf I— CHg— (j)— ------—►— CHj— <jî— -► — CHg—(j:—CHg—
OH O 0  Cl OI  I I I
P P h g  P h g P — fjih— P P h g
CD
Commercially available ion-exchange resins can also be a very attractive way 
of supporting charged catalytic metal complexes by using ion exchange ‘ The 
following reaction is an exanq)le of this application.
p r — ^  ' V - N R 3OH + P d c if  -----------► + "o h
2.1.3.2 Polymerisation of Functionalised Monomers
Another synthetic approach to produce polymer supported catalysts involves 
the preparation of a monomer, which contains the Hgand or Hgand-metal complex, 
followed by the polymerisation of this monomer to generate the appropriate resin. For 
many polymers, such as poly-4-vinylpyiidine, polymerisation of a functionalised 
monomer represents the only possible route. For others, synthesis by this route may 
represent a method of choice.
The following advantages may be achieved when a Hgand or Hgand-metal 
conoplex is polymerised in the form of its monomer:
(1) The concentration of the monomer can be controHed, so resins with a wide
range of Hgand concentrations can be synthesised.
(2) The nature of the polymer matrix can be varied depending on the co­
monomer.
(3) The degree of cross-linking can be systematically varied.
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(4) Tbe ligand or complex can be distributed throughout the resin at the 
microstructure level.
Polymerisation of functionalised monomers has been utilised in the production 
of polystyrene polymers modified with phosphines pyridine units and ring
halogens
The following reaction is an illustration of this method:
CH2=CH c h ,=.c h  CH2=CH
/ ) — PPh,
CH=CH2
The problems associated with this approach are: monomers with transition 
metal complexes may undergo undesirable reactions with radical, basic or acidic 
initiators; some fimctionalised monomers may not be commercially available and may 
require unacceptably expensive synthetic routes for then preparation; the use of 
co-monomers with different reactivities result in sequences of repeat units that are far 
fi-om bemg random
Some organometallic vinyl monomers which have been synthesised and both 
homo- and copolymerised are shown in Fig. 2. 1. They are (1) vinylferrocene (2) 
Ti^-(vittyicyclopenta-dienyl)tricarbonylmaganese (3) Ti^-(vinylcyclopentadienyl)- 
dicarbonylnitrosyl-chromium^^ ; (4)r| ^ -(vinylcyclop entadienyl)-tricarbonylmethyl-
tungsten (5)ri^-(styrene)-tiicarbonylchromium (6 ) T|^-(benzylacrylate)-
tricarbonylchromium and (7) its 2-phenylethyl analogue
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w /
Fe
O
(1)
CH=CH, VMo(CO)3
(2)
CH=CH, \\ //
Cr(CO),NO
(3)
V \ . / y CH=CH,
W(CO)3Me
(4)
Cr(C0)3 
(5)
CH. /y
Cr(C0)3
(6)
CHjOCOGHsCHj
CHgCHgOCOGH-CH^
Gr(G0)3
(7)
Fig. 2 .1  Some Organometallic Vinyl Monomers
2.1.4 Applications of Polymer Supported
Catalysts
2.1.4.1 Polymer Supported Acid Catalysts
Sulphonated cross-linked polystyrene resins, originally prepared as cation 
exchange resins, have found considerable applications in the acid catalysis of 
organic reactions. Nearly aU those organic reactions that are catalysed by acids in 
solution have been performed with the aid of a corresponding cation exchange 
resin. Nafion, a commercially available perfluorinated polymer, and Amberlyst-15, 
another commercially available polymer, con^rising a sulphonated macroreticular 
polystyrene resin, are two polymer supported acid catalysts that have proved to be 
particularly popular in organic chemistry
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2.1.4.2 Polymer Supported Base Catalysts
Polymer supported base catalysts, like their acidic couuteiparts, are usually 
based upon poly(styrene-divinylbenzene) and are functionalised with the quaternary 
trimethylammonium group and the tertiary dimethylanunonhun group to give 
strongly and weakly basic resins respectively. It was stated earlier that almost all of 
the reactions that occur under acid-catalysed conditions in solution have been carried 
out with the use of an acidic ion-exchange resin, A similar statement can be applied 
to base-catalysed reactions. Amberlyst-A21, a weakly basic dimethylamino- 
functionalised polystyrene, exenq>lifies the use of basic polymeric resins
Despite over thirty years of effort in atteicpting to iucrease the basicity of 
polymer supported base catalysts, the subject of base catalysis is very much the poor 
relation corcpared to acid catalysis using polymer supported acid catalysts. This is 
due in part to the limited range of usefiil bases that have been discovered and to a 
narrower range of applications that have been proposed. The negative environmental 
inçact of chemical processes using acidic reagents and catalysts such as AICI3 and 
H2SO4 has certainly attracted more headlines than those using NaOH, for example. 
The major limitation of polymer supported bases is their instability. Consequently the 
catalytic utilisation of this kind of catalyst is limited to low temperature applications.^^
2.1.4.3 Polymer Supported Lewis Acid Catalysts
The earliest investigation for polymer supported Lewis acids was started by 
Neckers^ .^ He and his colleagues used a tightly bound complex of styrene- 
divinylbenzene copolymer and anhydrous aluminium chloride styrene-divinylbenzene 
copolymer and anhydrous ahmhnium chloride as a mild Lewis acid catalyst for 
certain organic preparations. For example, dicyclopropylcai-binol when treated with 
the supported catalyst, produces di(dicyclopropylcarbinyl)ether in yields as high as 
81 %. Unfortunately, the activities of polymer supported Lewis acid catalysts are 
relatively low and the activities of the catalyst decrease after a few reaction cycles.
Lewis acids, when combined with Bronsted acids, wiH form superacids which 
can give maximum acidity. The superacids are active catalysts even for the most
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difficult hydrocarbon conversions involving paiaffins, including isomérisation, 
disproportionation, and alkane-alkene allsylation
Metal halides react with the sulphonic acid groups of cation-exchange resins to 
give anchored superacids. The &st exanq>les of these polymer supported superacids 
were -SO3H/BF3 con:plexes on gelular and macroporous resins prepared by low- 
tenperature contacting of the resin with BF3 ^  Polymer supported superacids were 
also prepared from AICI3 and sulphonic acid resins, having Cl : A1 atomic ratios of 1:1 
to 2: 1 Adsorbed aluminium oxyhalides may have been present at the resin surfaces 
along with coinplexes formed by reaction of -SO3H groups with AICI3. These resins 
have the catalytic activities characteristic of superacids. They can catalyse propylene- 
isobutane alkylation, n-butane isomérisation and n-hexane cracking at temperatures 
<100 °C Later, Gates and his colleagues prepared some polymer supported
superacids by bringing metal haUdes (AICI3, SnCfr, TiCU, BF3 or SbFs) in contact with 
macroporous sulphonic acid resins [sulphonated, cross-linked poly(styrene- 
divinylbenzene)] The polymers consist of supported metal oxyhalide particles, 
complexes of metal oxyhalides and sulphonate groups, and the remaining unreacted 
sulphonic acid groups. In the presence of HCl, these polymers are highly active 
catalysts for the butane isomérisation reaction.
More recently, Chung and his co-workers have developed a new supported 
Lewis acid catalyst which involves EtAlCl  ^ or BF  ^ species chemically bonded to
crystalline polyolefins, such as polypropylene and poly(l-butene) The polymer 
supported catalysts were used in the carbocationic polymerisation of isobutylene and 
were recovered and reused for many reaction cycles without significantly losing their 
activities.
The immobilisation of boron trifiuoiide can be illustrated by the following 
reaction:
(V)vVOH (T)v\AO-Li+------^  (^AA^O-BF
LiF
43
P is the partially crystalline polyolefin, such as isotactic polypropylene with 5 mole 
percent of hydroxyl groups, or isotactic poly(l-butene) with 12 mole percent of 
hydroxyl groups. The structures of the polymers are as follows:
(CHj)4 (CEt)4
OH OH
The metalation of hydroxyl groups was achieved by simply mbdng polymer 
particles with n-butyllithium solution. After washing out the excess n-butyUithium, the 
polymer particles were mixed with a BF /^CH^Cl  ^ solution for a few hours before
vacuum-removal of excess reagents. All the procedures were carried out at room 
temperature.
2.1.4.4 Polymer Supported Transition Metal Catalysts
Attachment of transition metal complexes to organic polymers appeared by the 
end of the 1960s as a suitable procedure^^  ^ to approach two of the main goals of 
research groups in catalysis:
(1) Formation of stable catalysts with as good reproducibility, activity and 
selectivity as homogeneous systems, and which are easily separable firom 
reaction products and heterogenous catalysts.
(2) Achievement of heterogeneous systems where the active sites have known
structures and may permit better understanding of the molecular 
mechanism of the catalytic reaction.
There are a number of excellent review papers available on this topic.
As early as 1973 Grubbs et al reported that polymer-attached titanocene on 
reaction with BuLi gives a more active hydrogaiation catalyst than titanocene 
dichloride or benzyltitanocene dichloride. This fact was attributed to the presence
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of a higher concentration of monomeric species in the polymer, thus indicating that 
polymer attachment hinders the coupling of the reduced titanocene complexes to 
mactive species. Activation of polymer-anchored Ir[(CO)Cl(PPh3)2] during 
hydrogenation cycles was observed by Pittman et al^ ®^, achieving a system with 
greater activity than that of the homogeneous analogue at low P:If ratios.
Although heterogenisation can be regarded as a diort-term application of 
transition metal-polymer complexes, the most fascinating aspect for the chemist is 
the discovery of new catalytic properties which can be related to the very specific 
structure of these systems. New catalytic species does not merely mean different 
behaviour with re jec t to monomeric analogues, but the capacity to catalyse a 
different process.
The new roles that can be assumed by polymer anchoring have been 
indicated m the case of a Pd (H) catalyst attached to a polymer matrix with 
anthranilic acid groups
Perkins and VoUhardt reported that a polystyrene supported r|^-cyclo- 
pentadienylcobalt derivative is catalytically active in the hydrogenation of carbon 
monoxide to give hydrocarbons, whereas the soluble analogue CpCo(CO)2 is 
inactive and decomposes under hydrogenation conditions.
A large number of reactions have been catalysed by polymer supported 
rhodium catalysts
2.1,4.5 Polymer Supported Catalysts in Radiochemistry
Polymer supported catalysts have not been widely used in radiochemistry, 
especially in the preparation of labelled compounds. Maeda studied the radio­
iodine exchange between alkyl iodides and Na^ ^^ I by using polymer supported 
phosphonates as catalysts, Mulholland used a polymer supported anion 
exchange resin (quartemary ammonium) in the labelling of and confounds.
The first application of polymer supported acids, and base catalysts in the 
field of hydrogen isotope exchange labelling was carried out by Brewer . A wide
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range of compounds, including aromatics, pyridine derivatives, quinoline derivatives, 
other heterocyclic compounds, and some drugs were labelled.
2.1.5 The Aim of This Work
LocMey demonstrated that hydrogen isotope exchange in the presence of 
rhodium trichloride provides a simple procedure for the regiospecific ortho- 
deuteriation of a, p-unsaturated and aromatic carboxylic acids C-arylamides and 
benzylamines N-arylamides Hesk, Jones and Lockley used homogeneous 
rhodium trichloride catalyst to obtain a wide range of deuteiiated and tritiated aromatic 
confounds, including aromatic acids, amides, aralkylamines, heterocyclic compounds, 
and some drugs by hydrogen exchange reactions. NMR spectroscopy demonstrated 
high regiospecificity of labelling oitho to carboxyl, carboxamide and aralkylamine 
groups.
The new class of polymer supported catalysts have started to show promise in 
that they combine the advantages of both homogeneous and heterogeneous processes. 
More interestingly, however, there is a possibility that when anchored to the surface of 
a solid a homogeneous catalyst can exhibit selectivities which are not observed in 
solution reactions. The aim of the present work is to prepare polymer supported 
organometallic catalysts, mainly rhodium trichloride, and to investigate whether the 
supported catalysts could offer a h i^er degree of labelhng regiospecificity, selectivity, 
ease of catalyst separation and product work-up.
46
2.2 Experimental
The Chemicals used in Chapter 2 were purchased from Aldrich Chemical 
Corcpany, unless otherwise stated. Poly(2-hydroxyethyl methacrylate) (PHM) and 
Poly(methyl-methacrylate-N-vinyl-2-pyrrolidone) (PMMAVP) were gifts from 
Dr. Highgate of the Department of Chemistry, University of Surrey.
2.2.1 Preparation of Polymer Supported Catalysts
2.2.1.1 Preparation of Polyvinylpyrrolidone (PVP) Supported 
Rhodium Trichloride (PVP-RhCL) Catalyst
To a 3-necked, round-bottomed flask (100 ml) fitted with a stirrer bar were 
added PVP (cross-linked, 2.05 g) and toluene (30 ml). The mixture was stirred at 
room temperature for 4 hours under the protection of nitrogen gas so that the polymer 
had time to swell. Then RhCls 3H20/ethanol solution (RhCls 3 H2O, 205 mg; absolute 
ethanol, 5 ml) was added dropwise to the flask through a dropping funnel (50 ml) with 
a pressure-equalising arm The stiiring was continued. After 13 hours, the solvents 
were filtered off by vacuum filtration. The solid was washed with toluene (60 ml), 
ethanol (60 ml) and petroleum ether (60 ml), respectively and dried under vacuum
2.2.1.2 Preparation of Poly(styrene(maleic anhydride)) (PMAn) 
Supported Rhodium Trichloride (PMAn-RhCls) Catalyst
To a 3-necked, round-bottomed flask (100 ml) fitted with a stirrer bar were 
added PMAn (1.0 g) and toluene (30 ml). The mixture was stirred under the protection 
of nitrogen gas at room temperature for 4 hours so that the polymer had time to swell. 
Then RhCl3’3H20/ethanol solution (RhCl3’3H20, 100 mg; absolute ethanol, 5 ml) was 
added dropwise to the flask through a droppmg funnel (50 ml) with a pressure- 
equalising arm After stirring for 14 hours at room temperature, the mixture was 
further stirred for one hour at 120°C. On cooling, the solvents were filtered off by 
vacuum fiUltration before the solid was washed with toluene (60 ml), and ethanol (60 
ml), respectively. Finally, the solid was dried under vacuum
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2.2.1.3 Preparation of Poly(2-hydroxyethyl methacrylate) (PHM) 
Supported Rhodium Trichloride (PHM-RhCb) Catalyst
RhCls (88 mg) was dissolved in water (2.5 ml) in a beaker before PHM (700 
mg) was added. The RbClg solution was trapped in the polymer and PHM supported 
RbClg (PHM-RhCls) was obtained after the solution was allowed to dry naturally.
2.2.1.4 Preparation of Poly(methyi-methacrylate-N-vinyl-2- 
pyrrolidone) (PMMAVP) Supported Rhodium 
Trichloride (PMMAVP-RhCIg) Catalyst
RhCls 3 H2O (100 mg) was dissolved in water (2 ml) ia a 25 ml round-bottomed 
flask before PMMAVP (1.0 g) particles were added to the flask. Ovemi^t the 
polymer became swollen. PMMAVP supported RhCls (PMMAVP-RhCls) catalyst was 
obtained after the contents were dried under vacuum.
2.2.1.5 Preparation of PMMAVP Supported Sodium 
Tetrachloropalladate (PMMAVP-NaiPdCU) Catalyst
NaiPdCfr (100 mg) was dissolved in water (2 ml) in a 25 ml round-bottomed 
flask before PMMAVP (1.0 g) particles were added. Overnight the polymer became 
swollen. PMMAVP supported NagPdCfr (PMMAVP-NaiPdCh) catalyst was obtamed 
after the contents were dried under vacuum
2.2.1.6 Preparation of PMMAVP supported Potassium 
Tetrachloroplatinate (PMMAVP-KgPtCL) Catalyst
The same procedure that was used for the preparation of PMMAVP-Na2PdCl4 
was used to prepare (PMMAVP-K2PtCl4) catalyst.
2.2.1.7 Preparation of Polyvinylpyrrolidone (PVP) Supported 
Ruthenium Acetylacetonate (Ru(acac)3) (PVP-Ru(acac)3) 
Catalyst
To a 3-necked, round-bottomed flask (100 ml) with a stirrer bar were added 
PVP (1.0 g) and toluene (30 ml). The mixture was stirred at room temperature for 4
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hours under the protection of nitrogen gas so as to allow the polymer to swell. Then 
Ru(acac)3 (100 mg)/ethanol (absolute ethanol, 5 ml) solution was added dropwise to 
the flask throu^ a dropping funnel (50 ml) having a pressure-equalising arm. The 
mixture was stirred overnight. The solvents were filtered off by vacuum filtration 
before the solid was washed with toluene (30 ml). Finally the polymer was dried under 
vacuum to leave the PVP-Ru(acac)s catalyst.
2.2.1.8 Preparation of PMMAVP Supported Ru(acac)s 
(PMMAVP-Ru(acac)3) Catalyst
The procedure used for the preparation of PVP-Ru(acac)3 catalyst was 
en^loyed to prepare PMMAVP-Ru(acac)3 catalyst.
2.2.1.9 Preparation of PMMAVP Supported Sodium 
Tetrachloroplatinate (PMMAVP-Na^PtCL) Catalyst
Na2PtCl4 (100 mg) was dissolved in 2 ml of water in a round-bottomed flask 
(25 ml) before PMMAVP (1 g) particles were added. The polymer was allowed to 
swell over the course of 24 hours. PMMAVP-Na2PtCl4 catalyst was obtained after the 
solution was dried under vacuum
2.2.1.10 Preparation of PMMAVP Supported Na3lrCl6  
(PMMAVP-Na3lrCl6) Catalyst
The procedure used for the preparation of PMMAVP-Na2PtCl4 catalyst was 
employed to prepare PMMAVP-NasIrCle catalyst.
2.2.2 Characterisation of PVP-RhCls Catalyst
Polymer supported PVP-RhClg and PMAn-RhClg catalysts were analysed by
X-ray Photoelectron Spectroscopy (XPS). XPS is sometimes called electron 
spectroscopy for chemical analysis (ESCA).
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XPS involves the measurement of binding energies of electrons ejected in 
reactions of a molecule with a monoenergetic beam of soft X-rays. The binding energy 
of an electron is partially determined by the number and location of electrons in the 
valence shell of the atom Anything which can alter the electron density around the 
atom can affect the Idnetic energy of the ejected electron. The chemical groups which 
are bound to the atom can change the electron density and cause a chemical shift in the 
XPS peak position. So, if a catalyst is supported on a polymer, there must be some 
difference in the electron bindiug energies before and after support has been put m 
place.
Normally, freshly ground samples of polymers and polymer supported catalysts 
were attached to sample holders using double-stick paper. Then the binding energies 
of interested elements were measured using Mg Ka^ ^  with photon energy of 1486.6
eV as X-ray source (X-ray Photoelectron Spectrometer ESCALAB MKII, VG
Scientific Ltd).
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The compounds used for the labelling studies are shown in Fig. 2. 7.
(1) Benzoic acid 
COOH (2) Sodium benzoate COONa
(3) Procanam ide hydrochloride
HgN ■CH2CH3•CONHCHgCHgNC • HCl
(4) Salicylic acid 
COOH
(5) Procainamide (6) Antypyrine
HgN CONHCHgCHgN CH2CH3
CH.
CH.
Fig. 2 .7  Chemical Structures of the Compounds Used in the Labelling
Work
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(7) Phenacetin (8) Aminopyrlne
CH,CH,0 r  V NHCOCH, CH. ,CH,
'CH,
(9) Flufenamic acid
.COOH
NH
CF.
(10) Hippuric acid
-CONHCHgCOOH
(11) Phenylbutazone (12) Phthalylsulfacetamide
OOH
OONH
t-Bu
(13) T o luene
O K
Fig. 2.7 (cont.) Chemical Structures of the Compounds Used in the 
Labelling Work
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2.2.3 Deuteriation of Substrates
In a typical reaction, a substrate (26 - 40 mg), solvent (0.5 - 1.0 ml) if 
necessary, polymer supported catalyst (20 - 203 mg) and deuteriated water (0.5 - 1.5 
ml) were added to a thick-walled Pyrex glass vial (5-10 ml). The vial was cooled with 
liquid nitrogen before being evacuated and flame sealed. Then the vial was placed in 
an oil bath controlled at the desired ten^erature. After being heated for a period of 
time, the vial was cooled with liquid nitrogen and cut open. The solid catalyst was 
removed by filtration before the product was isolated and purified by one of the 
following procedures.
2.2.4 Isolation and Purification of Deuteriated 
Substrates
2.2.4.1 Isolation and Purification of Benzoic Acid and Sodium 
Benzoate
The filtrate was poured into a solution of hydrochloric acid (4M, 5 ml) and 
extracted into ethyl acetate (3x10 ml). The solution was washed with water (2x10 ml), 
and extracted into a potassium hydroxide solution (IM, 3x2 ml). The latter fraction 
was re-acidified with hydrochloric acid (4M, 5 ml) and the product extracted into ethyl 
acetate (3x10 ml). The ethyl acetate extract was washed with water (2 ml), dried over 
anhydrous sodium sulphate and evaporated to dryness using a rotary evaporator.
2.2.4.2 Isolation and Purification of Procainamide Hydrochloride
The contents of the reaction vial were washed with water (2 ml) and potassium 
hydroxide solution (IM, 2 ml). The washings were filtered and the filtrates were 
combined before being extracted with ethyl acetate (3x10 ml). The latter solution was 
extracted with hydrochloric acid solution(4M, 3x2 ml). To the cooled solution, 
potassium hydroxide pellets were added until the product precipitated out (the pH 
value of the solution was about 11). After the product was extracted into ethyl acetate 
(3x10 ml), the solution was washed with water (2x2 ml). The solvent was removed by
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rotary evaporation before hydrochloric acid (4M, 0 .1  ml) and methanol (1 ml) were 
added. Finally, the product was dried under vacuum
2.2.4.3 Isolation and Purification of Salicylic Acid, Flufenamic 
Acid and Antipyrine by TLC
The contents of the reaction vial were washed with methanol (10 ml). The 
washing was filtered and the filtrates were combined before the solvents were 
separated off by rotary filtration.
A 200x200x0.25 mm F254 analytical silica gel glass-backed TLC plate was 
blown with nitrogen gas to eject loose silica gel firom the surface before applying a 
methanohc solution of the sangle to the base fine on the plate. A known standard 
saicple was placed at two ends of the base fine. The TLC plate was developed over a 
period of time in a tank containing a developing solvent and kept in a fume cupboard. 
After drying, the desired strip was marked with a pencil by viewing the plate with a 
LTV l i^ t  (wavelength 254 nm) comparing to the 1^ value to that of the standard 
sample on the plate.
A modified glass test tube was used to collect the silica gel. The narrow end of 
the tube at the bottom was plugged with cotton wool and connected to a length of 
rubber tubing which was attached to a water pump. An L-shaped adapter with a small 
end was fitted at the ground joint of the test tube. With the water pump on, the silica 
strip containing the pure sample was removed firom the TLC plate by scraping the 
small end of the L-shaped adapter across the TLC plate. The sample was then eluted 
firom the silica in the test tube using methanol. The methanol solution was filtered 
through a glass wool plug contained in a glass Pasteur pipette and evaporated using a 
rotary evaporator to leave a purified sample.
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The TLC developing solvents and Rf values are listed in Table 2. 2.
Table 2. 2 TLC Developing solvents and Rf values for the Purification of
Salicylic Acid, Flufenamic Acid and Antipyrine
Compound TLC solvent Rf value
Salicyhc acid chloroform : methanol : acetic acid : water 
40 : 20 : 2 : 10
0.43
Flufenamic
acid
cyclohexane : chloroform : methanol : acetic acid 
60 : 30 : 3 : 1
0.46
Antipyrine ethanol : ethyl acetate : chloroform 
2 : 1 :1
0 .6 6
2.2.5 Deuteriation Conditions Using Polymer 
Supported Catalysts
2.2.5.1 Deuteriation of Benzoic Acid and Sodium Benzoate Using
PVP-RhCls Catalyst
2.2.5.1.1 Using Different Solvents under Different Conditions
Several solvents were used in the deuteriation of benzoic acid and sodium 
benzoate under the conditions listed below.
Table 2 .3  Deuteriation of Benzoic Acid and Sodium Benzoate Using 
Different Solvents under Different Conditions
Batch
No
Compound Weight
(mg)
PVP-
RhCls
(mg)
D2O
(ml)
Temp
CC)
Solvent
(ml)
Reaction
time
(hr)
1 Benzoic acid 26 203 1.5 118 DMF, 0.75 23
2 Benzoic acid 29 52 0.75 118 DMSO
0.75
15
3 Benzoic acid 29 53 0.75 118 — 15
4 Benzoic acid 40 10 1 0.5 1 1 0 Dioxane
1 .0
24
5 Benzoic acid 40 1 0 2 0.5 1 1 0 DMF, 0.5 24
6 Sodium
benzoate
38 52 0.75 1 1 0 Ethanol
0.5
18
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2.2.5.1.2 At Different Temperatures
Benzoic acid was deuteriated at different temperatures using the conditions 
listed below.
Table 2. 4 Deuteriation of Benzoic Acid at Different Temperatures
Batch
No
Compound Weight
(mg)
PVP-
RhCls
(mg)
D2O
(ml)
Temp
(°C)
Solvent
(ml)
Reaction
time
(hr)
7 Benzoic acid 28 52 0.75 118 DMF, 0.75 15
8 Benzoic acid 29 52 0.75 8 6 DMF, 0.75 15
9 Benzoic acid 29 52 0.75 46 DMF, 0.75 15
2.2.5.1.3 Different Reaction Times
Table 2. 5 Deuteriation of Benzoic Acid for Different Periods of Time
Batch
No
Compound Weight
(mg)
PVP-
RhCls
(mg)
D2O
(ml)
Temp
CC)
Solvent
(ml)
Reaction
time
(hr)
1 0 Benzoic acid 27 54 0.75 118 DMF, 0.75 1
11 Benzoic acid 28 53 0.75 118 DMF, 0.75 4
1 2 Benzoic acid 29 53 0.75 118 DMF, 0.75 8
2.2.5,2 Deuteriation of Selected Drugs Using PVP-RhClg Catalyst 
Table 2. 6  Deuteriation of Selected Drugs Using PVP-RhCls Catalyst
Batch
No
Compound Weight
(mg)
PVP-
RhCls
(mg)
D2 0
(ml)
Temp
CC)
Solvent
(ml)
Reaction
time
(hr)
13 Procainamide
hydrochloride
30 1 0 0 0.5 1 1 0 DMF, 0.5 24
14 Antipyrine 47 1 0 0 0.5 1 1 0 DMF, 0.5 24
15 Salicylic acid 35 1 0 0 0.5 1 1 0 DMF, 0.5 24
56
2.2.5.3 Deuteriation of Benzoic Acid and Sodium Benzoate Using 
PMAn-RhCls Catalyst
Table 2 .7  Deuteriation of Benzoic Acid and Sodium Benzoate Using PMAn- 
RhCls Catalyst
Batch
No
Compound Weight
(mg)
PMAn-
RhCb
(mg)
D2 0
(ml)
Temp
C Q
Solvent
(ml)
Reaction
time
(hr)
16 Benzoic acid 30 1 0 0 0.5 1 1 0 DMF, 0.5 2 0
17 Sodium
benzoate
34 1 0 0 1 .0 1 1 0 DMF, 1 .0 2 0
2.2.S.4 Deuteriation of Benzoic Acid Using PHM-RI1CI3  Catalyst 
Table 2. 8  Deuteriation of Benzoic Acid Using PHM-RhCL Catalyst
Batch
No
Compound Weight
(mg)
PBM-
RhCb
(mg)
D2 0
(ml)
Temp
(°C)
Solvent
(ml)
Reaction
time
(hr)
18 Benzoic acid 30 1 0 0 1 .0 1 1 0 DMF, 0.5 48
2.2.S.5 Deuteriation of Selected Substrates Using PMMAVP 
Supported Catalysts
Table 2 . 9 Deuteriation of Selected Substrates Using PMMAVP Supported 
Catalysts
Batch
No
Compound Weight
(mg)
Supported
catalyst
(mg)
D2O
(ml)
Temp
CC)
Solvent
(ml)
Reaction
time
(hr)
19 Benzoic
acid
30 PMMAVP- 
RhCls ,100
0.5 110 DMF
0.5
24
20 Benzoic
acid
30 PMMAVP-
Na2PdCl4,100
0.5 110 DMF
0.5
24
21 Benzoic
acid
30 PMMAVP-
K2PtO4,100
0.5 110 DMF
0.5
24
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Table 2. 9 (cont.) Deuteriation of Selected Substrates Using PMMAVP 
Supported Catalysts
Batch
No
Compound Weight
(mg)
Supported
catalyst
(mg)
D2O
(ml)
Temp
(°C)
Solvent
(ml)
Reaction
time
(hr)
22 Benzoic
acid
30 PMMAVP-
Ru(acac)3 ,1 0 0
0.5 1 1 0 DMF
0.5
24
23 Flufenamic
acid
30 PMMAVP-
Ru(acac)3 ,1 0 0
0.5 1 1 0 DMF
0.5
24
24 Benzoic
acid
30 PMMAVP-
Na2PtCl4 ,1 0 0
0.5 1 1 0 DMF
0.5
24
25 Benzoic
acid
30 PMMAVP-
Na3lrCl6 ,1 0 0
0.5 1 1 0 DMF
0.5
24
26 Antipyrine 30 PMMAVP-
NaglrCklOO
0.5 1 1 0 DMF
0.5
24
27 Flufenamic
acid
30 PMMAVP-
Na3lrCl6 ,1 0 0
0.5 1 1 0 DMF
0.5
24
28 Toluene 0.5 ml PMMAVP-
NazPtC^lOO
0.5 1 2 0 DMF
0.5
72
29 Toluene 0.5 ml PMMAVP-
Na3lrCl6 ,1 0 0
0.5 1 2 0 DMF
0.5
72
30 Benzoic
acid
30 PMMAVP-
Na3lrCl6 ,1 0 0
0.5 1 2 0 DMF
0.5
2 2
2.2.6 Deuterium NMR Analysis
The labelled positions and regiospecr&cities of the deuteriated confound were 
ascertained by ^ H-NMR spectroscopy (Broker AC-300E, operating at 46 MHz).
2.2.7 Assessment of Degree of Deuterium 
Incorporation
When a hydrogen atom in a compound is replaced with a deuterium atom, the 
integration ratio of the proton signal to other proton signal(s) in the ^H-NMR spectrum 
will change. The h i^er the deuterium incorporation, the greater the decrease in the
58
integration ratio. In the limit when all the hydrogen atoms at a given position in a 
sanq)le are replaced by deuterium, no signal will appear at the position deuteriated.
The deuterium incorporation percentage was calculated using the following 
equation
^^^xlO O %lo
where lo —  Integration ratio of the signal from the specified position before labelling 
to that from other position(s) which can not be labelled
Id —  Integration ratio of the signal from the specified position after labelling to 
that from the same other position(s) which can not be labelled.
2.2.8 Tritiation of Substrates
hr a typical reaction, a substrate (15 - 58 mg), solvent (0.5 - 1.0 ml), polymer 
supported catalyst ( 2 2  - 142 mg) and tritiated water (5 - 1 0  pi, 12.4 mCi/ml - 2 0  
CFml) were inserted in a thick-walled Pyrex glass vial (5-10 ml). The vial was cooled 
with liquid nitrogen before being evacuated and frame sealed. Then the vial was placed 
in an oil bath at the desired ten^erature. After heating for a given time, the vial was 
withdrawn and cooled with liquid nitrogen and opened. The product was separated 
from the solid catalyst and purified by one of the following procedures.
2.2.9 Isolation and Purification of Tritiated 
Substrates
2.2.9.1 Isolation and Purification of Benzoic Acid, Sodium
Benzoate, Procainamide Hydrochloride, Procainamide, 
Salicylic Acid, Flufenamic Acid and Antipyrine
These tritiated substrates were isolated and purified using the procedures 
employed for the isolation and purification of the deuteriated analogues.
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2.2.9,2 Isolation and Purification of Tritiated Aminopyrlne, 
Phenacetin and Hippuric Acid
Similar procedures used in the isolation and purification of deuteriated salicylic 
acid, flufenamic acid and antipyrine were enaployed to obtain the tritiated analogues, 
using the TLC developing solvents shown in the following table.
Table 2. 1 0  TLC developing solvents for Aminopyrine, phenacetin and 
Hippuric Acid
Compound TLC solvent Rf value
Aminopyrine methanol : chloroform = 1 ; 10 0.75
Phenacetin ethyl acetate : toluene = 1 : 1 0.43
Hippuric acid methanol ; toluene : acetic acid : water = 30 : 50 : 2 : 2 0.49
2.2.10 Tritiation Conditions Using Polymer 
Supported Catalysts
2.2.10.1 Tritiation of Benzoic Acid Using HTO at High Specific 
Activity
Table 2.11 Tritiation of Benzoic Acid Using HTO at High Specific Activity
Batch
No
Compound Weight(mg) PVP-RhCL
(mg)
HTO 
( 2 0  Ci/ml)
Temp
CC)
DMF
(ml)
Reaction
time
(hr)
1 Benzoic acid 30 52 5pl 
1 0 0  mCi
108 0.5 2 2
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2.2.10.2 Tritiation of Sodium Benzoate Using Different Quantities 
of PVP-RhCb Catalyst
Table 2.12 Tritiation of Sodium Benzoate Using Different Quantities of PVP- 
RhCls Catalyst
Batch
No
Compound Weight
(mg)
PVP-
RhCls
(mg)
HTO
( 2  Ci/ml)
Temp
CC)
Ethanol
(ml)
Reaction
time
(hr)
2 Sodium
benzoate
36 2 2 5pl
lOmCi
1 1 0 0.5 23
3 Sodium
benzoate
36 62 5 pi 
lOmCi
1 1 0 0.5 23
4 Sodium
Benzoate
36 1 0 1 5pl 
10 mCi
1 1 0 0.5 23
5 Sodium
benzoate
36 142 5pl
lOmCi
1 1 0 0.5 23
2.2.10.3 Tritiation of Sodium Benzoate for Different Reaction 
Times
Table 2.13 Tritiation of Sodium Benzoate for Different Reaction Times
Batch
No
Compound Weight
(mg)
PVP-
RhCls
(mg)
HTO
( 2  Ci/ml)
Temp
(°C)
Ethanol
(ml)
Reaction
time
(hr)
6 Sodium
benzoate
36 60 5 pi 
10 mCi
1 1 0 1 .0 1
7 Sodium
benzoate
36 60 5pl
lOmCi
1 1 0 1 .0 4
8 Sodium
Benzoate
36 60 5pl
lOmCi
1 1 0 1 ,0 8
9 Sodium
benzoate
36 60 5pl
lOmCi
1 1 0 1 .0 16
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2.2.10.4 Tritiation of Sodium Benzoate at Different Temperatures 
Table 2.14 Tritiation of Sodium Benzoate at Different Temperatures
Batch
No
Compound Weight
(mg)
PVP-
RhCls
(mg)
HTO
(2 Ci/ml)
Temp
CC)
Ethanol
(ml)
Reaction
time
(hr)
1 0 Sodium
benzoate
36 62 5pl
lOmCi
70 1 .0 23
11 Sodium
benzoate
36 61 5pl
lOmCi
80 1 .0 23
12 Sodium
Benzoate
36 63 5 pi 
lOmCi
90 1 .0 23
13 Sodium
benzoate
36 62 5pl
lOmCi
1 0 0 1 .0 23
2.2.10.5 Tritiation of Benzoic Acid under Different Conditions 
Table 2.15 Tritiation of Benzoic Acid under Different Conditions
Batch
No
Compound Weight
(mg)
PVP-
RhCls
(mg)
HTO Temp
CC)
Solvent
(ml)
Reaction
time
(hr)
14 Benzoic
acid
40 1 0 0 10pl,124pCi
(12.4mCi/ml)
1 1 0 Dioxane
1 .0
24
15 Benzoic
acid
31 1 0 1 10pl,124pCi
(12.4mCi/ml)
1 1 0 DMF
1 .0
24
16 Benzoic
acid
31 RhCls
30
10pl,124pCi 
(12.4 mCi/ml)
1 1 0 DMF
1 .0
24
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2.2.11 Tritiation of Selected Drugs Using PVP-RhCIs
Catalyst
Table 2.16 Tritiation of Selected Drugs Using PVP-RhCls Catalyst
Batch
No
Compound Weight
(mg)
PVP-
RhCla
(mg)
HTO Temp
(°C)
Solvent
(ml)
Reaction
time
(hr)
17 Procainamide 29 1 0 0 10pl,200mCi
(20Ci/ml)
1 1 0 DMF
1 .0
15
18 Procainamide 29 1 0 0 10pl,200mCi
(20Ci/ml)
1 1 0 DMF
1 .0
75
19 Antipyrine 47 1 0 0 10pl,200mCi
(20Ci/ml)
1 1 0 DMF
1 .0
24
2 0 Aminopyrme 58 1 0 0 10pI,200mCi
(20Ci/ml)
1 1 0 DMF
1 .0
24
2 1 Phenacetin 30 1 0 0 10pl,200mCi
(20Ci/ml)
1 1 0 DMF
1 .0
24
2 2 Flufenamic acid 30 1 0 0 10pl,200mCi
(20Ci/ml)
1 1 0 DMF
1 .0
24
23 Hippuric acid 30 1 0 0 10pl,200mCi
(20Ci/ml)
1 1 0 DMF
1 .0
24
24 Salicylic acid 30 1 0 0 10pl,200mCi
(20Ci/ml)
1 1 0 DMF
1 .0
24
25 Phenylbutazone 30 1 0 0 10pl,200mCi
(20Ci/ml)
1 1 0 DMF
1 .0
24
26 Phthalyl
sulfacetamide
30 1 0 0 10pl,200mCi
(20Ci/ml)
1 1 0 DMF
1 .0
24
27 Flufenamic acid 15 1 0 0 10pl,200mCi
(20Ci/ml)
1 1 0 DMF
0.5
168
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2,2.12 Tritiation of Procainamide Using RhCls
Catalyst
Table 2.17 Tritiation of Procainamide Using BI1CI3 Catalyst
Batch
No
Compound Weight
(mg)
RhCla
(mg)
HTO Temp
(°C)
Solvent
(ml)
Reaction
time
(hr)
28 Procainamide 30 29 10pl,200mCi
(20Ci/ml)
1 1 0 DMF
1 .0
15
29 Procainamide 30 29 10jrl,200mCi
(20Ci/ml)
1 1 0 DMF
1 .0
75
2.2,13 Tritiation of Flufenamic Acid Using PHM- 
RhCla Catalyst
Table 2.18 Tritiation of Flufenamic Acid Using PHM-RhCls Catalyst
Batch
No
Compound Weight
(mg)
PHM-
RhCls
(mg)
HTO Temp
CC)
Solvent
(ml)
Reaction
time
(hr)
30 Flufenamic
acid
30 1 0 0 10pl,200mCi
(20Ci/ml)
1 1 0 DMF
1 .0
24
2.2.14 Analysis of Tritiated Compounds
2.2.14.1 Measurement of the Specific Activities of Tritium
Labelled Compounds
The degree of tritium incorporation was determined using liquid scintillation 
counting. Typically the tritium labelled compound was dissolved in methanol (10 ml) 
and an accurately known volume of the solution was added to a scintillation counting 
vial containing scintillator (a 0.4 % w/v solution of 2,6-diphenyloxazole (PPO) in 
toluene, or Ecoscint A, from National Diagnostics, 5 or 1 0  ml). The radioactivity was 
counted using a Beckmann LSI800 Liquid Scintillation Counter calibrated for accurate 
DPM (disintegrations per minute) measurement. The specific activity of the tritium
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labelled compound was calculated from the ratio of the radioactivity of the product and 
the weight.
2.2.14.2 Tritium NMR Analysis
In all of the cases where the extent of tritium incorporation was high (at the 
millicurie level) the positions labelled were detennined using ^H-NMR spectroscopy, 
using a Broker AC-300E spectrometer. In this case the tritium labelled compound was 
dissolved in a deuteriated solvent and the solution was transferred to a Teflon tube (4 
mm diameter), which was then put into a glass screw-capped NMR tube (5 mm 
diameter). Typically, 128 transients and 30000 transients were collected for ^H-NMR 
and ^H-NMR respectively. The spectrometer was operated at 320 MHz with broad 
band decoupling.
2.2.14.3 Radiochemical Purity Measurement
The radiochemical purities of the samples were determined by 
radiochromatogram scanning (Berthold LB2842 Radiochromatogram Scanner) of the 
TLC plates (fluorescent silica gel pre-coated). Known standards were used on the TLC 
plates for visual comparison with the radiolabelled samples.
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2.3 Results and Discussions
2.3.1 Results
2.3.1.1 Characterisation of PVP-RhClg and PMAn-RhCy Using 
XPS
Table 2. 19 reports the binding energies of Rh3d,s/2 Oi^and Nisin PVP, PVP- 
RhCls, PMAn and PMAn-RhCls measured by XPS.
Table 2,19 Binding Energies Obtained by XPS
Sample Binding energy Eb(eV)
Rh3d,5/2 Ols Nis
RhCl3*3%0 310.2
PVP 530.8 399.6
PVP-RhCls 307.7 531.6 399.6
PMAn 533.0
PMAn-RhCh 310.0 533.4
6 6
2.3.1.2 Deuteriation Using Polymer Supported Catalysts
2.3.1.2.1 Deuteriation of Benzoic Acid and Sodium Benzoate Using 
PVP-RhCb Catalyst
2.3.1.2.1.1 Using Different Solvents under Different Conditions
Table 2. 20 Deuteriation of Benzoic Acid and Sodium Benzoate Using
Different Solvents under the Conditions Shown in Table 2 . 3
Batch
No
Compound
No
Structure Chemical
shift
(ppm)
Assignment Regiospecificity
1 (1) a
a
7.94 a 1 0 0 %
2 (1 ) a
-----COOH
a
3 (1) __ a
-----COOH
a
4 (1) a
a
7.94 a 1 0 0 %
5 (1 ) a
< ^ ~ ^ C O O H
a
7.94 a 1 0 0 %
6 (2 )
\ \  /}----- COONa
a
7.94 a 1 0 0 %
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2.3.1.2.1.2 At Different Temperatures
Table 2. 21 Deuteriation Results of Benzoic Acid at Different Temperatures
Batch
No
structure Temp
CC)
Chemical 
shift (ppm)
Assignment RegiospeciBcity
7 a
a
COOH
118 7.94 a 100%
8 a
a
COOH
8 6 7.94 a 1 00%
9 o-
a
COOH
46
2.3.1.2.1.3 Different Reaction Times
Table 2. 22 Deuteriation of Benzoic Acid for Different Periods of Time
Batch
No
structure Reaction time 
(hr)
Chemical 
shift (ppm)
Assignment Regiospecificity
10
d -
a
COOH
1 7.94 a 100%
11 a
O
a
— COOH
4 7.94 a 100%
12
d -
a
COOH
8 7.94 a 100%
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2.3.1.2.2 Deuteriation of Selected Drugs Using PVP-RhCIs Catalyst
Table 2.23 Deuteriation of Selected Drugs Using PVT-RhCls Catalyst
Structure & 
Compound No
Batch
No
Chemical Assignment Regio- 
shift specificity
(ppm)
7.94 100%CONH(CH2)2N(Et)2-HCI
CH.
63%7.3
37%5.3
7.7 73%COOH
6.8 b+c 27%
2.3.1.2.3 Deuteriation of Benzoic Acid and Sodium Benzoate Using
PMAn-RhCI3 Catalyst
Table 2.24 Deuteriation of Benzoic Acid and Sodium Benzoate Using PMAn-
RhCls Catalyst
Batch
No
structure Chemical 
shift (ppm)
Assignment Regio­
specificity
Incorporation
16 ___ a
COOH
a
7.94 a 1 0 0 % 1 1 %
17 / = \ _/ \----- COONa
a
7.94 a 1 0 0 % 35%
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2.3.1.2.4 Deuteriation of Benzoic Acid Using PHM-RhCIs Catalyst
Table 2.25 Deuteriation of Benzoic Acid Using PHM-RhCU Catalyst
Batch structure Chemical Assignment Regio­ Incorporation
No shift (ppm) specificity
18
a
COOH
a
7.94 a 1 0 0 % 60%
2.3.1.2.5 Deuteriation of Selected Substrates Using PMMAVP 
Supported Catalysts
Table 2 . 26 Deuteriation of Selected Substrates Using PMMAVP Supported 
Catalysts
Batch
No
Structure & 
Compound No
Chemical Assign- Regio- Incorpora
shift (ppm) ment specificity -tion
7.94 100% 58%COOH
(1)a
20 COOH
COOH
(1)a
22 100%7.94 5.5%COOH
(1)a
.COOH
NH
(9) OF.
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Table 2.26 (cont.) Deuteriation of Selected Substrates Using PMMAVP 
Supported Catalysts
Batch
No
Chemical Assign- 
shift (ppm) ment
Regio­
specificity
24 100%7.5COOH
7.94 84%COOH
7.5 14%
CH.
26 N— I 5.3 100%
,GOOH
NH
‘OF,
CH. 7.1, 7.2 41%
(13) 59%2.2
CH.
(13)
7.94 100%COOH
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2.3.1.3 Tritiations Using Polymer Supported Catalysts
2.3.1.3.1 Tritlation of Benzoic Acid Using HTO at High Specific 
Activity
Table 2.27 Tritlation of Benzoic Acid Using HTO at High Specific Activity
Batch
No
Structure & 
Compound No
Chemical 
shift (ppm)
Assign­
ment
Regio­
specificity
Specific activity 
(mCi/mmole)
1
a (1)
8 .0 a 1 0 0 % 0.72
2.3.1.3.2 Tritiation of Sodium Benzoate Using Different Quantities of 
PVP-RhCIs Catalyst
Table 2. 28 Tritiation of Sodium Benzoate Using Different Quantities of PVP- 
RhCls Catalyst
Batch
No
Compound
No
Structure PVP-RhCIa
(mg)
Specific activity 
(mCi/mmole)
2 (2 ) ^  ^ ------COONa 2 2 0.46
3 (2 ) ^ ^ ------COONa 62 0.49
4 (2 ) ^  ^ ------COONa 1 0 1 0.63
5 (2 ) ^  ^ ------COONa 142 0.69
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2.3.1.3.3 Tritiation of Sodium Benzoate for Different Reaction Times
Table 2.29 Tritiation of Sodium Benzoate for Different Reaction Times
Batch
No
Compound
No
Structure Reaction 
time (hr)
Specific activity 
(mCi/mmole)
6 (2 ) O COONa 1 0.077
7 (2 ) O COONa 4 0.158
8 (2 ) o COONa 8 0.413
9 (2 ) o- COONa 16 0.450
2.3.1.3.4 Tritiation of Sodium Benzoate at Different Temperatures
Table 2.30 Tritiation of Sodium Benzoate at Different Temperatures
Batch
No
Compound
No
Structure Temperatme
CC)
Specific activity 
(mCi/mmole)
10 (2 ) O— COONa 70 0.070
11 (2 ) O COONa 80 0.198
1 2 (2 ) a COONa 90 0.372
13 (2 ) o COONa 1 0 0 0.461
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2.3.1.3.5 Tritiation of Benzoic Acid under Different Conditions 
Table 2,31 Tritiation of Benzoic Acid under Different Conditions
Batch
No
Compound
No
Catalyst
M s)
Solvent
(ml)
Specific activity 
(pCi/mmole)
14 (1) PVP-RhCls Dioxane 7.6100 1.0
15 (1) PVP-RhCls DMF 25^101 1.0
16 (1) RhCls DMF 53.830 1.0
2.3.1.3.6 Tritiation of Selected Drugs Using PVP-RhCIs Catalyst 
Table 2.32 Tritiation of Selected Drugs Using PVP-RhCb Catalyst
Batch
No
Structure & 
Compound No
Chemical Assign- Regio- 
shift ment specificity 
(ppm)
Specific
activity
(mCi/mmole)
7.6 100% 8.9
7.6 100% 13.5
CH.
5.4 95%
34.5
7.4 5%
CH. 2.2 9%
2.7 55% 6.9
‘CH. 7.4 36%
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Table 2.32 (cont.) Tritiation of Selected Drugs Using PVF-RhCls Catalyst
Structure & 
Compound No
Chemical Assign- Regio- 
shift ment specificity 
(ppm)
Specific
activity
(mCi/mmole)
Batch
No
NHCOCH. 7.6 100% 2.6
.COOH
NH 100%8.0 16.8
‘OF.
3.8 82%CONHCH,COOH 16.9(10) 18%7.9
7.78 a
6.73+6.75 b+c
38%
62%COOH 9.2
decomposed
t-Bu (11)
OOH
decomposed
CONH
(12)
.COOH
NH 100%8.0 20.8
‘CP.
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2.3.1.3.7 Tritiation of Procainamide Using RhCb Catalyst 
Table 2, 33 Tritiation of Procainamide Using RhCIs Catalyst
Batch
No
Structure & 
Compound No
Chemical
shift
(ppm)
Assign­
ment
Regio­
specificity
Specific
activity
(mCi/mmole)
28
H^ N CONH(CH2)2N(Et)2 7.59 a 10% 4.8
b a (5) 6.57 b 90%
29 HgN ■ryC0NH(CH2)2N(Et)2 7J^ a 45% 10.5
b a (5) 6.57 b 55%
2.3.1.3.8 Tritiation of Flufenamic Acid Using PHM-RhCIs Catalyst
Table 2. 34 Tritiation of Flufenamic Acid Using PHM-RhCls Catalyst
Batch 
No
Structure & 
Compound No
Chemical Assign- Regio- Specific
shift ment specificity activity
(ppm) (mCi/mmole)
COOH
100%
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2.3.2 Discussions
It can be seen from the binding energy table (Table 2. 19) that the binding 
energy of Ois in PVP-RhCls (531.6 eV) is larger than that in PVP (530.8 eV). 
However, the binding energy of Rhsd, 5/2 in PVP-RhCh (307.7 eV) is less than that in 
RhClsHzO (310.2 eV). It means that some electrons moved from oxygen atoms 
towards rhodium atoms when the complex PVP-RhCls formed. That is to say, polymer 
supported PVP-RhCls catalyst has been formed. It is very clear, by comparison of the 
XPS spectrum of PVP ( Fig. 2.12, page 83 ) and that of PVP-RhCls (Fig. 2.13, page 
83), that rhodium trichloride has been supported on PVP polymer.
Table 2.19 also tells us that the binding energies of Rhsd, 5/2 and Ois change in a 
similar way, as in the case of PVP-RhCls, before and after immobilisation. The XPS 
spectrum of PMAn (Fig. 2.14, page 84) and that of PMAn-RhCls (Fig. 2.15, page 84) 
also indicate that polymer supported catalyst, PMAn-RhClshas been obtained.
When the deuteriation reaction was carried out using PVP-RhCls as catalyst at 
110 - 118°C for 15 - 24 hours, different solvents (see Table 2. 3 and Table 2. 20) 
caused different results. When DMF and dioxane were used as solvents, benzoic acid 
was deuteriated. Sodium benzoate was labelled using ethanol as solvent. In all the 
cases, the substrates were labelled with 100% regiospecificity at the ortho 
positions (see Table 2. 20), But when DMSO was used as solvent, or no solvent was 
used, benzoic acid was not deuteriated. The reason for that is when DMSO was used, 
it poisoned the catalyst since DMSO contains sulphur. Benzoic acid does not dissolve 
in deuteriated water (used as isotope source), so the deuteriation reaction did not take 
place in this solvent.
Benzoic acid was deuteriated when the temperature was 118°C and 86°C but 
not at 46°C, at least not in 15 hours (Table 2. 21). At the h i^er tençerature the 
regiospecificity was 100% (Table 2. 21 and Table 2. 22).
Procainamide hydrochloride, antipyrine and salicyhc acid were deuteriated with 
different regiospecificities (see Table 2. 23), when using PVP-RhCls catalyst under the 
conditions hsted in Table 2. 6. Only procainamide hydrochloride was labelled with
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100% regiospecificity at one position, the others were labelled at two or three 
positions. Althou^ antipyrine was deuteriated at the ortho positions (position a) with 
63% regiospecificity, and sahcyHc acid with 73%, in both cases, the regiospecificities 
were higher than those obtained with homogeneous rhodium trichloride as catalyst. 
Under similar conditions (in Hesk’s work antipyrine was tritiated at the ortho
position with only 40% regiospecificity and salicylic acid with only 37%. This means 
that the catalytic regiospecific property of the catalyst, RhCls, was improved when it 
was supported on PVP polymer.
Not only PVP-RhCls, but also PMAn-RhCls, can be used as catalyst to prepare 
deuteriated benzoic acid and sodium benzoate specifically labelled at the oitho 
positions (see Table 2. 24), although different levels of incorporation were obtained.
Benzoic acid was deuteriated to a much higher incorporation (60 %), when 
PHM-RhCls catalyst was used (see Table 2. 25) for a longer period of time.
A similar level of deuterium incorporation was obtained when PMMAVP- 
RhCls was used to label benzoic acid (Batch 19 iu Table 2. 9 and Table 2. 26). But 
when another polymer supported catalyst, PMMAVP-Ru(acac)s was employed, the 
level of deuterium incorporation dropped to 5.5% (Batch 22 in Table 2. 9 and Table 
2. 26), whilst the catalyst was totally inactive for flufenamic acid (Batch 23, in Table 2. 
26). When PMMAVP-NazPdCL and PMMAVP-KzPtCh were tried under the same 
condition(Batch 20, 21 in Table 2. 9), no deuteriation of benzoic acid (Batch 20, 21 in 
Table 2. 26) took place. A different picture was presented when PMMAVP-Na2PtCl4 
was used to label benzoic acid. The substrate was deuteriated in the non-aromatic ring 
(position b, 100% regiospecificity, see Batch 24 in Table 2. 9 and Table 2. 26). 
PMMAVP-Na2PtCl4 was also active for the deuteriation of toluene, which was labelled 
at the aromatic ring and methyl positions (Batch 28 in Table 2. 26). Unlike PMMAVP- 
Na2PtCl4, PMMAVP-NasIrClô was inactive for the deuteriation of toluene (Batch 29 in 
Table 2. 26), and like PMMAVP-Ru(acac)3 it was also inactive for flufenamic acid 
(Batch 27 in Table 2. 26). When PMMAVP-NasIrCtj was used at 110°C, benzoic acid 
was deuteriated at the ortho position with only 84% regiospecificity (Batch 25 in Table 
2. 26). When the temperature rose to 120°C, it was deuteriated at the ortho position 
with 100% regiospecificity (Batch 30 in Table 2. 26). Antipyrine was deuteriated at
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position b with 100% regio^ecificity (Batch 26 in Table 2. 26) when PMMAVP- 
NasIrClô was used as catalyst. The substrate was labelled with 37% regiospecificity at 
position b and 63% at position a, when PVP-RhCls was employed (Batch 14 in Table 
2. 23).
When PVP-RhCls catalyst was enq)loyed to label benzoic acid with tritiated 
water as the isotope source, the same regiospecificity was observed. That is, benzoic 
acid was tritiated at the ortho position with 100% regiospecificity (see Table 2. 27).
The level of tritium incorporation (the specific activity of tritiated sodium 
benzoate) increased with the amount of PVP-RhCls used (see Table 2. 28). The 
specific activity of tritiated sodium benzoate increased as the reaction time increased 
(see Table 2. 29). The same situation happened when the reaction temperature 
increased. This can be seen fi:om Table 2. 30.
Not only DMF, but also dioxane can be used as solvent in the tritiation of 
benzoic acid (Batch 14 and 15 in Table 2. 31). The same result has aheady been 
obtained in the deuteriation reaction of benzoic acid. It also can be seen from Table 2. 
15 and Table 2.31 that under the same conditions, benzoic acid became labelled with 
different specific activities when different forms of catalyst was used. Lower specific 
activities were obtained with PVP-RhCls catalyst. There are two reasons for this: the 
amount of RhCls in PVP-RhCls (101 mg) was about 10 mg, less than the RhCls (30 
mg) used ia the reaction; the reaction was heterogeneous when PVP-RhCls catalyst 
was used so that it would take a longer time for the reaction to reach the equilibrium 
state.
As expected fi’om the result obtained in the deuteriation of procainamide 
hydrochloride using PVP-RhCls catalyst (see Batch 13 in Table 2. 23), procainamide 
could be tritiated at the ortho positions with 100% regiospecificity (see Batch 17 and 
18 in Table 2. 32). A higher specific activity was obtained when the tritiation reaction 
was carried out for a longer time.
Antipyrine was tritiated with a different regiospecificity to that obtained in the 
deuteriation of antipyrine when PVP-RhCls was used . In the tritiation reaction.
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position b was labelled with. 95 % regiospecificity (Batch 19, m Table 2. 32), while in 
the deuteriation reaction, 37% was achieved (Batch 14, Table 2. 23).
Three positions in aminopyiine were tritiated (Batch 20 in Table 2. 32), while 
phenacetin was labelled at position a with 100 % regiospecificity (Batch 21, Table 2. 
32).
The specific activity of tritiated fiufenamic acid increased slightly from 16.8 
mCi/mmole to 20.8 mCi/mmole (Batch 22 and 27 in Table 2. 32) when the reaction 
time was increased from 24 hours to 168 hours (Batch 22 and 27 in Table 2. 16), while 
the regio^ecificity remained at 100%.
Another example of tritiation with less than 100% regiospecificity is the base of 
hippuric acid, which was tritiated with 82% regiospecificity at the ortho positions 
(Batch 23 in Table 2. 32).
Two compounds, phenylbutazone and phthalylsidfacetamide, decomposed 
under the reaction conditions.
Unlike the tritiation reaction of procainamide using PVP-RhCls catalyst, 
procainamide was tritiated with only 10% regiospecificity at position a, when RhCls 
was employed as catalyst, although the regiospecificity climbed to 45 % when the 
reaction time was increased to 75 hours (see Batch 28 and 29 in Table 2. 17 and Table
2. 33).
Flufenamic acid was tritiated at the ortho position with 100 % regiospecificity 
when both PVP-RhCls and PHM-RhCls were enployed as catalysts (see Batch 22, 
Table 2. 32 and Batch 30, Table 2. 34) respectively.
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Fig. 2. 9 XPS Spectrum of Rhsd 5/2 in PVP-RhCls
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Fig. 2.17 H-NMR (^H-Decoupled) Spectrum of ^ H-Benzoic Acid
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Fig. 2. 25 H-NMR (^H-Decoupled) Spectrum of ^ H-Benzoic Acid
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Fig. 2.27 H-NMR (^H-Decoupled) Spectrum of ^ H-Procainamide
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Fig. 2. 29 H-NMR ('H-Decoupled) Spectrum of ^ H-Antipyrine
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Fig. 2.31 H-NMR (^H-Decoupled) Spectrum of ^ H-Aminopyrine
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Fig. 2.35 H-NMR (^H-Decoupled) Spectrum of ^ H-Flufenamic Acid
94
mi.MRR Of Hl-Mirrumc nCtOCflSOSCISSi U  06-OnS0.^Vf-»KCtJlS«
:  i . t  % \.A ;  \  -• A :
Fig. 2. 36 H NMR Spectrum of ^ H-Eüppuric Acid
m ^ u n n  o r  Wl.MlfPURIC ACtQ(ISISI79Sl IN 06 0MS0.fVP.RMCL5(S:
reesesst.zos
OATC JS-3-9S rjRC 77:S8
C O N H C H 2 COOH
Fig. 2.37 H-NMR (*H-Decoupled) Spectrum of ^ H-Hippuric Acid
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3.1 Introduction
Deuteriated and tritiated products are important in the life sciences^ The 
most widely applied synthetic methods for the preparation of deuteriated and 
tritiated compounds are (1) hydrogenation^; (2) dehalogenation (3) reduction 
with deuteriated or tritiated metal hydrides^ .
Compounds containing unsaturated groups other than carbon-carbon 
bonds, such as carboxylic acids, esters, aldehydes, ketones and nitiiles, can be 
reduced with deuteriated or tritiated metal hydrides to form isotopically labelled 
compounds, which are specifically labelled on the carbon atom forming the 
unsaturated group.
The most widely used tritiated metal hydrides are sodium borotritide, 
lithium borotritide and lithium aluminiumtritide. Sodium or lithium borotritide was 
until very recently only accessible via exchange reagents, with a tritium content of 
up to 60%. Lithium aluminiumtritide is made from Hthium tritide and aluminium 
bromide but is only available at very low specific activity. This has limited the 
apphcations where tritium compounds with very h i^  specific activities are needed, 
such as those used in radio-immunoassays and in receptor binding studies .^
The recent work of Andres,  ^based on the work of Schleyer ,^ shows that 
highly reactive hthium tritide with high specific activity can be prepared from butyl 
hthium The hthium tritide reacted smoothly with a solution of aluminium bromide 
hi THF to form carrier-fiee hthium aluminiumtritide
TMEDA/Tg 
B u ll  ► LiT + BuT
4 U T +  AlBfg ------- ► LiAIT^ + SLIBr
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Hence, many tritiated reagents can be made with lithium tritide, (as the 
scheme below shows), which will in turn lead to many usefiil tritium labelled 
compounds with high specific activities.
LiEt^BT^ Lit  ► LiBT,
BF.
B T
AIBr. BUx,SnCI
LiAIT  ^ BujSnT
Recently a new procedure has been developed by Danks ,^ in which three 
deuterium atoms can be incorporated into organic molecules via 
dienetricarbonyliron(0) complexes. The aim of this work is to take advantage of 
the findings of Andres  ^ and Danks  ^ to develop a new procedure for 
incorporation of three tritium atoms hito organic compounds, thereby producing 
conpounds of very high pecific activity. frara-Cinnamaldeliyde was used to 
optimise the reaction conditions in this work.
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3.2 Experimental
3.2.1 Operation of the Deuterium Gas Line
The deuterium gas line is riiown in Fig. 3.1.
Fig. 3.1 Deuterium Gas Line. 1. Reaction Vial, 2. Mercury Reservoir, 3, 
Bulb, 4. Burette, 5. Deuterium Gas Cylinder
The procedure for operating the deuterium gas line was as follows. Firstly 
the reaction vial was connected to the deuterium gas line and the whole system 
evacuated and flushed with helium gas three times before reagents and solvents 
were added to the reaction vial using syringes. After being cooled with liquid 
nitrogen, the reaction vial was evacuated. Then, tap G was closed before the vial 
was warmed up to room temperature, and dissolved gas was released ftrom the 
solution. The vial was evacuated again after being cooled with Hquid nitrogen. This 
degassing process was repeated three times. Taps A, B, C, D, F, and G were 
closed when tap E was carefiilly opmed to the atmosphere to let the mercury level
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rise to near the top of the burette (4). Taps F, B and D were opened and a drop in 
the mercury level in the burette (4) provided visual confirmation that the deuterium 
gas was being transferred into the burette. When about one fourth of the volume of 
the bulb (3) was filled with deuterium gas, taps F, B and D were closed and tap E 
was opened very carefidly to the atmosphere. The volume and the pressure of the 
deuterium gas were adjusted by opening and closing taps A, B, D, E, and F. The 
mercury level should stay at the bottom of the burette (4) when the pressure had 
equihbrated after the reaction vial was warmed up to room temperatme and taps C, 
D, E, as well as G were opened. At this stage the vacuum pump was switched off 
and the solution was stirred for a desired period of time. After reaction, taps C, D, 
E and G were closed and the reaction vial (1) was cooled with liquid nitrogen and 
removed from the gas line.
3.2.2 Preparation of Lithium Aluminiumdeuteride
To a two-neck vial (5 ml) connected to a deuterium gas line, were added n-
butyl lithium (n-BuLi, 200 pi, 0.5 mmol in hexane),
tetramethylethyldiamine (TMEDA, 100 pi 0.625 mmol) and anhydrous diethyl 
ether (1 ml) using syringes. The vial was cooled with liquid nitrogen and evacuated 
before deuterium gas was introduced. Then, the vial was warmed up to room 
temperature and the solution stirred rapidly for one hour.
To a measuring cylinder with a septum, was added aluminium bromide
(AIBrg, 125 pi 0.125 mmol, in dibromomethane) using a syringe and the
dibromomethane was evacuated off. Then, the aluminium bromide was dissolved 
with diethyl ether (anhydrous, 2x0.5 ml) and the solution transferred to the two- 
neck vial after the latter was cooled with liquid nitrogen, and evacuated. The vial 
was warmed up to room temperature and the mixture stirred vigorously for 20 
minutes, leaving the desired lithium aluminiumdeuteride in the vial.
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3.2.3 Deuteriation of Precursors
The structures of the precursors used in the present study are shown in 
Fig. 3. 2.
OCH,
Fe(CO),
(1 ) Trans-cinnamaldehyde (2) (1-(4-Methoxyphenyl)-4-phenyi-1 - 
azabuta-1,3-diene)tricarbonyliron(0)
(3) 1 -(4-Methoxyphenyl)-4-phenyl-1 • 
azabuta-1,3-diene
Fig, 3. 2 Chemical Structures of the Precursors
rmfzs-cinnamaldehyde (1) (0.125 mmol) was added to the two-neck vial 
containing lithium aluminiumdeuteride and the mixture stirred for 3 hours at room 
temperature before 0.5 ml of methanol was added to quench the reaction. The 
stirring was continued for another hour.
( l-(4-Methoxyphenyl)-4-phenyl- 1-azabuta- l,3-diene)tiicarbonyliron(0) (2) 
(0.053 mmol dissolved in 1 ml of diether ether), and l-(4-methoxyphenyl)-4- 
phenyl-1-azabuta-1,3-diene (3) (0.135 mmol) were reduced using the same 
procedure.
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3.2.4 Preparation of Lithium Aluminiumtritide
The procedure used for the preparation of lithium aluminiumdeuteride was 
repeated by replacing deuterium gas with a mixture of tritium and hydrogen gas 
(1.5 ml) to prepare lithium aluminiumtritide.
3.2.5 Tritiation of (l-(4-MethoxyphenyI)-4-phenyI- 
l-azabuta-l,3-diene)tricarbonyliron(0)
(l-(4-Methoxyphenyl)-4-phenyl- 1-azabuta- l,3-diene)tricarbonyliron(0) 
(0.106 mmol) was added to the two-neck vial containing lithium aluiuiniumtritide 
and the mixture stirred for 3 hours at room temperature before methanol (0.5 ml) 
was added to quench the reaction. The stirring was continued for another hour.
3.2.6 Isolation and Purification of Reduced 
Products
3.2.6.1 Isolation and Purification of Reduced Products by
TLC
After the reaction was complete, the mixture in the two-neck vial was 
filtered and the products purified by TLC using the developing solvents listed m 
Table 3. 1.
Table 3.1 TLC Developing Solvents and Rf Values
Product Developing solvent Rf value
[l-^HJ-cinnamyl alcohol petroleum ether: chloroform: methanol = 5 : 
5 : 1
0.40
[l,2,3-^H]-(3-phenyl)-iV^4-
methoxyphenylpropylamine
petroleum ether : diethyl ether = 2 :1 0.55
[l-^H]-(3-phenyl)-iV-4-
methoxyphenylaUylaruine
petroleum ether : diethyl ether = 1 : 1 0.71
[l,2,3-^H]-(3-phenyl)-7V-4-
methoxyphenylpropylamine
petroleum ether : diethyl ether = 2 :1 0.55
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3.2.6.2 Purification of Tiitiated [l,2,3-^H]-(3-Phenyl)-iV-4-
methoxyphenylpropylamine by Radio-HPLC
The sample containing the tritiated product and impurity was dissolved in 
methanol (100 pi) before the solution was divided into 2 portions which were in 
turn injected into a radio-HPLC system using the conditions ^ecified in Table 3. 2:
Table 3 .2  Radio-HPLC Purification Conditions
Radio-HPLC system Elution condition
Waters Associates, Model 660; pressure: 1000 psi; 
Solvent Programmer: Model 440; Absorbance 
Detector, 254 nm. Sensitivity 0,2
initial 30% methanol in water 
final: 100 % water 100 minutes, 
2 ml/min
The eluates corresponding to each peak in the UV absorbance were 
collected and the radioactivity measured using a liquid sciutillation counter. The 
eluants with the maximum radioactivity were combined m a flask and the solvents 
were removed under reduced pressure, leaving the desired product in the flask.
3.2.7 Analysis of Tritiated Compounds
3.2.7.1 Measurement of the Specific Activity of the Tritium 
Labelled Compounds
The levels of tritium incorporation were measured by liquid scintillation 
counting. Typically a known amount of the tritium labelled confound was 
dissolved in methanol (10 ml) and an accurately known volume of the solution was 
added to a scintillation counting vial containing liquid scintillator (0.4 % w/v 
solution of 2,6-diphenyloxazole (PPO) in toluene, or Ecoscint A, from National 
Diagnostics, 5 or 10 ml). The vial was counted using a Beckmann LSI800 Liquid 
Scintillation Counter calibrated for accurate DPM (disintegrations per minute) 
measurement. The radiospecific activity of the tritium labelled confound was
112
calculated from the total radioactivity of the product and the w ei^t of the 
compound.
3.2.7.2 Tritium NMR Measurement
In all of the cases where the extent of tritium incorporation was sufdciently 
high the labelled products were analysed by ^H-NMR spectroscopy, using a Bruker 
AC-300E spectrometer operated at 320 MHz with broad band decoupling. The 
tritium labelled compound was dissolved in a deuteriated solvent and the solution 
was transferred into a Teflon tube (4 mm diameter). The tube was stoppered and 
inserted into a glass screw-capped NMR tube (5 mm diameter). Typically, 128 
transients and 30000 transients were collected for H-NMR and ^H-NMR 
respectively.
3.2.7.3 Radiochemical Purity Measurement
The radiochemical purity of the saitçles was determined by 
radiochromatogram scanning (Berthold LB2842 Radiochromatogram Scanner) of 
the TLC plates (fluorescent silica gel precoated). Known standards were used on 
the TLC plates for visual comparison with the radiolabeUed samples.
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3.3 Results and Discussions
The products obtained after TLC purification are listed in Table 3. 3 with 
the total yield and radiochemical purity.
Table 3.3 Products Obtained Using Lithium Aluminiumdeuteride (or 
Tritide) as Reducing Reagent
Precursor Product Total yield Radiochemical
(mmol) (mmol) (%) purity (%)
7>«rts-cionamaldehyde [1-^H]-Cinnamyl alcohol 24 -
(0.125) (0.03)
( l-(4-Methoxyphenyl)-4- [l,2,3-^H].(3-Phenyl)-7V-4- 23 -
phenyl- 1-azabuta-1,3- methoxyphenylpropylamine
diene)tricarbonyliron(0) (0.012)
(0.053)
l-(4-methoxyphenyl)-4- [l-^Hj-(3-phenyl)-7V-4- 6.7 -
phenyl- 1-azabuta- 1,3-diene methoxyphenylallylamine
(0.135) (0.09)
( l-(4-Methoxyphenyl)-4- [l,2,3-^H]-(3-Phenyl)-iV^4-
phenyl- 1-azabuta-1,3- methoxyphenylpropylamine
diene)tricarbonyliron(0) (first purification)
(0.106) (0.016) 15 87.4
(second purification)
(0.009) 8.5 94.4
In Fig. 3, 3 and Fig. 3, 4 we have the and ^H-NMR spectra of the 
reduced product, cinnamyl alcohol, respectively. There is one peak at 4.3 ppm in 
the ^H-NMR spectrum. From Fig. 3. 3 and Fig. 3. 4, it is clear that [l-^HJ-cinnamyl 
alcohol was obtained from the reaction.
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H LiAID,
CDHOH
The results also show that lithium alumioixundeuteride was successfiilly 
synthesised throng the following reactions:
TMEDA/D2 
BuLi ------------- ► LID + BuD
4Ü D  + A IB fg  ► UAID4+ 3LIBr
In Fig. 3. 5 and Fig. 3. 6 we have the and ^H-NMR spectra of the 
purified product, after the reduction of ( l-(4-methoxyphenyl)-4-phenyl- 1-azabuta- 
1,3-diene)tricarbonyliron(0)
-0 CH3LiAID
Fe(C0)3
In Fig. 3. 6, apart fi*om the peaks at 1.89 ppm (CHDCHDCHD), 2.69 ppm 
(CBÜDPh), and 3.07 ppm (CHDN) fi*om the reduced product, [l,2,3-^H]-(3- 
phenyl)“A^’4-methoxyphenylpropylamine, and the peak at 7.23 ppm, firom 
chloroform (the solvent), there is another peak at 3.87 ppm This peak most likely 
comes ftom the reduced product, uncomplexed l-(4-methoxyphenyl)-4-phenyl-l- 
azabuta- 1,3-diene. This conclusion is consistent with the and ^H-NMR spectra 
(Fig. 3. 7 and Fig. 3. 8) of [l-^H]-(3-phenyl)-Ar-4-methoxyphenylallylamine, the 
reduced product of l-(4-methoxyphenyl)-4-phenyl- 1-azabuta- 1,3-diene.
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Fig. 3. 5 ^H-NMR Spectrum of [l,2,3-‘H]-(3-Phenyl)-iV-4- 
methoxyphenylpropylamine
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Fig, 3. 7 H-NMR Spectrum of [l~^B[]-(3-Phenyl)-iV-4-
methoxyphenylallylamine
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Fig. 3.8 H-NMR (^H Decoupled) Spectrum of [l-^H]-(3-PhenyI)-A^-4- 
methoxyphenylallylamine
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The following reactions were expected in view of the results obtained from 
the deuteriation of ( l-(4-methoxyphenyl)-4-phenyl- 1-azabuta-1,3-
diene)tricarbonyliron(O).
OCH
Fe(CO),
 ^ 1- UAIHJ, 3 hr  ^
2. MeOH
OCH.
OCH, 1.UAlH,T,3hr
2. MeOH
-OCH,
This was indeed the case. Similar results were found for the ^H- and ^H- 
NMR spectra of the first purified product, obtained by the tritiation of (l-(4- 
Methoxyphenyl)-4-phenyl-1-azabuta-l,3-diene)tricarbonyliron(0) (Fig. 3. 9 and 
Fig. 3. 10). The impurity peak at 3.87 ppm in Fig. 3. 10 remained after the first 
purified product was repurified (using TLC) (see ^H-NMR spectrum of the 
repurified product, Fig. 3. 12). Clearly a more e&cient purification method, such as 
HPLC should be used to obtain the fully purified product.
Fig. 3. 13 and Fig. 3. 14 give the charts of the radioactivity of each peak 
plotted against the peak numbers, which were obtained after radio-HPLC 
purification, 761 [iCi of sample was obtained.
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Fig. 3. 9 H-NMR Spectrum of the Tritiated Pi’oduct (First Fm ified by 
TLC) by Reducing (l-(4-Methoxyphenyl)-4-phenyl-l-azabuta- 
1,3-diene)tricarbonyIiron(0)
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Fig. 3.10 H-NMR ( H Decoupled) Spectrum of the Tritiated Product 
(First Purified by TLC) by Reducing (l-(4-MethoxyphenyI)-4- 
phenyl-l-azabuta-l,3-diene)tricarbonyliron(0)
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Fig. 3.11 H-NMR Spectrum of the Tritiated Product (Second TLC
Purification) by Reducing (l-(4-Methoxyphenyl)-4-phenyl-l- 
azabuta-l,3-diene)tricarbonyliron(0)
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Fig. 3.12 ^H-NMR ( H Decoupled) Spectrum of the Tritiated Product
(Second TLC Purification) by Reducing (l-(4-Methoxyphenyl)- 
4-phenyi-l-azabuta-l,3-diene)tricarbonyIiron(0)
121
300 T
250 -
<3 200 -  
a*
> 150-
%o
100  -1
50 -
15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
peak number
Fig. 3.13 Radio-HPLC Puritication Chart (First Portion)
600 T
C  500
400 -
.> 300 -
O 200 -
14 13 12 11 10 9 8 7 6 5 4 3 2 1
peak number
Fig. 3.14 Radio-HPLC Purification Chart (Second Portion)
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The signal at 5 3.87 (radiochemical impurity) was removed after radio- 
HPLC purification (see ^H-NMR spectrum of the repnrified product, Fig. 3. 12). 
Now only three peaks at 1.92, 2,71, and 3.09 ppm remain. As the amount of the 
product purified by radio-HPLC was very small, it is hard to see the peaks in the 
^H-NMR spectrum which correq)ond to the peaks in the ^H-NMR spectrum
The results also show that LiAlHsT was successfiilly synthesised through 
the following reactions:
TMEDAn"2(H2)
BuLi ---------------------- ^ lit  (LIH) + Bu t  (BuH)
4L1T (LIH) + A IB fg  ► LiAIH_T + SLIBr
Furthermore a tritiated product with very h i^  specific activity could be obtained if 
pure tritium gas is used as isotope source.
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F%. 3.15 ‘H-NMR Spectrum of [l,2,3-‘H]-(3-PhenyI)-.N-4-
methoxyphenylpropylamine (Pm*ified by Radio-HPLC)
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Fig. 3.16 ^H-NIMR (^H Decoupled) Specti'um of [l,2,3-'^H]-(3-PhènyI)-iV- 
4-methoxyphenylprcpylamine (Purified by Radio-HPLC)
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4.1 Introduction
One of the most useful general methods for the deuteriation and tritiation of 
organic compounds uses hydrogen isotope exchange reactions^’ The reactions 
can be catalysed by metal (homogeneous or heterogeneous), base or acid catalysts, 
using deuteriated water or tritiated water as isotope source. There are two kinds of 
acid catalysts to be chosen as acid catalyst. One is the Bronsted acid, an acid which 
can donate a proton, such as H2SO4 and HCl, when it reacts with a base. Another 
kind is the Lewis acid, which can accept electron pairs, e.g. FeCls, BF3 and AICI3
With either homogeneous (PtCL '^ ) \  or with a heterogeneous platinum 
catalyst some steric hindrance has been found. For some aromatic compounds, 
the heterogeneous catalyst is not efficient enough to deuteriate the compound with
high incorporation and within a limited time  ^ Sometimes, coupling reactions
7occur when heterogeneous catalysts are used .
A number of problems associated with base catalysed exchange labelling 
are: elimination, cyclisation, condensation or decarboxylation. Normally, these side 
reactions take place more rapidly than the exchange reaction .^ Reactions with 
Bronsted acids can be slow and in such circumstances radiation damage to the 
substrate can be a problem
Lewis acid type catalysts have been used to effect the very rapid
9 - 1 2deuteriation and tritiation of aromatic and some aliphatic compounds • Among 
the Lewis acid catalysts, such as SbCls, AICI3, BBrs, BF3, the alkylaluminium 
halides are believed to be the most efficient.
The procedures for the deuteriation and tritiation exchange reactions 
catalysed by Lewis acids have many advantages over other exchange procedures 
e.g. Lewis acids can be used at room temperature and the reactions are frequently 
very fast, going to completion in short time e.g. 5 minutes^^to 61 hours^ '^ .
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Recently, a simple and mild procedure for Lewis acid catalysed tritium
exchange labelling has been developed^  ^which uses BFs-EtaO as both the catalyst 
and solvent, and tritiated water as the isotopic source. The method uses only 
commercially available, reasonably stable reactants, requires no special equipment, 
and can be easily performed in a single vessel on a microscale.
Polymer supported catalysts offer unique advantages over conventional 
solution techniques. First and foremost is the simplification of the separation of the 
catalyst from the reaction mixture, so that the supported catalysts can also be 
reused. In this way waste is reduced, cost minimised and product purification 
simplified. So, considerable effort has been devoted to the development of 
supported catalysts.
One of the earliest studies of polymer supported Lewis acids involved the
impregnation of a polystyrene resin with aluminium chloride^ .^ Unfortunately, the 
activities of the polymer supported Lewis acid catalysts were relatively low and 
decreased after a few reaction cycles.
Sulfonated poly(styxene divinylbenzene (Amberlyst 15)) was used to 
prepare superacid polymer-BFg which can catalyse the butane isomérisation
reaction. This reaction was studied by Dooley and Gates \
Several polymers were used as supporters of BF3 in Arab's work on
"Polymer Lewis Acid Catalysts"They included: poly(p-methoxystyrene); poly(p- 
methoxystyrene-co-styrene); poly(p-methoxystyrene-co-divinylbenzene); poly(2 ,6 - 
xylyl vinyl ether); poly(phenyl vinyl ether); poly(methyl vinyl ether). The relevant 
structures are shown in Fig. 4. 1:
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Poly(p-inetlioxystyrene): Poly(p-methoxystyrene-co-styrene)
/  \
\ /  n \
ÎCR ?CH,
A/
Poly(p-methoxystyrene“Co-divmylbenzeiie) Poly(2,6~xylyl vinyl ether)
/  \  
CH2-CH-CH2-CH
\
=CH
CR
/ \
CHa-CH-
i  /
Poly(phenyl vinyl ether) Poly(methyl vinyl ether)
y \
-  CR-CH-I\  o  /  n
/  \  
CH2-CH
CR
Fig. 4.1 Chemical Structures of Polymers Used in Arab’s Work 18
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More recently, Chung and co-workers have developed a new supported 
Lewis acid catalyst which involves EtAlCh, BF3 species chemically bonded to
19crystalline polyolefins, such as polypropylene and poly(l-butene) . The polymer 
supported catalyst was used in the carbocationic polymerisation of isobutylene and 
was recovered and reused for many reaction cycles without significant loss of 
activity.
The im m obilisation of boron trifluoride can be illustrated in the following 
manner:
( 7 ) w OH " ' ^ ' > (T )w O -L i+ -----^  (^-W O-BFj
-L if
P is the partially crystalline polyolefin, such as isotactic polypropylene with 5 mole 
percentage of hydroxyl groups, or isotactic poly(l-butene) with 1 2  mole 
percentage of hydroxyl groups. The structures of the polymers are as follows:
-(CHj-CH)-(CH2-CH)- .(CH2-CKD-(CH2-CH);,I X  y I
(CH2)4 CEjCHj
OH OH
The metallation of hydroxyl groups was achieved by simply mixing polymer 
particles with n-butyllithium solution. After washing out the excess n-butylhthium, 
the polymer particles were mixed with a BF3/CH2CI2 solution for a few hours 
before vacuum-removal of excess reagents. All the procedures were carried out at 
room temperature.
Polymer supported catalysts have not been used widely in radiochemistry, 
the first studies only being carried out recently by Brewer and colleagues ‘ 
They used polymer supported acid, Lewis acid and base catalysts to label a range 
of organic compounds via hydrogen isotope exchange reactions.
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It would be very exciting and interesting if polymer supported BF3 
catalysts could be used in the preparation of tritium labelled confounds. In order 
to compare the catalytic efficiency of polymer supported boron trifluoride catalyst 
with that of its homogeneous analogue, there is a need to use homogeneous boron 
trifluoride as catalyst to deuteriate and tritiate some aromatic confounds and 
selected drugs.
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4.2 Experimental
The chemicals used in this chapter were purchased from Aldrich. The 
structures of the compounds are shown in Fig. 4. 2.
1. Benzene 2. Toluene 
CH.
3. Chlorobenzene 
Cl
4. p-Xylene 
OH,
OK
5. Anisole 
OCH,
6. Nitrobenzene 
NO,
7 .1 ,4-Dichlorobenzene
Cl
8. Naphthalene
Cl
Fig. 4. 2 Structures of Compounds Used in the Labelling Procedures
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9. 4-Aminoacetophenone 10. 4-Hydroxy-3-methoxybenzoic acid
COCK
NK
COOH
OCK
OH
11. 2,4,6-Trimethoxybenz- 
aldehyde 12. 2,4-Dihydroxypyrimidine
CHO
CH3O- OCH,
OCK
OH
N
L
H O -^  N
13. 2,6-Dlhydroxyaceto- 
phenone
14. 3,5-Dlmethoxybenzoic acid
COCK
H OH
COOH
CH3O ' 0 CH3
Fig. 4.2 (Cont.) Structiu*es of Compounds Used in the Labelling 
Procedures
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15. Antipyrine 16. Aminopyrine
CK
CH.
CH,
CH.
‘CH.
17. Procainamide 18. Phenacetin
HgN n  CONHCHgCHgN CH2CH3
CH,CH,0-
19. Phenylbutazone
t-Bu
Fig. 4. 2 (Cont.) Structures of Compounds Used in the Labelling 
Froceduies
4.2.1 Deuteriation of Some Aromatic Compounds 
and Drugs Usiug BPs-Et^O Catalyst, and 
D2O as the Isotope Source
4.2.1.1 Deuteriation Reactions
To a thick-walled vial (5 ml) was added the required amount of cono^ound 
and BFs-EtzO. The vial was cooled to about -20°C. Then, D2O was introduced to
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the vial before it was sealed and warmed up to the required temperature for a 
period of time. The reaction conditions are listed in Table 4. 1.
Table 4. 1 Deuteriation Conditions
Run
No
Compound Millimole of 
compound
RFs-EtiO
(ml)
D2O
(ml)
Temperatme
CC)
Time
(hr)
1 Benzene 4.0 4.0 0.4 2 0 96
2 Toluene 4.0 4.0 0.4 2 0 96
3 Chlorobenzene 4.0 4.0 0.4 2 0 96
4 p-Xylene 4.0 4.0 0.4 2 0 96
5 p-Xylene 4.0 4.0 0.4 2 0 24
6 Anisole 4.0 4.0 0.4 2 0 96
7 Anisole 4.0 4.0 0.4 2 0 24
8 Nitrobenzene 4.0 4.0 0.4 90 72
9 Chlorobenzene 4.0 4.0 0.4 90 72
10 1,4-Dichloro-
benzene
2.0 2.0 0.2 90 72
11 Naphthalene 2.0 2.0 0.2 90 72
12 Antipyrine 1.0 1.0 0.1 90 72
13 Aminopyrine 1.0 1.0 0.1 90 72
14 Procainamide 1.0 1.0 0.1 90 72
15 Phenacetin 1.0 1.0 0.1 90 72
16 Phenylbutazone 1.0 1.0 0.1 90 72
17 Anisole 1.0 0.5
+
EtiO 0.5 ml
0.1 20 40
136
Table 4. 1 (cont.) Deuteriation Conditions
Run
No
Compound Millimole of 
compound
BFa-EtjO
(ml)
D2O
(ml)
Temperature
C Q
Time
(hr)
18 Anisole 1.0 0,5
+
CH2CI2 
0.5 ml
0.1 20 40
19 4-Amino­
acetophenone
1.0 1.0 0.1 90 72
20 4-Hydroxy-3-
methoxybenzoic
acid
1.0 1.0 0.1 90 72
21 2,4,6-
Trimethoxy-
benzaldehyde
1.0 1.0 0.1 90 72
22 2,4-Dihydroxy-
pyiimidine
1.0 1.0 0.1 90 72
23 2,6-Dihydroxy-
acetophenone
1.0 1.0 0.1 90 72
24 3,5-Dimethoxy- 
benzoic acid
1.0 1.0 0.1 90 72
4.2.1.2 Purification of Aromatic Compounds
The reaction was stopped by cooling the vial (if necessary) and adding 10 
ml of water to the solution. The compound was extracted with diethyl ether (2x5 
ml), the extract waAed with water (2x5 ml), and dried with anhydrous sodium 
sulphate. The excess diethyl ether was removed by passing N2 over the surfece of 
the solution until only approximately 0.4 ml of the solution remained.
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4.2.1.3 Purification of Drugs
The drugs were purified using the following procedures.
4.2.1.3.1 Aminopyrine and Procainamide:
The contents of the vial were removed and the vial was washed with water 
(5 ml), and KOH (IM, 2 ml). The pH of the washings was adjusted to about 11 
using potassium hydroxide pellets. The drug was extracted into ethyl acetate (3x10 
ml), and then extracted back into HCl (4M, 3x2 ml), cooled in ice, and precipitated 
by the addition of potassium hydroxide pellets (pH = 11). The drug was then 
extracted into ethyl acetate (3x10 ml), washed with water (3x2 ml), dried over 
anhydrous sodium sulphate, and the solvent removed by rotary evaporation.
4.2.1.3.2 Antipyrine, Phenacetin and Phenylbutazone:
The contents of the vial were removed and washed with water (5 ml). The 
pH of the washings was adjusted to neutral using potassium hydroxide pellets. The 
drug was extracted iuto ethyl acetate (3x10 ml), and the extract was successively 
washed with NazCOs (50g/l, 2 ml), HCl (4M, 2 ml) and H2O (3x2 ml). The 
washings were combined and extracted with ethyl acetate (10 ml), and the extract 
was washed with water (3x2 ml). Later, the extracts were combined and dried over 
anhydrous sodium sulphate, and the solvent removed by rotary evaporation.
AH the aromatic compounds and drug sangles were analysed by H-NMR 
and ^H-NMR spectroscopy.
4.2.2 Tritiatioa of Some Aromatic Compounds 
and Drugs Using BF3 -Et2 Ü as Catalyst, and 
Low Specific Activity THO as Labelling 
Source
A similar procedure to that used in the deuteriation work was used in the 
tritiation work. The tritiation conditions are listed in Table 4. 2.
138
Table 4. 2 Tritiation Conditions
Run
No
Compound Millimole
of
compound
BFs-EtzO
(ml)
THO
(pi) (pCi)
Temperature
(°C)
Time
(hr)
25 Benzene 1.0 1.0 18 1.8 20 96
26 Toluene 1.0 1.0 18 1.8 20 96
27 Chlorobenzene 1.0 1.0 18 1.8 20 96
28 p-Xylene 1.0 1.0 18 1.8 20 96
29 Anisole 1.0 1.0 18 1.8 20 96
30 Nitrobenzene 1.0 1.0 18 1.8 90 72
31 Chlorobenzene 1.0 1.0 18 1.8 90 72
32 1,4-Dichloro-
benzene
1.0 1.0 18 1.8 90 72
33 Naphthalene 1.0 1.0 18 1.8 90 72
34 Procainamide 0.25 1.0 4.5 0.45 90 72
35 Phenacetin 0.25 1.0 4.5 0.45 90 72
4.2.3 Tritiation of Some Aromatic Compounds
and Drugs Using BFa-EtiO Catalyst, Higher 
Specific Activity THO as the Isotope Source
The procedures used in the tritiation work using low specific activity THO 
were also used in the h i^  specific activity work. The tritiation conditions are listed 
in Table 4. 3.
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Table 4. 3 Tritiation Conditions
Run
No
Compound Millimole
of
compound
RFg-EtzO
(ml)
THO 
(pi) (mCi)
Temperature
CC)
Time
(hr)
36 p-Xylene 1.0 1.0 4.5 9.0 20 96
37 Anisole 1.0 1.0 4.5 9.0 20 96
38 Procainamide 0.25 1.0 4.5 9.0 90 72
39 Phenacetin 0.25 1.0 4.5 9.0 90 72
40 Naphthalene 1.0 1.0 4.5 9.0 90 72
* Procainamide hydrochloride was used as starting compound but it did not 
dissolve completely in BFs-EtaO.
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4.3 Results and Discussions
4.3.1 Deuteriation of Some Aromatic Compounds 
and Drugs Using BFs-EtiO Catalyst, and 
D2 O as the Isotope Source
The results of the deuteriation experiments are given in Table 4. 4.
Table 4. 4 Deuteriation Results for Aromatic Compounds and Drugs
Run Compound Deuteriated Deuteriated Note
No significantly position
1 Benzene no
2 Toluene yes ortho + para 
(100%)
3 Chlorobenzene no
4 p-Xylene yes ortho (100%)
5 p-Xylene yes ortho (100%)
6 Anisole yes ortho (ca.40%) 
para (ca.60%)
7 Anisole yes ortho (ca.40%) 
para (ca.60%)
8 Nitrobenzene no aliphatic deuteriated 
compound formed
9 Chlorobenzene yes ortho (ca. 33%) 
para (ca. 67%)
aliphatic deuteriated 
compound formed
10 1,4-Dichloro-
benzene
no aliphatic deuteriated 
compound formed
11 Naphthalene yes a  (50%) 
3 (50%)
12 Antipyrine no
13 Arninopyrine no
14 Procainamide yes ortho position to 
amino group (100%)
15 Phenacetin yes ortho position to 
ethoxyl group (90%) 
meta position (10%)
16 Phenylbutazone no
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Table 4. 4 (cont.) Deuteriation Results for Aromatic Compounds and 
Drugs
Run Compound Deuteriated Deuteriated Note
No significantly position
17 Anisole yes ortho-f^ara (100%)
18 Anisole yes ortho+para (100%)
19 4-Amino-
acetophenone
no decomposed 
products were 
deuteriated
20 4-Hydroxy-3-
methoxybenzoic
acid
yes ortho to -COOH 
(ca. 67%) 
meta to -COOH 
(ca. 33%)
21 2,4,6-Trimethoxy-
benzaldehyde
no decomposed 
products were 
deuteriated
22 2,4-Dihydroxy-
pyiimidine
can not be dissolved
23 2,6-Dihydroxy-
acetophenone
no decomposed 
products were 
deuteriated
24 3,5-Dimethoxy- 
benzoic acid
yes ortho to -COOH 
(ca. 67%) 
para to -COOH 
(ca. 33%)
In Fig. 4 . 3 -  Fig. 4. 24 we have the NMR spectra of the deuteriated 
products. The peaks at 1.2 and 3.4 ppm in the ^H-NMR spectra of the aromatic 
products are from the solvent, diethyl ether, which was used in the work-up.
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ppm
*H-NMR Spectrum of ^ H-Toluene in Diethyl EtherFig. 4.3
ppm
Fig, 4 .4  H-NMR (^H-Decoupled) Spectrum of ^ H-Toluene in Diethyl
Ether
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ppm
Fig. 4. 5 H NMR Spectrum of ^ H-Chlorobeiizene in Diethyl Ether
Fig. 4, 6 H-NMR (^H-Decoupled) Spectrum of ^ H-Chlorobenzene in
Diethyl Ether
ppm
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ppm
Fig, 4, 7 H ISMR Spectrum of ^ H-p-Xylene in Diethyl Ether
ppm
Fig, 4. 8 H-NMR (^H-Decoupled) Spectrum of ^ H-p-Xylene in Diethyl
Ether
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Fig. 4. 9 H-NMR Spectrum of ^ H-Anisole in Diethyl Ether
Fig. 4.10 H-NMR (^H-Decoupled) Spectrum of Anisole in Diethyl
Ether
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ppm
Fig. 4.11 H-NMR Spectrum of ^ H-Chlorobenzene in Diethyl Ether
(Reaction Temperature 90 °C)
ppm
Fig. 4.12 H-NMR (^H-Decoupled) Spectrum of ^ H-Chlorobenzene in
Diethyl Ether (Reaction Temperature 90 °C)
147
y y yy yy89 ppm
Fig. 4.13 H NMR Spectrum of ^ H-Naphthalene in Diethyl Ether
ppm
Fig. 4.14 ^H-NMR (^H~Decoupled) Spectrum of ^ H-Naphthalene in
Diethyl Ether
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Fig. 4.15 H-NMR Spectrum of ^ H-Procainamide
ppm
Fig. 4.16 H-NMR (^H-Decoupled) Spectrum of ^ H-Procainamide
149
ppm
Fig. 4.17 ^H-NMR Spectrum of ^ H-Phenacetiu
ppm
Fig. 4.18 H-NMR (^H-Decoupled) Spectrum of ^ H-Phenacetin
150
ppm
Fig. 4.19 H^NMR Spectrum of ^ H-Anisole in Diethyl Ether (BF3-Et20 
was diluted with CH2O 2 or Et2 0 )
ppm
Fig. 4. 20 H-NMR (^H-Decoupled) Spectrum of ^ H-Anisole in Diethyl
Ether (BFs-EtzO was diluted with CH2CI2 or Et20)
151
ppm
Fig. 4. 21 H-NMR Spectrum of ^ H-4-Hydroxy-3-methoxybeiizoic Acid in 
Diethyl Ether
ppm
Fig. 4. 22 H-NMR (^H-Decoupled) Spectrum of ^ H-4-Hydroxy-3-
methoxybenzoic Acid in Diethyl Ether
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'H-NMR Spectrum of ^H-3,5-Dimcthoxybenzoic Acid In DiethylFte. 4. 23
Ether
ppm
Fig. 4. 24 H-NMR (^H-Decoupled) Spectrum of ^H-3,5-Dimethoxybenzoic
Acid in Diethyl Ether
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The results in Table 4. 4 and Fig. 4 . 3 -  Fig. 4. 24 show that:
(1) The deuteiiation reaction using BF3 as catalyst is an example of an 
electrophilic substitution reaction, so that the aromatic compounds containing 
electron donating and activating group(s), such as toluene, p-xylene, anisole, were 
deuteriated at the ortho and para positions at room temperature, and in a short time 
(24 hours).
(2) Chlorobenzene, which contains a deactivating group, was not 
deuteriated at room tenq>eratuie, but deuteriated at 90 °C.
(3) The aromatic compounds containing deactivating group(s), such as 
chlorobenzene and nitrobenzene, produced deuteriated aliphatic impurities when 
the reaction was carried out at 90 °C. These could not be separated from the 
aromatic compound using the separation procedure.
(4) Naphthalene was deuteriated at 90°C.
(5) Piocainamide was deuteriated at the positions ortho to the electron 
donating group, -NH2. Whilst phenacetin was deuteriated at the ortho positions to 
the -OEt group.
(6 ) Antipyrine, aminopyrine and phenylbutazone which contain the
- N
O
(a)
5-membered ring (a) were not deuteriated at any position.
(7) Benzoic acid derivatives with electron donating groups, e.g. -OCH3 and 
-OH, were successfidly deuteriated, but the keto and aldehyde derivatives could 
not be labelled.
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(8) 4-Hydroxy-3-methoxybenzoic acid and 3,5-dimethoxybenzoic acid were 
deuteriated with low regiospecificities.
4.3.2 Tritiation of Some Aromatic Compounds
and Drugs Using BFs-EtiO as Catalyst, and 
Low Specific Activity THO as Labelling 
Source
The tritiation results using low specific activity THO are summarised in 
Table 4. 5.
Table 4. 5 Tritiation Results for Aromatic Compounds and Drugs
Run
No
Compound Sample measured 
(mmole) (pCi)
Specific
activity
(pCi/mmole)
Relative 
incorporation (%)
1 Benzene 0.06 1.1x10-3 0.019 1
2 Toluene 0.10 3.5x10-3 0.035 2
3 Chlorobenzene 0.20 1.1x10-3 0.006 0.3
4 p-Xylene 0.20 1.1x10-3 1.1 61
5 Anisole 0.26 0.22 1.7 94
6 Nitrobenzene can not be separated 
jfrom the mixture
7 Chlorobenzene 0.16 0.15
8 1,4-Dichloro-
beozene
0.21 0.15
9 Naphthalene 0.15 0.23 1.5 83
10 Procainamide 0.20 0.066 0.33 18
11 Phenacetin 0.19 0.15 0.79 44
The following conclusions can be drawn firom the results in Table 4. 5;
(l)The aromatic samples containing electron donating and activating 
group(s), such as toluene, p-xylene, and anisole were tritiated at room tenperature. 
The degree of tritiation increased in the following order: toluene<p-xylene<anisole
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(2) Chlorobenzene could be tritiated at 90°C but some aliphatic tritiated 
products were formed. So, the tritiation of chlorobenzene can not be achieved in 
this way.
(3) 1,4-Dichlorobenzene also could not be tritiated. Again some aliphatic 
tritiated material was produced.
(4) Naphthalene was tritiated at 90°C with h i^  incorporation.
(5) Both procainamide and phenacetin were tritiated. The percentage 
incorporation in phenacetin was higher than in procainamide. If procainamide is 
used as the starting compound instead of procainamide hydrochloride 
(procainamide was more soluble in the reaction solution than its salt), the 
incorporation could be increased,
4.3.3 Tritiation of Some Aromatic Compounds 
and Drugs Using BF3-Et20 Catalyst,
Higher Specific Activity THO as Labelling 
Source
The results of the tritiation of aromatic conpounds and drugs using high 
specific activity THO are summarised in Table 4. 6 and Table 4. 7.
Table 4. 6 Tritiation Results Using H i^  Specific Activity THO
Run
No
Compound Sample obtained 
(mmole) (mCi)
Specific activity 
(mCi/mmole)
Relative 
incorporation (%)
1 p-Xylene 0.67 0.21 0.31 3
2 Anisole 0.75 4.7 6.3 70
3 Naphthalene 0.80 4.3 5.4 60
4 Procainamide 0.20 0.8 4.0 11
5 Phenacetin 0.16 1.1 6.9 19
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Table 4. 7 ^H-NMR Results for Tritiated Conpounds Obtained by Using High 
Specific Activity THO
Run
No
Compound Peak position 5 (ppm) and regiospecificity
1 p-Xylene no peak (insuJBBcient radioactivity)
2 Anisole 6.92 (para ca. 60%) 
6.96 (ortho ca. 40%)
3 Procainamide 6.58 (impurity, 15% of the total activity) 
6.65 (ortho position to amino group, 100%)
4 Phenacetin 6.68 (ortho position to ethoxyl group, 100%)
5 Naphthalene 7.43 (a, 43%) 
7,80 (p, 67%)
In Fig. 4. 25 - Fig. 4. 32 aie the NMR pectra of the tritiated compounds 
obtained using higher pecific activity HTO isotope source and BFg-Et20 as 
catalyst.
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Fig. 4. 25 H-NMR Specti'um of ^ H-Anisole
Fig. 4.26 H-NMR (^H-Decoupled) Spectrum of ^ H-Anisole
158
ppm
Fig. 4. 27 H-NMR Spectrum of ^ H-Naphthalene
Fig. 4.28 ^H-NMR (^H-Decoupled) Spectrum of ^ H-Naphthalene
ppm
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Fig. 4.29 H-NMR Spectrum of ^ H-Procaiuamide
kLilAjült. liLiiiJliinilik jkiidlii
G 5  ' ' 4  3  * ' 2  1 ppm
Fig. 4. 30 H-NMR (^H-Deeoupled) Spectrum of ^ H-Procainamide
160
ppm
Fig. 4. 31 H-NMR Spectrum of ^ H-Phenaeetin
1 ppm
Fig. 4. 32 H-NMR (*H-Decoupled) Spectrum of ^ H-Phenacetin
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The following conclusions can be drawn from the results in Table 4. 6, 
Table 4. 7 and Fig. 4. 25 - Fig. 4. 32:
(1) The tritium incorporation varied from 3-70 % but there was no clear 
pattern. The result for p-xylene was surprisingly low but this could be because 
equilibrium had not been reached.
(2) Procainamide was tritiated at the ortho position to the amino group 
with 100% regiospecificity. Phenacetin was tritiated at the ortho position to the 
ethoxyl group with 100% regiospecificity. The incorporation percentage in 
phenacetin was higher than in procainamide. If procainamide is used as the starting 
confound instead of procainamide hydrochloride, the incorporation could be 
higher for the reason stated earlier.
4.4 Further Work
Whilst several examples of good isotope incorporation were observed, the 
reaction conditions used either require long times and/or elevated tenq>eratures, 
neither of which is particularly attractive when employing sensitive pharmaceutical 
confounds. These Lewis acid catalysed exchange reactions could possibly benefit 
from the use of microwave enhanced conditions.
No polymer supported Lewis acids were enq>loyed in the present study 
(due to lack of time). This also is an area where further studies could be justified.
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Chapter 5 
Synthesis of Deuterium and Tritium 
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5.1 Introduction
5.1.1 The Application of Biomaterials
5.1.1.1 Definition of Biomaterials and Historical Background
“ A biomaterial is a systemically, pharmacologically inert substance designed 
for implantation with or incorporation with a living system”. This is the definition given 
by the Clemson University Advisory Board for Biomaterials (The 6th Annual 
International Biomaterial SyiDposium, April 20-24, 1974) \  In common words, a 
biomaterial is a material used to replace part of a Irving system or to function in 
intimate contact with living tissues. Biomaterials may be of natural origin, such as 
purified collagen, protein fibre (silk, wool, and hair), polysaccharides (cotton, 
cellulosic material), and treated tissues (pericardium, hetero, hetro, and allografts). In 
most of the cases, biomaterials are referred to as synthetic materials used in contact 
with a human body.
Nearly4000years ago, people began to use biomaterials in medical practice for 
the treatment of patients in which the materials come into direct and often sustained 
contact with the tissues of the body, e.g. sutures were used for wound repair. About 
2500 years ago, ancient Indians used tree bark, cotton, leather, hair and animal sinew 
as suture materials. The first recorded apphcation of a biomaterial was the use of gold 
wire sutures in 1550 But the use of biomaterials did not become practical until the 
advent of aseptic surgical techniques developed by Lister in the 1860s. As a result of 
infection, earher surgical procedures, whether they involved biomaterials or not, were 
generally unsuccessful.
The earhest successfid implants were in the skeletal system Bone plates were 
introduced in the early 1900s. Following the introduction of stainless steels and cobalt 
chromium alloys in the 1930s, great success was achieved in firacture fixation, and the 
first joint replacement smgeries were performed. Following fiirther advances in 
materials and in surgical techniques, blood vessel replacements were tried in the 1950s
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and heart valve replacements and cemented joint replacements in the 1960s. Table 5. 1 
contains a brief summary of the historical developments relating to implants.
Table 5.1 Notable Developments Relating to Implants
Year Investigator Development
Late 18th- Various metal devices to fix fi*actuies;
19th century wires and pins fi*om Fe, Au, Ag, and Pt
1860-1870 J, Lister Aseptic surgical techniques developed
1893-1912 W. A. Lane Steel screws and plates for firacture fixation
1912 W. D. Sherman Vanadium steel plate, first alloy developed 
exclusively for medical use; lesser stress 
concentration and corrosion
1924 A. A. Zierold StelHte (CoCrMo alloy), a better material than 
Cu, Zn, steels. Mg, Fe, Ag, Au, and A1 alloy
1938 P. Wiles First total hip replacement
1940s M. J. Dorzee,
A. Franceschetti
Acryhcs for comeal replacement
1946 J. and R. Judet First biomechanicaUy designed hip prosthesis. 
First plastics used in joint replacement
1952 A. B. Voorhees, 
A. Jaretrta,
A. H. Blackmore
First blood vessel replacement made of cloth
1958 J. Chamley First use of acryhc bone cement in total hip 
replacements
1960 A. Starr,
M. L. Edwards
Heart valve
1970s W. J. Kolif Total heart replacement
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5.1.1.2 Modem Application of Biomaterials
Biomaterials have changed dramatically during the past 20 years. In the early 
days, relatively few materials, such as stainless steel, were used to make artificial parts 
of relatively simple design. Now, more than 50 different materials are being used as 
biomaterials in more than 40 types of complex prosthetic devices. These devices vary 
from long term in-vivo apphcations, e.g. heart pacemaker and artificial hips to short 
term ex-vivo apphcations, e.g. blood filters and tubing. Table 5. 2 fists some examples 
of the applications of biomaterials in implant devices.
Table 5. 2 Selected Examples of Implant Devices in Use, Their Function, and 
the Biomaterials Used
Device Function Biomaterial
Intraocular lens Correct problems caused by 
cataracts
PMMA (lens); nylon, 
polypropylene, Pt, Ti, Au 
loops
Heart pacer Maintain heart rhythm Stainless steel; silicone 
mbber, wax epoxy 
encapsulants; Pt or Pt-fr 
alloy electrode
Chronic shunts and 
catheters
Assist hemodialysis Polyethylene, hydrophilic 
coatings
Cardiac heart valves Replace diseased valves Co-Cr alloys; low- 
tenoperature isotropic carbon; 
porcine grafts; Ti alloy with 
Silastic or pyrolytic carbon 
disks or balls
Facial contouring and 
filling prostheses 
(nose, ear, cheek)
Replace diseased, tumorous, 
or traumatised tissue
Silicone mbber (Silastic), 
polyethylene, PTFE, silicone 
fluid, dissolved collagen fluid
Mammary prosthesis Replace or augment breast Silicone gel and mbber. 
Dacron fabric
Artificial skin Treat severe bums Processed collagen; ultrathin 
silicone membrane
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Medical and pharmaceutical apphcations of hiomaterials contribute significantly 
to the quahty and effectiveness of the world’s health care system. For instance, left 
ventricular assist devices (LVAD) have been used for keeping defective hearts 
pumping - sometimes for as long as 17 months - until a donor becomes available. Last 
year the Food and Drug Administration in the USA approved another use for LVADs : 
transplant alternatives. So these devices not only act as a bridge to a transplant but also 
as a long-term treatment of end-stage heart disease. According to the National 
Institutes of Health in the USA, as many as 35,000 people in the USA could benefit 
fiom the combined use of LVADs
Similarly more and more people are benefiting fiom the use of prostheses and 
medical devices. This is illustrated in Table 5.3.
Table 5.3 Typical U S. Usage of Prostheses and Medical Devices (in 1987) ^
Devices No, of Patients
Heart valves 42,000
Pacemakers 120,000
Over the needle catheters 90,000,000
Intraocular lenses 1,200,000
Mammary prostheses 100,000
Nose, chin 10,000
With total sales in the range of $11 bilhon in the U.S.A. alone, the medical 
devices industry has clearly emerged as a major new industry, in which synthetic 
biomaterials play an important role.
5.1.2 Biocompatibility
5.1.2.1 The Concept of Biocompatibility
The performance of biomaterials is controUed by two sets of characteristics, 
those which determine the abüity of a device to perform the appropriate and specified
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fimction and those which determine the compatibihty of the material within the body. 
The two terms, biofunctionality and biocompatibility are used to denote these 
characteristics. Biofunctionahty may be considered in relation to a set of properties 
which allow a device to perform a function which involves replacing or augmenting 
living tissues or organs which are highly organised but dynamically responsive and 
structurally complex with synthetic materials that are non-living, structurally naive and 
unresponsive. Biocompatibility refers to the abihty of the device to continue to perform 
the biofunctionahty. That is to say, bioconpatibihty is the abihty of a material to 
perform with an appropriate host response in a specific apphcation
Althou^ many medical devices have been used successfidly in the human 
body, at the same time there have been many failures as well, some because of poor 
biofunctionahty, but most of them because of the poor biocompatibihty of materials 
used in the devices. For exanqple, the implantation of left ventricular assist devices can 
lead to infections around the heart and stomach (where they are often implanted ) in 
10% of recipients as weh as blood clots
5.1.2.2 Body Response to Implants
The biocompatibihty of a biomaterial or a prosthetic device is a dynamic and 
two-way process that involves the time dependent effects of the host on the material 
and the material on the host. It is a complex subject that is concerned with all of the 
interactions between biomaterials and tissues. The implantation of any synthetic 
material initiates a wound healing process that is characterised by the inflammatory 
response. When tissues are injured or destroyed, the adjacent ceUs respond to repair 
them An immediate response to any injury is the inflammatory reaction. A typical 
inflammation gives signs of redness, swehing and heat which can lead to local pain.
The response of the body toward implants varies widely according to the host 
site and species, the degree of trauma imposed during implantation, the type of tissue, 
the physical and chemical characteristics of the material and the general status (age, 
sex, health) of the host. The response can be divided into two categories: local 
response and systemic response.
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5.1.2.2.1 Local Response
Removal of the foreign materials is the natural reaction of the body. The 
foreign material could be extruded fiom the body if it can be moved, or wr apped up if 
it can not be moved.
The degree of the tissue response varies with both the physical and chemical 
nature of the implants. For example, surface roughness and porosity affect the 
morphology of the implant material as well as the amount of area exposed to the 
tissues; the extent and size of porosity can affect the rate of tissue ingrowth and 
attachment; inteifacial forces, surface charge, the shape and size of the implant, 
hydrophdicity, chemical composition and extent of leaching of chemicals mto the 
tissues also greatly affect the tissue response.
5.1.2.2.2 System Response
When an interfacial reaction between the tissue and an inplanted device using 
poor bioconpatible material occurs, some products (corrosive and wear particles, 
degradable polymers, etc.) will be released into the tissue. The distribution of these 
products plays a very important role in the system réponse. Not only can the products 
be precipitated locally, or form complexes locally, but also may passively diffise 
through the tissue under a concentration gradient. Apart fiom passive diffusion, more 
importantly, the products can reach remote organs or tissues by active methods, e.g. 
soluble products can move quickly to the vascular system and pread rapidly in the 
blood.
When a product is taken up intravascularly it can reach many organs and 
tissues throughout the body. For different metallic elements, the various organs have 
different affinities That means that the elevated ion concentrations in various organs 
may interfere with normal physiological and biochemical activities. In some cases, the 
product may undergo biotransformation and/or metabolism and be found in urine or 
faeces without any residues being left, hi other circumstances the product may be 
deposited at storage sites. This may not be a problem if the stored product is at such a
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low level that it is tolerated without an adverse effect. But for most of the time, the 
product will give rise to systemic effects of non-bioconpatibihty
5.1.2.2.3 Williams’ Model of Tissue-Biomateriai Interactions
In order to achieve a better understanding of the local réponse Williams 
has developed a model to explain the way in which the tissue around an implanted 
device reponds to its presence.
When hiomaterials are in contact with tissues, four main events can take place:
(1) The initial events which take place in a matter of seconds or minutes 
following contact between biomaterial and tissues.
(2) Tissues réponse towards the biomaterial which takes place in a matter of 
minutes to years.
(3) Deterioration of the biomaterial (corrosion or degradation) as a result of
events (1) and (2).
(4) Systemic réponse towards the presence of the biomaterial.
Altogether, these four events form the subject of bioconpatibility. The most 
important initial event is the adsoption of proteins onto the surface of the biomaterial. 
The properties of the adsorbed layer play an inportant role in mediating cellular 
réponse to the material .
The mechanism of the reactions between proteins and the surface of any 
biomaterial is very complex. As a result of research the following results have been 
obtained: The physical and chemical surfece properties of hiomaterials can greatly 
determine the level of protein adsoption. Adsorbed proteins greatly influence cellular 
reactions with hiomaterials. The sensitivity to adsorbed proteins, the variation in 
cellular réponse to pecific proteins, and the rapid adsoption of proteins to all 
surfaces exposed to the biological environment, have led to the idea that the cellular 
réponse to implanted polymers is the result of pecific interactions between 
components of the adsorbed protein layer on the biomaterial and the cell periphery.
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5.1.2.3 Blood-Biomaterial Interactions
In the human body, blood flows through the vascular system and does not clot. 
When a blood vessel is injured, blood has the abihty to form clots in order to stop 
bleeding.
There are many kinds of inplants and devices which are in contact with blood 
either for a relatively short time (hke kidney dialysers, catheters circulatory assist 
devices and blood o^Q^ genators) or for years (total artificial heart , heart valves 
and vascular grafts). One of the consequence of the interactions of blood with foreign 
material is that thrombosis may take place. There are three groups of conponents 
which interact in different ways at varying degrees, leading to the process of 
thrombosis at foreign interfaces. These are : (1) the biomaterial; (2) the nature of the 
blood flow; and (3) the biological environment.
The following material properties will influence the blood biocompatibihty of 
the material: surface conposition, water soption, surface crystalline/amophous 
structure, surface smoothness, roughness, and porosity; mechanical conphance of 
surface, regular or irregular distribution of surface “domains” of the above, bulk 
leachables and degradation products.
When a biomaterial is in contact with blood, many interactions take place due 
to the inconpatibhity of the material. Four important interactions are:
(1) Protein deposition and dénaturation.
(2) Platelet adhesion and activation.
(3) Activation of the clotting cascade and then production of a thrombus.
(4) Cellular damage and bacterial colonisation.
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5.1.3 Solutions to Non-Biocompatibility
Many studies have been made in order to find ways of overcoming the lack of 
bioconpatibility, so that the biomaterial can perform its biofiinctionality in the very 
hostile physiological environment for as long as possible.
5.1.3.1 Early Approaches to Biocompatiblity
Both platelets and blood vessel walls have negative surface charges which
prevent platelet adhesion to the normal vessel wall. Approaches to biocompatibihty in 
the early stage were concerned with using hiomaterials with a negative surface 
charge ; using hiomaterials with surface energies of less than 30 ergs/cm^ 20,21
Another way of ensuring biocompatibihty is the so caUed “natural” approach, in 
which a viable cehular layer is coated onto the surface of the biomaterial , or
denatured tissue is embedded into a polymer matrix to form “biohsed” material
5.1.3.2 Modification of Materials by Physical and Chemical
Procedures
Surface modification of biomaterials using a physical method is becoming an 
increasingly popular method of improving device function and biocompatibihty without 
the expense and time required to develop new materials. lon-beam-based processes, 
such as ion implantation and ion-beam-assisted deposition (IBAD), have proved to be 
particularly successful in this area because they offer a wide array of beneficial surface 
property modifications without adversely affecting bulk properties For instance, 
orthopedic prostheses are made harder and more wear resistant by ion implanting the 
articulating surfaces. Many other devices, such as orthodontic apphances, surgical 
instruments and venous catheters, are treated to inq)rove fiiction, Jfietting resistance 
and biocompatibihty. IB AD is used to apply antimicrobial coatings to catheters and 
other devices, to apply sealant coatings to prevent oxygen or water vapour permeation, 
and to create metalhsed traces on polymers for use in flexible circuitry.
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An example of the modification of hiomaterials using a chemical method to 
gain biocompatibihty is the case of heparin . Heparin is an anti-coagulant found 
in liver cehs, and it has a pharmacological effect on the blood, changing its 
biochemical properties and reducing its abihty to coagulate. A disadvantage of the 
heparinised surfaces is that the heparin slowly erodes off or leaches out of the 
material . Platelet adhesion and hemolysis of red blood cehs are also known to occur 
on heparinised surfaces ^
The ideal biocoiupatible material should not cause any adverse reactions to 
occur between itself and the blood it is in contact with. Although considerable time and 
effort has been expended on developing bioconpatible materials, very few of them are 
truly biocompatible, due to the complexity and interdependence of the factors 
controlling the interactions between host and biomaterial.
It has been found that bioconpatibihty of implant materials in blood can not be 
explained in terms of a single parameter, such as critical surface tension, wettabihty, 
contact angle, or surface charge Obviously a more detailed understanding of the 
properties of natural tissues is necessary to understand the interaction of these factors.
5.1.3.3 Surface Biomimicry
Based on many studies of the structure and function of biological membranes. 
Chapman has developed an alternative approach, the mimicry of biologically inert 
interfaces
The plasma membrane is the medium through which all cells interact with their 
environment. Fig. 5. 1 shows a fluid matrix of bilayer Upid in or upon which proteins 
and glucoproteins are located
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E x t r ac e l l u l a r
Cytoplasmic
Fig. 5.1 A Representation of a Biological Membrane
In the picture, lipid asymmetries are shown as a difference in the distribution of 
the polar head groups, with the negatively charged lipids localised predominately in the 
cytoplasmic leaflet.
The specific membrane functions are controlled by proteins which are about 
half the weight of biomembranes. But protein fimction as well as cell behaviour may be 
modulated by the chemical composition and the physical properties of plasma 
membrane lipids.
Normally, the conposition of mammalian membranes are quite different. There 
are over 100 different kinds of lipids in membranes. The variations in the hydrophobic 
(acyl chain) and hydrophilic polar head group portions of these anphiphilic structures 
contributes to this diversity. The acyl sections of pho^holipids provide the 
hydrophobic environment that is necessary for the functioning of the intrinsic 
membrane protein. The polar head groups are in contact with water and therefore 
contribute largely to the interfacial properties of the cell surfaces. The head group 
frequently present in biological membranes is phosphoryl choline. Its structure is 
shown in Fig. 5. 2.
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Fig. 5.2 Structure of Phosphoryl Choline Headgroup
One of the inportant features of membranes is their functional and conposition 
asymmetry^ "^ . It is clear now that the high content of the electrically neutral 
phopholipids, which contain the phophoryl choline headgroup, is the simplest 
common feature among the non-active cellular and model membranes. By mimicking 
these natural membranes, it is possible to prepare a surface formed by a polymer 
containing a phosphoryl choline headgroup to overcome the non-biocompatible 
problems.
5.1.3.4 Phosphoryl Choline Containing Coatings
Phophoryl choline forms a zwitterionic headgroup with no overall charge and 
high binding afiSnity for water . When a material is coated with a compound or 
polymer containing a phophoryl choline headgroup, the surface formed is very 
hydrophihc. The bound water will inhibit the interactions between a protein and the 
surface when the protein is close to the surface. Hence, a material coated with a 
phophoryl choline material is bioconpatible. The force between the phopholipid and 
the material surface is a weak force (Van der Waal’s force), so the coated surface will 
lose its bioconpatible function gradually , if the phophoryl choline compound 
contains only two hydrophobic points of attachment, as e.g. 
dipalmitoylphophatidylcholine (DPPC).
This problem can be overcome by using polymers with multiple hydrophobic 
points of attachment, hke polymerised diacetylenicphophatidyl choline (DAPC), 
shown in Fig. 5.3^^.
180
OH3 ÇH)
C
c
(C% (CHg),
c = 0  c:
O i
CK CH
1h, -PC
CH3 CH3 CH3 CH3 9H3 9H3
( C H a l i ^  ( C H a ) i^  ( ^ ^ 2 ) 1 1  ( ^ ^ 2 ) 1 1
UV or Gamma  ►
Radiation —
(CHz), (CHa),
c = o  c^ =
o
CH, CH
CHa PC
PC =
C
C
(ÇHals (ÇHa)g (0%  (CHa),
:q  C = 0  C =1
CH,
■O  C 
0
CH
in.
CH,
-PC
p— o / x / "
CHL -PC
Fig. 5 .3  Formation of Polymerised DiacetylenicphosphatidylchoUne
(DAPC)
Many polymeric materials, such as PVC, polyethylene, polypropylene and 
polystyrene, etc., have been coated with polymeric diacetylenicphosphatidylcholine 
(DAPC). In Table 5. 4 some of the coated materials are listed.
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Table 5. 4 Biocompatibility of Phosphoryl ChoUne Coated Surfaces in-viti o 
Compared to Uncoated Surfaces
Material Reduction in Adsorption 
(%)
fibrinogen platelets
Platelet Activation
PVC 90 99 no
Polyamide 84 90 no
Polyethylene 86 99 no
Polyimide 91 99 no
Polypropylene 83 86 no
Polystyrene 90 80 no
Polyurethane 69 97 no
PTFE 90 90 no
The results were obtained by bringing the coated materials into contact with 
firstly fibrinogen, which is a blood protein found in thrombus formation, and secondly 
whole blood , The higher level of the reduction in adsorption of fibrinogen and 
platelets and in activation of platelets, the better is the bioconpatibility 
(haemocompatibihty). As expected, all the surfaces coated with the polymer e?diibit 
very good biocompatibility.
Similar bioconpatibilities of coated surfaces with phosphoryl choline have been 
obtained when tested “in-vivo”
5.1.3.5 Biomembrane Mimetic Modifications of Polymer 
Surfaces
A better method of modifying polymer surfaces is to attach a phosphoryl 
choline containing compound by covalent bonding to the surface of a polymer . For 
instance, when a polymer contains hydroxyl groups on the surface, phophoiyl choline 
dimethylsilyl chloride can be used to modify the surface, as shown in Fig. 5. 4.
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Fig. 5.4 Modification of Surface Containing Hydroxyl Group Using 
Phosphoryl Choline Derivatives
Fig. 5. 5 illustrates the modification reactions of surface containing acid or 
chloride groups, using phsphoryl choline ethylene glycol or phosphoryl choline 
ethanolamine.
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Fig. 5. 5 Modification of Surface Containing Acid or Chloride Group Using 
Phosphoryl Choline Derivatives
The advantage of this modification is the mechanical properties of the material 
remain unchanged, whilst the material acquires a biomembrane surface.
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5.1.4 Synthesis of Polymers Containing 
Phosphoryl Choline
As phospholipids are important components of biological membranes 
this led some Japanese researchers to devote considerable efforts to synthesise 
vinyl phospholipid monomers and polymers. Nakai ^  first carried out the 
polymerisation of 2-(methacryloyloxy)ethyl-2-aminoethyl hydrogen phosphate - the 
structure is as given in [(1), Fig. 5. 6]. The polymerisation was performed in 
methanol at 65°C over 12 hours using 2, 2’-azoisobutyronitrile (AIBN) initiator. In 
order to increase the hydrophobic character of the polymer, another polymer 
containing a benzoate group was then synthesised by using 2-aminoethyl-2-(p- 
methacryloyloxybenzoyloxy)ethyl hydrogen phosphate as monomer - its structure 
is given in [(2), Fig. 5. 6 ]. Similar conditions were employed for the 
polymerisation (65°C, 7 hours, AIBN initiator).
Another polymer, containing the phospholipid in the side chain, was 
synthesised using 2-(p-methacryloyloxybenzoyloxy)ethyl-2’-(phthalimido)ethyl- 
hydrogen phosphate [(3), Fig. 5. 6] as monomer.
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Fig. 5. 6 Some Phosphoryl Choline Containing Compounds
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Fig. 5. 6 (cont.) Some Phosphoryl Choline Containing Compounds
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The phosphoryl chohae part of the molecule can also be located in other parts 
of the polymer. One example is given below^ .^
H O  R — OH
O
I /  \bLC  O 01
(^ 2^ 5)3^
2 H /T H F
HgC
► I20-0 0 HgO
P—O — R—O—P O - O K
■OK
O o O K O H ,
II II 1+ 1 +• OHgOHg O — P — O —  R  O —  P — O —  OHgNOHgOHgN —
°  °  O H , O H ,- '
H 3\ O K
H ,0
N— (OHg)^ —
OH,
Fig. 5.7 Synthesis of a Copolymer with Phosphatidylcholine in the Main 
Chain
It is believed that a trimethyl ammonium cation needs to be part of the polymer 
in order that it can mimic biomembrane function. 2-(Methacryloyloxy)ethyl 
phosphorylcholine (MPC) [(4) in Fig. 5. 6] is a water-soluble monomer^  ^ and can be 
easily homopolymeiised or copolymerised with other vinyl compounds by 
conventional radical polymerisation techniques. For exanq)le, poly(2- 
methacryloyloxyethyl phosphorylcholine-co-n-butylmethacrylate [poly(MPC-co- 
BMA)] '^  ^ [(5) in Fig. 5. 6], poly(2-methacryloyloxyethyl phosphorylchobne-co- 
styrene)^  ^ [(6) in Fig. 5, 6], poly(MPC-co-BMA)^^ [(7) in Fig. 5. 6], poly(2- 
(methacryloyloxy)ethyl phosphorylcholine-co- lauryl methacrylate) (PmMl2) [(9) in 
Fig. 5. 6].
Copolymers of 2-(methacryloyloxy)ethyl phosphorylcholine (MPC) with 
hydrophobic alkyl methacrylates, particularly n-butyl methacrylate (BMA) have shown 
excellent non-thrombogenicity even when poly(MPC-co-BMA) is in contact with 
human whole blood and in the absence of an anticoagulant. Poly(MPC-co-BMA) can 
reduce protein adsorption from plasma^  ^ ’ . Because the MPC copolymers have a
phosphoryl choline group which is a typical phospholipid polar group, the copolymers
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have a strong affinity for phospholipids^ .^ Nakahayashi^  ^ suggests that the 
phospholipid molecules are adsorbed on the surface of the MPC copolymer from the 
plasma, resulting in the formation of a “self-assembled biomimetic membrane” 
constructed from adsorbed phospholipid molecules and MPC moieties on the surface. 
The self-assembled biomimetic membrane surface can interact weakly with blood cells 
and proteins, and does not induce activation of these components.
Segmented polyurethanes (SPUs) are widely used as biomedical materials 
because of their excellent mechanical properties and blood compatibility However, 
the blood compatibility of the SPUs is not satisfactory for long-term implantation as a 
vascular grafr of small diameter. SPU degrades by adsorption of protems, adhesion of 
macrophages and peroxide formation. The soft segment of SPU, which is mainly a 
polyether chain, is degraded by the oxygen radicals produced by the macrophages In 
order to reduce cell adhesion to prevent degradation of SPU when it is used in vivo for 
long-term, surface modification of SPU was carried out based on the fundamental 
properties of poly(MPC-co-BMA). Polymer PMBB2TJ [(8) in Fig. 5. 6] is the result 
of this effort. The polymer is composed of MPC, BMA and methacrylate with a 
urethane bond. When SPU is coated with this polymer, the polymer is hardly detached 
in water or ethanol, both of which are good solvents for MPC copolymers
5.1.5 Isotopically Labelled Phosphoryl Choline 
Polymers
There is no doubt that surfaces coated with polymers containing a phosphoryl 
choline headgroup will produce biocompatible (haemoconq)atible) surfaces, and hence 
inhibit protein adsorption, platelet adhesion and activation. This they do by mimicking 
the main component of the outer biomembrane of the red blood cell. A series of 
copolymers of MPC and lauryl methacrylate (Ml) [one exanq)le of the copolymers, 
PmMl2 is given, (9) in Fig. 5. 6] have been prepared and used as coating material. As a 
result of the very good bioconpatible properties which have been obtained with these 
polymers, it is necessary to synthesise radiolabelled poly(MPC-co-Ml) to test the 
stability of the coatings. If the polymers leach from the coated surface under the 
application conditions, they may not be suitable for human studies. Such studies have
189
their counterparts in the pharmaceutical industry where the behaviour of drugs has to 
be analysed very carefidly prior to approval being given for their use. Then the 
polymers would have to undergo strict clinical trials to see the effects which they have 
on the subject, in a similar way to drug trials.
There are several ways of labelling MPC and Ml copolymers, the favoured 
route being the one in which the alkyl chains of the polymers ar e labelled. Another 
approach is to label the phosphoryl choline headgroups.
Alkyl chain labelled poly(MPC-co-Ml)s were prepared by the reduction of 
unsaturated precursor polymers with tritium gas using Wilkinson’s catalyst ^  . The
labelling regiospecificity was determined using ^H-NMR spectroscopy. Selected 
tritiated polymers were coated onto polyethylene, PVC and silicon tubing. The tubing 
was filled with various buffer solutions (pH ranging fiom 4 -9)  and incubated at 20, 40 
and 60°C. The percentage polymer removed as determined by liquid scintillation 
counting was found to be less than the detectable level of impurities using the radio gel 
permeation chromatography method.
5.1.6 Proposed Procedures for synthesis of poIy(2- 
(methacry loy loxy ethy l)-2 ’ -(trimethyl- 
ammoniumethyl) phosphate, inner saIt)-co-(n- 
dodecylmethacraylate) (1:2) (PmMl2):
The stability studies involve the use of polymers that have been tritiated in the 
alkyl chains. However biocompatibihty relates to the interface between phosphoryl 
choline headgroups and e.g. proteins. Consequently it would be of considerable 
interest if a polymer would be synthesised in such a way that the label was located in 
the phosphoryl choline headgroup.
The following are the proposed procedures for synthesis of headgroup labelled 
polymer, poly(2-(methacryloyloxyethyl)-2'-(trimethylammoniumethyl) phosphate, inner 
salt)-co-(n-dodecylmethacraylate) (1:2) (PmMl2 ):
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1. Synthesis of lidiium aluminium tritide
n-BuIi + Tg (Hz) LiT(LiH)
4LÎT (LiH) + ABi 3 -» liAlTHs
2. Synlliesis oftiitiatedtiiinethylattime
+
+
a:
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C H .
.C H .
1) LiAITHg 4
2) 4  MeOH
C y  CH, 
I
C H .
3. Synthesis of tritiated HEMA-PC>n4 r\—I Et,NCl o-
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HEMA dioxaphospholane (COP)
n-BuT
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N(CH3)2CH2T
tritlated HEMA-PC
4. Synthesis of tritiated PmMlz
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n 2n
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The procedures should be optimised by first synthesising the deuterium labelled 
version of the polymer before any radioactive work is involved.
A general synthesis of secondary and tertiary amines has been described by 
Alan et al®^. This follows the route shown:
ICH.
NaBH, ,R+  CH3— R’
When R = R' = Me, trimethylamine will be the product although the route has 
not been used to produce this particular compound. Because of the difficulty in 
handling this material (the boiling point is 2.9 °C), the procedure was established by 
preparing N,N-dimethylaniline, which has a boiling point of 193 °C.
Sodium borohydride can be replaced by lithium aluminium deuteride, or lithium 
aluminium tritide (synthesised for another project).
LÎA1D. C^D^CH3N
Once deuteriated dimethylamline has been prepared, then a synthesis of 
deuteriated trimethylamine can be attempted:
LiAlD. CH2D CH3 NICM,
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Que objective of this project is therefore to prepare tritiated poly(MPC-co-Ml) 
via the reduction of unsaturated Pm2Ml3Mly [(10) in Fig. 5. 6]. This has the further 
advantage that the confound could be used for the solid state ^H-NMR studies that 
are currently being progressed by the Tritium group.
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5.2 Experimental
5.2.1
Fig. 5. 8
Operation of Tritium Gas Line
A block diagram of the tritium gas-line is given in Fig. 5. 8 .
L
6  5 A 3 2 1
Tritium Gas Line 1. Reaction vial; 2. Gas line; 3, Liquid nitrogen 
trap; 4. Vacuum pump; 5. Trap; 6. Ethylene glycol bubbler trap
But the details can be shown more clearly in Fig. 5. 9.
Fig. 5. 9 Tritium Gas Line. 1. Reaction Vial, 2. Mercury Reservoir, 3. Bulb, 
4. Burette, 5. Tritium Ampoule, 6. Side arm, 7. Hydrogen balloon
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vial using syringes. After being cooled with liquid nitrogen, the reaction vial was 
evacuated. Then, tap G was closed before the vial was warmed up to room 
temperatme, and dissolved gas was released from the solution. The vial was evacuated 
again afrer cooling with liquid nitrogen. This degassing process was repeated three 
times. Taps A, B, C, D, F, G were closed when tap E was carefully opened to the 
atmosphere to let the mercury level rise to near the top of the burette (4). The glass 
breakseal of the tritium ampoule (5) was broken by the magnet contained in the side- 
arm (6 ). Taps B and D were opened and a drop in the mercury level in the burette (4) 
provided visual confirmation that the breakseal had been broken and tritium gas was 
being transferred into the burette. When the transfer had stopped, the mercury 
reservoir' (2) was evacuated very carefully. As the mercury flowed in to fill the vacuum 
in the reservoir (2) it drew the tritium gas into the bulb (3). When the flow stopped, 
taps B and D were closed and tap E was opened very carefully to the atmosphere. 
Once the pressure had equilibrated the volume of the tritium gas that had been 
transferred could be measured from the graduations on the burette (4). The mercury 
reservoir was very carefldly evacuated again. The tritium arcpoule (5) was flushed with 
hydrogen by opening tap F, and after a suitable time closed it. Taps B and D were 
opened to let the hydrogen fill the burette (4) and then closed. Tap E was opened to 
the atmosphere very carefldly. After the reaction vial was warmed up to room 
temperature, taps D and C were opened very slowly to transfer the tritium and 
hydrogen mixture to the reaction vial (1). At this stage the vacuum pump was switched 
off and the solution was stirred for a fixed time. After reaction, the mercury reservoir
(2 ) was carefldly evacuated and the reaction vial (1) was cooled with liquid nitrogen. 
Finally all the taps were closed and the reaction vial was removed from the gas line.
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5.2.2 Reduction of Polymer PmiMlsMly
The following reaction was used to prepare tritiated PmMlz.
Tritium g a s
T/H
T/H
(1) (2)
RhCi(PPh.O—p=o O—p=o
H ydrogen g a s
T/H T/H
•T/HT/H T/HT/H-
(3)(2)
5.2.2.1 Tritiation
To a reaction vial (5 ml) were added polymer PmzMlgMly (57.6 mg), 
Wilkinson’s catalyst (ttis(ttiphenylphosphine)rhodium (I) chloride) (15.9 mg), benzene 
(0.9 ml) and absolute ethanol (0.3 ml). After the reaction vial was connected to the 
tritium gas line and cooled with liquid nitrogen, the whole system was evacuated and 
flushed with helium three times. The solution in the reaction vial was degassed three
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times before being stirred under an atmosphere of tritium and hydrogen (tritium 1 : 
hydrogen 6.5, total 4.8 ml, 57.4 GBq, 1.55 Ci) for six hours.
After reaction, the solution in the reaction vial was transferred to a pre­
weighed pear-shaped flask before the vial was washed with acetone (4x1 ml). The 
solution in the pear-shaped flask was combined with the acetone washings and allowed 
to stand until precipitation was complete. Then the solution was removed, the residue 
washed with acetone (3x1 ml) and dried under vacuum to give the labelled product 
(49.7 mg, 281 MBq, 76.5 mCi).
Some of the labelled product (27.8 mg, 158 MBq, 42.8 mCi) was transferred to 
a solid ^H-NMR rotor to carry out solid state ^H-NMR spectroscopy studies. The 
remainder was analysed by ^H- and ^H-NMR spectroscopy using CDCI3/CD3OD as 
solvent/intemal lock.
5.2.2.2 Hydrogenation of Partially Reduced Polymer
In some cases the partially reduced polymer (as determined by ^H- and ^H- 
ISIMR) was prepared. It was then fiuther reduced by placing in a reaction vial to which 
were added Wilkinson’s catalyst (tris(triphenyl-phosphine)rhodium (I) chloride) (12.8 
mg), benzene (0.45 ml) and absolute ethanol (0.15 ml). After the reaction vial was 
connected to the gas line and cooled with liquid nitrogen, the whole system was 
evacuated and flushed with helium three times. The solution in the reaction vial was 
degassed three times before being stirred under an atmosphere of hydrogen. After 23 
hours reaction, labelled product (24.9 mg. 1003 MBq, 27.1 mCi) was obtained usmg 
the same work-up procedme as used previously. Later, the product was analysed by 
^H- and ^H-NMR spectroscopy.
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5.2.3 Synthesis of Deuteriated Dim ethyl aniline
5.2.3.1 Operation of Deuterium Gas Line
Hie deuterium gas line is shown in Fig. 5. 10.
G
V
hOG
Fig. 5,10 Deuterium Gas Line. 1. Reaction Vial, 2. Mercury Reservoir, 3.
Bulb, 4. Burette, 5. Deuterium Cylinder
After the reaction vial was connected to the deuterium gas line, the whole 
system was evacuated and ftuAed with helium gas three times before reagents and 
solvents were added to the reaction vial using syringes. After being cooled with liquid 
nitrogen, the reaction vial was evacuated. Then, tap G was closed before the vial was 
warmed up to room temperature; any dissolved gas was released from the solution. 
The vial was evacuated again after cooling with liquid nitrogen. This degassing process 
was repeated three times. Taps A, B, C, D, F, and G were closed when tap E was 
carefully opened to the atmosphere to let the mercury level rise to near the top of the 
burette (4). Tap E was closed and taps B and D were opened before tap F was opened 
very carefully to let deuterium gas to be transferred to the burette (4). When the 
mercury level reached about 3/4 of the height of the bulb (3) (depending on the volume 
of the vial and the amount of deuterium gas required), taps F, B and D were closed.
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Tap E was opened very carefully to the atmosphere. After the reaction vial was 
warmed up to room temperature, taps C, D, and G were opened so as to transfer the 
deuterium gas to the reaction vial (1). At this stage the vacuum punç was switched off 
and the solution was stirred for the required time. After reaction, the mercury reservoir 
(2 ) was carefully evacuated and the reaction vial (2 ) was cooled with liquid nitrogen. 
Finally all the taps were closed and the reaction vial was removed from the gas line.
S.2.3.2 Preparation of Deuteriated Dimethyianiline
To a two-arm, round-bottom flask (15 ml) were added n-BuLi (0.5 mmole, 200 
til in n-hexane), fresh distilled N,N,N',N'-tetramethylethylenediamine (TMEDA, 
1 0 0  pi), and fresh distilled diethyl ether (1  ml) using syringes, after the flask was 
connected to the deuterium gas line. The gas line was flushed with helium gas three 
times, and the solution in the reaction flask degassed before deuterium gas was 
introduced into the gas line. The contents were stirred for 45 minutes.
To a bottle capped with a septum was added AJBrg (150 pi in 
dibromomethane, 0.94 mmole) using a syringe. After the solvent was evacuated diethyl 
ether (1 ml) was added to the bottle to dissolve the AlBrg. Then, the AlBrs-diethyl 
ether solution was added to the reaction flask. The contents were stirred for 15 
minutes before N-methyl-N-phenyl-benzotriazol-l-yl-methylamine (57.8 mg, 0.24 
mmole) diethyl ether solution was added. After 2 2  hours stirring at room tençerature, 
the reaction was quenched using 0.5 ml of H2O-THF (1:9 v/v) solution. The reaction 
flask was then disconnected from the deuterium gas line and connected to a freeze- 
drying tube with an enqjty round-bottom flask at the other end. The reaction flask was 
cooled with liquid nitrogen before the whole freeze-drying system was evacuated. 
Then the empty flask was cooled with liquid nitrogen and the reaction flask left at 
room temperature overnight. The product was obtained by blowing off the solvents 
transferred to the empty flask with nitrogen gas. The product was analysed by and 
^H-NMR spectroscopy.
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5.2.4 Synthesis of N,N-Dimethyibenzotriazol-l-yl- 
methylamlne
To a solution ofbenzotriazole (11.9 g, 100 mmole) and dimetbylamine (4.96 g, 
110 mmole, 19.6 ml of 5.6 M ethanol solution) in methanol (130 ml, cooled at 0°C) in 
a round-bottom flask (250 ml with a 3-neck adapter) was added formaldehyde (3.6 g, 
120 mmole, 9.0 ml of 37% water solution) dropwise under stirring at 0®C. On 
completion, the stirring was continued for a further hour at 0°C. The solution was then 
warmed to room temperature and stirred for another hour (the reaction product 
dissolved in the solvent at room temperature). The solution was evacuated and cooled 
at - 1 0 °C for 2  minutes before the mixture was filtered. The white-coloured crude 
product was dried under vacuum for one hour to give the crystallised product.
The latter was placed in a round-bottom flask (100 ml) and dissolved in diethyl 
ether (50 ml) and methanol (10 ml) (the product could not be dissolved fully in diethyl 
ether alone) with heating. Then, the solution was kept at 2°C for 2 days. The product 
was filtered and washed with diethyl ether before drying under vacuum to give the 
recrystaUised product.
Both the crystallised and recrystallised product were analysed by 
spectroscopy (CDCI3 solvent).
5.2.5 Synthesis of Deuteriated Trimethylamine
To a two-arm, round-bottom flask (15 ml) connected to an adapter with a tap, 
were added n-BuLi (200 pi in n-hexane, 0.5 mmole), fi-esh distilled N,N,N',N'- 
tetramethylethylenediamine (TMEDA, 100 pi), and fresh distilled diethyl ether (1 ml) 
using syringes after the flask was connected to the deuterium gas line. The gas line was 
flushed with helium gas three times, and the solution in the reaction flask was degassed 
before deuterium gas was introduced into the gas line. The contents were stirred for 50 
minutes. Then the flask was cooled in liquid nitrogen before being evacuated.
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To a bottle capped with a septum was added AlBig (150 pi in dibromo­
methane, 0.94 mmole) using a syringe. After the solvent was evacuated, diethyl ether 
(1  ml) was added to dissolve the AlBrg. Then, the AIBrg-diethyl ether solution was
added to the reaction flask, when it was cold. The contents were stirred for 2 0  
minutes, before the reaction flask and the adapter were taken off the gas line and 
connected to the freeze-drying tube with a pear-shaped flask. After N,N- 
dimethylbenzotriazol- 1-yl-methylamine 117.7 mg (0.67 mmole)-THF(fresh distilled) 
solution was added to the reaction flask, the contents were stirred at room tenperature 
for 2 1  hours.
The pear-shaped flask was cooled in liquid nitrogen, before the tap on the 
adapter was opened and methanol (0.5 ml) was added to quench the reaction. After 2  
hours Jfreeze-drying, HCl solution (0.5 ml, 4M) was added to the pear-shaped flask to 
convert the trimethylamine to its hydrochloride.
After the pear-shaped flask was warmed up, the diethyl ether, methanol, and 
THF solvents were removed using the freeze-drying apparatus, leaving the 
hydrochloride salt (43.7 mg). The product was analysed by ^H- and ^H-NMR 
spectroscopy.
5.2.6 Synthesis of Deuteriated 2-MethacryloyIoxy- 
ethyl-2’-trimethylammoniumethyI phosphate, 
Inner Salt (HEMA-PC)
After the small scale procedure for preparing HEMA-PC (developed at 
Biocompatibles Ltd) had been modified, the procedure could now be used for the 
synthesis of deuteriated HEMA-PC through the following reactions:
1 . Synthesis of lithium aluminium deuteride
n-BuLi + D2  LÎD + n-BuD
4LiD + AlBrg ^  LiAlD^ + 3LiBr
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2. Synthesis of deuteriated trimethylamine
0 :> DUAID4
^ % C H 3 2 ) 4  M eOH 
N I
C H ,
► 4
CHp CH3
+ 4I
C H ,
| |  + LiOM e + AI(OMe)g
3. Synthesis of deuteriated HEMA-PC
» • >c Et,N
(CH^,NCH,D A  / \+  /  M 'O —P—O /V CHgD-CH3
CH,
5.2.6.1 Synthesis of Lithium Aluminium Deuteride
To a 3-neck round-bottom flask (100 ml) connected to the deuterium gas line 
through an adapter containing a vacuum tap on it were added by means of syringes
diethyl ether (40 ml, anhydrous), n-BuLi (4.0 ml, 10 mmole), and N,N,n ',N- 
tetramethyl-ethylenediamine (TMEDA, 2.0 ml, 13 mmole). The whole gas line system 
was evacuated and flushed with helium three times. After the solution in the flask was 
degassed, deuterium gas (about 250 ml) was introduced into the gas hne and the flask. 
The solution in the flask was stirred for 5 hours (the solution turned white after 1 
hour). After disconnecting from the gas line with the vacuum tap, the flask (flask 1) 
was connected to a freeze-drying tube with another 3-neck round-bottom flask (flask 
2, 100 ml) on the other end. Flask 1 was cooled with liquid nitrogen and evacuated
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before AlBrg/dietbyl ether solution (10 ml) (0.69 g, 2.6 mmole in diethyl ether) was 
added to the solution (the solution turned a mdky colour) to form LiAID^.
5.2.6.2 Synthesis of Deuteriated Trimethylamine
1 . One hour after the AlBrg was added, N,N-dimethylbenzotriazol-1-yl- 
methylamine (1.59g, 9.0 mmole, in THF (5 ml)) was added to flask 1. The contents 
were stirred for 2 0  hours before the flask was connected to a freeze-drying tube with 
another 3-neck round-bottom flask (flask 2, 1 0 0  ml) at the other end. Acetonitrile ( 2 0  
ml, anhydrous) was transferred to flask 2, before the flask was kept at -20° C and 
evacuated. Flask 1 was cooled with liquid nitrogen and evacuated. Then flask 1 was 
warmed up to the room temperature, while flask 2 was still kept at -20°C.
2. Afrer the vacuum tap on the adapter was opened, methanol (1 ml, 25 mmole, 
anhydrous) was added to flask 1. The stirring in both flasks was continued for one 
hour to allow the acetonitrile in flask 2  to dissolve the deuteriated trimethylamine 
formed. Then 0.5 ml solution was taken out from flask 2 and added to a HCl solution 
(4M, 1 ml) to form the deuteriated trimethylamine hydrochloride (sample 01301095).
5.2.6.3 Preparation of HEMA-phospholane
1. A 3-neck round-bottom flask (250 ml) with a thermometer, a dropping 
funnel with a septum, and a septum connected to a syringe containing silica gel, was 
flushed with nitrogen. Then, the syringe containing silica gel was replaced by a 
nitrogen balloon.
2. Acetonitrile (20 ml, anhydrous) and 2-chloro-2-oxo- 1,3,2-dioxa- 
phospholane (16) (CCP, 9.3 g , 0.065 mole) were added to die dropping funnel. 
Acetonitrile (100 ml, anhydrous), 2-hydroxyethyl-methacrylate (15) (HEMA, 8 ,6  g 
,0.066 mole) and triethylamine (6 .8  g, 0.067 mole) were added to the 3-neck flask.
3. The CCP/acetonitrile solution in the dropping funnel was added dropwise to 
the 3-neck flask over the course of 30 minutes when the solution in the flask was kept
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at between -10°C to -15°C. Then the mixture in the flask was warmed up to 0°C over 
the course of one hour.
4. The dropping funnel was replaced with a septum and the 3-neck flask was 
connected to a specially designed filter funnel under the protection of nitrogen. The 
mixture in the flask was filtered imder the protection of nitrogen and the filtrate was 
collected to another 3-neck round-bottom flask (250 ml) with a septum, and a vacuum 
stopcock. Then, a closed condenser was connected to the flask.
5.2.6.4 Preparation of Deuteriated HEMA-PC
1 . Acetonitrile (30 ml, anhydrous) was transferred to a round-bottom flask (50 
ml), and the latter weighed. Trimethylamine (anhydrous) was bubbled into the 
acetonitrile for about 30 minutes, whilst the flask was kept below -10°C to allow 
trimethylarnine (3.6 g, 0.061 mole) to dissolve in the acetonitrile.
2. The cold deuteriated trimethylarnine/acetonitrile solution and 
trimethylamine/acetonitrile solution were then transferred to the 3-neck flask 
containing HEMA-phoq)holane/acetonitrile solution. The mixture in the flask was 
stirred at 50°C for 16 hours.
5.2.6.5 Crystallisation and Reci*ystallisation of Deuteriated 
HEMA-PC
1. The excess trimethylamine was removed under vacuum and the solution was 
concentrated to about 30 ml (over 1 hour). Then the solution was warmed to 75 °C 
before the solution was filtered through a pad of Celite under nitrogen. The filtrate was 
collected in a 2-neck round bottom flask (50 ml).
2 . Some "seed" (recrystallised HEMA-PC synthesised before, several mg) were 
added to the flask containing the filtrate whilst the flask was kept at 0°C. On standing 
(24 hours) the product crystallised.
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3. The HEMA-PC was filtered through a specially designed filter fimnel under 
nitrogen, washed successively with acetonitrile ( 1 0  ml, anhydrous) and ethyl acetate 
( 1 0  ml, anhydrous) and dried under vacuum at room temperature.
4. The crystallised HEMA-PC was transferred to a 2-neck round-bottom flask 
(50 ml) in a glove-box and 1 0  ml of acetonitrile was added to the flask.
5. The flask was heated at 70°C in a water bath until the solid dissolved. The 
flask was then kept at 0°C for 24 hour.
6 . The recrystallised HEMA-PC was filtered, washed with acetonitrile ( 1 0  ml, 
anhydrous) and ethyl acetate ( 1 0  ml, anhydrous) and dried under vacuum to give the 
recrystallised product (2.4 g) (sample No. 03301095). .
5.2.6.6 NMR Measurement
RecrystaUised HEMA-PC (03301095) (38 mg) was dissolved in 0.5 ml of D2 O
containing 0.75 % 3-(trimethylsilyl-sodium salt), and the solution was subjected to ^H- 
NMR analysis. RecrystaUised HEMA-PC (090895) (80 mg) was dissolved in 0.5 ml of 
H2 O, and analysed by ^H-NMR
5.2.6.7 TLC Measurement
About 2 0  mg of the recrystaUised HEMA-PC (090895) was dissolved in 0.5 ml 
of methanol and subjected to TLC analysis (reverse-phase plate, eluted with methanol). 
One plate was coloured with acid molybdate, and another with 1% aqueous potassium 
permanganate.
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5.2.7 Synthesis of Deuteriated Poly(2-
(methacryloyl-oxyethyI)-2’-(trimethyl- 
ammoniumethyl) phosphate, inner salt)-co-(n- 
dodecylmethacraylate(l:2) (PmMl2)
Having successfully prepared PmMl2  on a small scale, the corresponding 
deuteriated compound was prepared as follows:
n + 2nX :0 >=0O
I0 = p — O'
“fS ;
iÎMejCHjD ° \ v / \ NMe,CH,D
Pm Ml PmML
5.2.7.1 Copolymérisation of HEMA-PC and Lauryl 
Methacrylate
1. Deuteriated Pm (^H-HEMA-PC, 1.8160g) was transferred to a 3-neck 
round bottom flask with a stiiTer bar (in a dry-box).
2 . Anhydrous 2-propanol (33 ml) was transferred to a measuring column (50 
ml). Then the 2-propanol was transferred to the 3-neck flask to dissolve the 
deuteriated HEMA-PC.
3. Lauryl methacrylate (MÜ, about 6  ml) was purified by passing throu^ a 
column packed with aluminium oxide (about 1 g) to remove the inhibitor which was 
added to prevent polymerisation. The purified Ml was collected in a sample bottle from 
which 3.1337g was taken out and put in another sanple bottle.
4. Anhydrous ethyl acetate (13 ml) was transferred to a measuring cylinder and 
then transferred to a sample bottle.
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5. 2 ,2 '-Azo-bis(2 -methylpropioiiitrile) (0.2%x(WpjQ+W]vfl), 9.9 mg) was 
weighed into a sample bottle and dissolved in ethyl acetate (1  ml, taken from the 
sample bottle containing ethyl acetate). After the solution was added to the reaction 
flask, the bottle was linsed with ethyl acetate (1  ml) and the solution was added to the 
flask.
6 . Ml was dissolved in ethyl acetate (4 ml) before the solution was added to the 
3-neck flask. The bottle was rinsed with the remainder of the ethyl acetate solution and 
then added to the flask.
7. A thermometer, a double surface condenser, and a Quickflt stopcock were 
fitted to the reaction flask before the solution in the flask was degassed under vacuum
8 . The solution in the flask was stirred at 62°C for 42 hours.
5.2.7.2 First Precipitation
1. The solution in the reaction flask was cooled and filtered mto a pre-weighed 
round bottom flask (100 ml). The reaction flask was rinsed with 2-propanol (2x5 ml) 
and the solution was filtered into the round bottom flask.
2. The solution in the round bottom flask were removed using a rotary 
evaporator at 40°C until a solid foam formed (5.2865 g foam left m the flask).
3. A mixture of solvents was prepared according to the following ratio:
Solvent Total Monomer (Pm + Ml)/Solvent Volume Required
Dichloromethane 0.274 g/ml 18 ml
Methanol 3.287 g/ml 1.5 ml
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4. The polymer foam in the flask was dissolved using the solvent prepared 
above (15 ml). The solution was added to a dropping funnel ( 1 0 0  ml). The flask was 
rinsed with the reminder of the solvent and the solution was added to the dropping 
funnel.
5. Acetone (130 ml, 0.04 g monomer/ml) was added to a beaker (250 ml) with 
a large stirrer bar. The beaker was covered with a foil sheet before the polymer was 
precipitated by adding the polymer solution in the dropping funnel dropwise into the 
acetone.
6 . After the polymer had settled the solvent was decanted very carefully 
retaining the polymer. Then acetone (50 ml) was added to the beaker.
7. The mixture was stirred rapidly before the polymer settled. The acetone was 
decanted again.
8 . The polymer was isolated by filtration and washed thoroughly with acetone 
(50 ml).
9. After transferring to a re-weighed round bottom flask (50 ml) the polymer 
was dried under vacuum at room temperature, giving 3.994 g (81 %) of polymer.
S.2.7.3 Second Precipitation
1. A solvent mixtuie was prepared according to the following ratio:
Solvent Total Monomer (Pm + Ml)/Solvent Volume Required
Dichloromethane 0.346 g/ml 14.3 ml
Methanol 1.096 g/ml 4.5 ml
2. The dried polymer was dissolved using the solvent prepared above (15 ml). 
After the solution was transferred to a dropping funnel, the flask was rinsed with the 
remainder of the solvent and the solution was added to the fimnel.
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3. Steps 2.5 - 2.9 were repeated, leaving dried deuteriated PmMl2  (3.5062 g, 
71 % yield).
5.2.8 Synthesis of Tritiated PoIy(2-(methacryloyl- 
oxyethyI)-2’-(trimethyI-ammoniumethyl) 
phosphate, inner salt)-co-(n-dodecyI- 
methacrylate (1:2) (PmMl2)
The procedure was based on the following reactions:
1. Synthesis of lithium aluminium tritide
n-BuLi + T2 (H2>-> LiT(LiH) + n-BuT
4LiT(LiH) + AlBrs LiAlTHs 3LiBr
2 . Synthesis of tritiated trimethylamine
I
C H ,
1) LiAITH
.C H , 2} 4 MeOH
CHJ CH,
I
C H ,
3. Synthesis of tritiated HEMA-PC
+ LiOMe + Al(OMe),
A r - ° ^ o „ - > G01 o
2-chloro-2-oxo- 1,3,2- 
HEMA dioxaphospholane (CCP) HEMA-phospholane
N(CH3)2CH2T
. C H J
CH3
CM,
tritiated HEMA-PC
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4. Synthesis of tritiated PmMl^
2nn
0 = P — O’
' \ / \  +NMejCHJ
NM e,CH,T
5.2.8.1 Synthesis of Lithium Aluminium Tritide
The whole tritium gas line system including a 3-neck round bottom flask (flask 
1,100 ml) was evacuated and flushed with helium three times before diethyl ether (40
ml, anhydrous), n-BuLi (4.0 ml, 10 mmole), and N,N,N',N-tetramethyl- 
ethylenediamine (TMEDA, 2 .0  ml, 13 mmole) were added, using syringes. After the 
flask was cooled with liquid nitrogen, the solution was degassed three times before 
tritium (74 GBq, 2 Ci) and hydrogen gas (5.9 ml) were transferred to the reaction 
flask. After 24 houis reaction, most of the tritium gas should have been used up as the 
n-BuLi conypound was in large excess. The reaction continued under the hydrogen 
atmosphere for another 24 hours to ensure almost all the tritium gas could be used up 
and the reaction come to con^letion..
There should be no tritium gas left in the gas line before the reaction flask (1) 
was cooled with liquid nitrogen and the butane (including tritiated butane) formed 
should be frozen in the flask (if there was any butane in the gas line which has not 
dissolved in the ether). After 30 minutes taps C and D were closed, the reaction flask 
(flask 1) with the adapter was disconnected from the gas line and connected to a 
freeze-drying tube with a 3-neck round-bottom flask (flask 2, 100 ml) at the other end. 
The whole freeze-drying system was evacuated while flask 1 was cooled with liquid 
nitrogen. AIBr^ (0.69 g, 2.6 mmole) in diethyl ether (10 ml) was added to flask 1 to 
form lithium aluminium tritide.
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After one hour flask 2 was kept cold with Hquid nitrogen while flask 1 was at 
room tenyperature. After all the solvent and butane were transferred to flask 2 , the tap 
on the adapter was closed. Flask 2 was disconnected from the tube. Ethanol (50 ml) 
was added to flask 2  before the radioactivity of the solution was measured.
5.2.8.2 Synthesis of Tritiated Trimethylamine
N,N-dimethylbenzotriazol-l-yl-methylaniine (1.76 g, 10 mmole) was dissolved 
in diethyl ether (40 ml) before the solution was transferred to flask 1. The contents 
were stirred for 2 0  hours.
5.2.8.3 Preparation of Tritiated HEMA-PC
Acetonitrile (30 ml, anhydrous) was transfeiTed to a round-bottom flask (flask 
3, 50 ml), and weighed. Trimethylamine (anhydrous) was bubbled into the acetonitrile 
for about 30 minutes, whilst the flask was kept below -10°C to allow trimethylamine 
(3.6 g, 0.061 mole) to dissolve in the acetonitiile.
A 3-neck round-bottom flask (250 ml) with a theimometer, a dropping fimnel 
with a septum, and a septum connected to a syringe containing silica gel, was flushed 
with nitrogen. Then, the syringe containing silica gel was replaced by a nitrogen 
balloon.
Acetonitrile (20 ml, anhydrous) and 2-chloro-2-oxo-l,3,2-dioxaphospholane 
(CCP, 9.45 g, 0.066 mole) were added to the dropping fimnel. Acetonitrile (100 ml, 
anhydrous), 2-hydroxyethyl-methacrylate (HEMA, 8.49 g,0.065 mole) and 
triethylamine (6.96 g, 0.067 mole) were added to the 3-neck flask.
The CCP/acetonitrile solution in the dropping fimnel was added dropwise to 
the 3-neck flask over the course of 30 minutes when the solution in the flask was kept 
at between -10°C and -15°C. Then the mixture in the flask was warmed up to 0°C 
over the course of one hour.
The dropping fimnel was replaced with a septum and the mixture in the flask 
was filtered under the protection of nitrogen. The filtrate was collected in a 3-neck
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round bottom flask (flask 4, 250 ml). Then, the flask was connected to the jfreeze- 
drying tube with flask 1 at the other end. Both flask 1 and flask 4 were cooled with 
liquid nitrogen and evacuated. Flask 4 was cooled with hquid nitrogen while flask 1 
was kept at room temperature to transfer trimethylamine which was formed aider the 
mixture in flask 1 had been stirred for 20 hours and methanol (anhydrous, 1 ml, 25 
mmole) was added to flask 1 . Aider 30 minutes, all the solvent (diethyl ether) was 
transferred to flask 4 (all the trimethylamine including tritiatd trimethylamine should 
have been transferred to flask 4). Then the flreeze-drying tube was replaced by a 
closed-condenser. The trimethylarnine/acetonitrile solution in flask 3 was transferred to 
flask 4 before the solution was stirred at 50°C for 16 hours.
5.2.8.4 Concentration of Tritiated HEMA-PC-Acetonitrile 
Solution
The radioactivity of the reaction solution was measured. Only 29 mCi was 
found in the solution. The excess trimethylamine was removed tmder vacuum and the 
solution was concentrated to about 50 ml (over 1 hour) Unreacted trimethylamine 
including tritiated trimethylamine was collected in the acetonitrile (if there was any 
tritiated trimethylamine lefl: after reaction). A HCl solution (4 M, 20 ml) was added to 
the condenser to react with trimethylamine to form trimethylamine hydrochloride. 
Ethanol ( 2 0  ml) was added to the condenser to make a homogeneous solution. The 
total radioactivity in the condenser was 6.4 mCi. That means there was some tritiated 
trrmethylamine left after the reaction.
5.2.8.5 Crystallisation of HEMA-PC
After standing at 0°C for 26 days, HEMA-PC was filtered using a specially 
designed fimnel, under the protection of nitrogen gas, then washed with cold 
acetonitrile (anhydrous, 20 ml) and cold ethyl acetate (anhydrous, 20 ml). The product 
was dried under vacuum overnight to give crystallised HEMA-PC (3.276 g, 6.9 MBq, 
186.7 jiCi). The specific activity of HEMA-PC was 0.057 pCi/mg.
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After crystaJlisation of HEMA-PC there was about 10 mCi left in the mother
liquor.
S.2.8.6 Preparation of Tritiated Poly(2-(methacryloyloxyethyl)- 
2^-(trimethyl-ammoniumethyl)phosphate, inner salt)-co- 
(n-dodecylmethacrylate(l :2) (PmMl2)
5.2.8.6.1 Copolymerisation of HEMA-PC and Lauryl Methacrylate
After the solvents (acetonitrile and ethyl acetate) in the mother liquor in a flask 
containing tritiated HEMA-PC were removed by freeze-drying, 0.4 mCi radioactivity 
was found in the solvents and 13.1800 g was left in the flask. The appearance of the 
HEMA-PC was like that of a soft solid. Assuming that 20 % weight was from water 
absorbed by the HEMA-PC, it was calculated that there was 10.544 g of tritiated 
HEMA-PC in the flask.
1. Tritiated HEMA-PC (01290796, 10.544 g) was dissolved with 2-propanol 
(anhydrous, 188 ml) in a round bottom flask (100 ml). Then the solution was 
transferred to a 3-neck round bottom flask (250 ml).
2. Lauryl methacrylate (Ml, about 30 ml) was purified by passing throu^ a 
column packed with aluminium oxide (about 5 g) to remove the inhibitor which was 
added to prevent polymerisation. The purified Ml was collected in a sanq)le bottle from 
which 18.194 g was taken out and placed ia another sample bottle.
3. Ethyl acetate (anhydrous, 74.5 ml) was transferred to a sample bottle.
4. 2 ,2 '-Azo-bis(2 -methylpropionitrile) (0.2% x(Wu e MA-PC W]vfl), 57.5 mg)
was weighed out into a sanq)le bottle and dissolved in ethyl acetate ( 2  ml, taken from 
the sarqple bottle containing ethyl acetate). After the solution was added to the 
reaction flask, the bottle was rinsed with ethyl acetate (1  ml) and the solution was 
added to the flask.
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5 . A thermometer, a closed condenser, and a Quickflt stopcock were fitted to 
the 3 -neck bottom reaction flask before the solution in the flask was degassed under 
vacuum
6 . The solution in the flask was stirred at 62®C for 42 hours.
5.2.S.6.2 First Precipitation
1. The solution in the reaction flask was cooled and filtered into a pre-wei^ed 
round bottom flask (250 ml).
2 . The solvents in the round bottom flask were removed using a rotary 
evaporator until a solid foam formed. Then the foam was freeze-dried (24.8653 g foam
left in the flask). 10.3 mCi radioactivity was found in the solvents.
3. A mixture of solvents was prepared in the following ratio:
Solvent Total Monomer (HEMA-PC + Ml)/ Volume
Solvent Required
Dichloromethane 0.274 g/ml 104.9 ml
Methanol 3.287 g/ml 8.7 tol
4. The polymer foam in the flask was dissolved using the solvent prepared 
above (80 ml). The solution was added to a dropping funnel (250 ml). The flask was 
rinsed with the remainder of the solvent and the solution was added to the dropping 
fimnel.
5. Acetone (718 ml, 0.04 g monomer/ml) was added to a beaker (1000 ml) 
with a stirrer bar. The beaker was covered with a sheet of foil before the polymer was 
precipitated by adding the polymer solution in the dropping funnel dropwise whilst the 
acetone was being stirred.
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6 . After the polymer had settled the solvent was decanted off very carefully, 
retaining the polymer. Acetone (50 ml) was added to the beaker.
7. The mixture was stirred rapidly before the polymer settled. The acetone was 
decanted off
8 . The polymer was isolated by filtration and washed thoroughly with acetone 
(50 ml).
9. After transferring to a re-weighed round bottom flask ( 1 0 0  ml) the polymer 
was fteeze-dried, leaving the dried polymer (230996,14.4272 g). The specific activity 
of the polymer, PmMl2 (230996) was 0.063 pCi/mg.
5.2.S.6.3 Second Precipitation
1. A solvent mixture was prepared in the following ratio:
Solvent Total Monomer (HEMA-PC+ Ml)/Solvent Volume Required
Dichloromethane 0.346 g/ml 83.0 ml
Methanol 1.096 g/ml 26.2 ml
2. The dried polymer was dissolved with the solvent prepared above (90 ml). 
After the solution was transferred to a dropping funnel, the flask was rinsed with the 
remainder of the solvent and the solution was added to the funnel.
3. Steps 5 - 9 in the first precipitation were repeated and eventually gave dried 
tritiated PmMl2  (260996, 7.6109g, 479 pCi, the specific activity of PmMl2 (260996)
was 0.063 pCi/mg).
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5.2.S.7 Radio-TLC Analysis of HEMA-PC Mother Liquor, 
Crystallised HEMA-PC and PmMla
After the plates loaded with the mother liquor, crystallised HEMA-PC and 
PmMl2 respectively were developed with methanol, analysed by radio-TLC (Automatic 
TXC-Linear Analyzer, Berthold LB2842, Laboratory Lnpex Limited).
The plates loaded with the mother liquor, crystallised HEMA-PC and PrnMl] 
were developed with methanol and sprayed with 1 % potassium permanganate and 
acid molybdate respectively.
5.2.9 Preliminary Investigations of Deuteriation of
HEMA-PC and PmMl  ^by the Microwave- 
assisted Method
The overall yield of the procedure used for preparing tritiated recrystallised 
HEMA-PC was very low. Consequently, the overall yield for the procedures used for 
preparing tritiated PmMlz was very low as well. If microwave-assisted exchange 
method could give higher yield it would be very helpful.
The aim of this work is to try to find out: 1. Whether HEMA-PC or PmMl2 can 
be labelled by the microwave-assisted method? 2. If the answer to question 1 is yes, 
which position can be labelled? 3. Can HEMA-PC or PmMl2 be labelled at the N- 
methyl part of the head group?
5.2.9.1 Stability of HEMA-PC under Microwave Irradiation
To a test tube (35 ml) were added HEMA-PC (104 mg) and D2O (1 ml). The 
tube was cooled with liquid nitrogen and evacuated before it was inserted in a 
microwave oven for 15 minutes at low power level. Later the solution in the tube was 
analysed by ^H-NMR spectroscopy.
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5.2.9.2 Reduction of Pt02
To a beaker (100 ml) with a stirrer bar, were added Pt0 2  (203 mg, 0.92 
mmole), and H2O (50 ml). NaBHLj (403 mg, 10.6 mmole) was added slowly to the 
beaker while the mixture was stirred. Then, the mixture was heated to 70 °C for 10 
minutes. Finally, the platinum metal formed was filtered and washed with H2O (50 ml) 
before being dried in an oven.
5.2.9.3 Deuteriation of HEMA-PC
To a test tube, were added HEMA-PC, platiuum metal, deuteriated solvent, 
and CH3OH as in Table 5. 5,
Table 5. 5 Reaction conditions for HEMA-PC
Sample
No.
HEMA-PC
(mg)
Pt
(mg)
D2O
(ml)
CD3OD
(ml)
CH3OH
(ml)
Reaction time 
in microwave 
(min)
01230596 2 0 1 42 0 .2 0 0 .8 5
02230596 198 63 0 0 .2 0 .8 5
03230596 217 42 0 0 0 5
01240596 1 0 1 2 1 0 .2 0 0 .8 5 + 10
02240596 99 32 0 0 .2 0 .8 5 + 10
03240596 109 2 1 0 1 .0 0 5 + 10
03300596 129 47 0 0 .2 0 .8 24 hours 
(at 100 °C, not in 
microwave)
04300596 93 52
(PtOi)
0 .2 0 0 .8 5
01070696 6 6 .6 54.5 0.05 0 0.95 5
02070696 178.2 45.3 0.05 0 0.95 5
The tube was cooled with liquid nitrogen and evacuated before the tube was 
irradiated in a microwave at low energy level for 5 minutes.
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After half of the contents were removed from the tube, the same amount of 
solvent was added to the tube. The tube was cooled with liquid nitrogen and evacuated 
before the tube was irradiated in the microwave for 1 0  minutes.
5.2.9.4 Isolation of Samples
The mixture in the test tube was jBltered with a ‘'pipette fimnel” filled with 
cotton wool (when D2O was used as isotope source, anhydrous sodium sulphate was 
placed above the cotton wool). The tube was washed with methanol (0.5 ml) before 
the funnel was waAed with the methanol solution. Then the filtrates were combined in 
a small round bottom flask and the solvent was evaporated by passing nitrogen gas 
over its surface. The funnel was wadied with methanol (0.5 ml) again and the methanol 
was evaporated by passing nitrogen gas, leaving the sample in the flask.
5.2.9.5 Deuteriation of PmMla
To a test tube were added HEMA-PC, platinum metal, deuteriated solvent and 
CH3OH as in Table 5. 6 .
Table 5. 6  Reaction conditions of PmMlz
sample No. PmMlz
(mg)
Pt
(mg)
D2O
(ml)
CD3OD
(ml)
CH3OH
(ml)
reaction time 
in microwave (min)
01300596 81 48 0 0 .2 0 .8 5
02300596 80 58 0 .2 0 0 .8 5
The tube was cooled with liquid nitrogen and evacuated before being irradiated 
in a microwave at low energy level for 5 minutes.
After reaction, the sample was isolated using the method described above.
S.2.9.6 Analysis of Samples
Samples were analysed by ^H-NMR spectroscopy using CH3OH as solvent and 
^H-NMR spectroscopy using CD3OD as solvent, respectively.
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5.3 Results and Discussions
5.3.1 Reduction of Polymer PmiMlgMly
After tritiation of the PmaMlsMly polymer, the product was analysed by H- 
and NMR spectroscopy. The spectra are given in Fig. 5. 11 and Fig. 5. 12, 
re^ectively.
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ppm
Fig. 5.11 H-NMR Spectrum of Tritiated PmzMlsMly
9 8 7
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ppm
Fig. 5.12 H-NMR ( H Decoupled ) Spectrum of Tritiated PmzMlsMly
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The chemical shifts of the hydrogen atoms of Pm2Ml3Mly (Fig. 5. 13) are listed 
in Table 5, 7.
o —p = o
Fig. 5.13 Structure of PmgMlsMly
Table 5, 7 Chemical Shifts of the Hydrogen Atoms in Pm^MlgMly
Proton number Proton type Chemical shift (ppm)
1 Terminal methyl protons 0 .8 - 1 .1
2 Methylene protons 1 .2 - 1 .8
3 Methylene protons (a-alkyne) 2 .1
4 Trimethylammonium protons 3.3
5 Methylene protons 3.5 - 4.4
If the precursor had been fully reduced, there should not be a peak appearing at 
about 5.4 ppm in the ^H-NMR spectrum. If the triple bonds had just been reduced to 
double bonds, then there should not be a peak showing at 1.28 ppm in the ^H-NMR 
spectrum (Fig. 5. 1 2 ). The NMR spectra indicate that the product obtained after
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tritiation was a mixture of partially and fully reduced products. Fortunately the sample 
was ideal for solid ^H-NMR spectroscopy studies, as the two peaks in the ^H-NMR 
spectrum are reasonably weU separated, with about the same radioactivities.
In order to obtain the fully reduced polymer, PmMlz, needed by Biocompatibles 
Ltd for the coating stability studies, the product obtained after tritiation needed to be 
hydrogenated. After hydrogenation, the product (24.9 mg, 1003 MBq) was analysed 
by ^H-NMR q>ectroscopy. There is no longer a peak at 5.4 ppm in the 
spectrum (Fig. 5. 15), only one peak appears at 1.3 ppm This indicates that the double 
bond was fiiUy hydrogenated. In other words, fully reduced tritiated polymer 
PmMlz was obtained. The specific activity of the polymer was 41 MBq/mg (1.1 
mCi/mg).
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Fig. 5.14 *H-NMR Spectrum of ^ H-PmMl,
ppm
Fig. 5.15 ^H-NMR ( H Decoupled ) Spectrum of ^ H-PmMlz
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5.3.2 Synthesis of Deuteriated Dimethylaniline
Dimethylamline was used as a model confound for trimethylamine. If 
deuteriated dimethylaniline could be obtained properly, the procedure could then be 
adopted for the preparation of labelled trimethylamine. Fig. 5. 16 and Fig. 5. 17 give 
the and ^H-NMR spectra of deuteriated dimethylaniline respectively. The spectra 
show that (^H-N-methyi)-N,N-dimethylaniline was synthesised successhdly. So, the 
procedure could be adapted for the synthesis of deuteriated trimethylamine.
224
ppm
Fig. 5.16 Spectrum of Dimethylaniline
ppm
Fig. 5.17 H-NMR ( H Decoupled ) Spectrum of H- Dimethylaniline
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5.3.3 Synthesis of N,N-Dimethylbenzofriazol-l-yl-
methylamine
There is an “impniity" peak at 1.76 ppm in the ^H-NMR spectrum of the 
crystalhsed N, N-dimethylbenzotriazol-l-yl-methylamine (Fig. 5. 18), which is not 
present in the ^H-NMR spectrum of the recrystalHsed product (Fig. 5. 19).
It is a common situation that N, N-disubstituted aminomethylbenzotriazole 
derivatives exist in solution as an equilibrium mixture of the corresponding 1-(N, N- 
disubstituted aminomethyl)- and 2-(N, N-disubstituted aminomethyl)-benzotriazoles^^’^^ .
The following equation represents the equilibrium between the 1- and 
2-isomers when N, N-dimethylbenzotriazol- 1-yl-methylamine is dissolved in a solvent.
1-isomer 2-isomer
Equation 5.1
The peak at 5.4 ppm for -N-CüG-N- in the ^H-NMR ^ectrum comes from the 1- 
isomer, and that at 5.5 ppm from 2-isomer. Similarly, the peak for -N(Ci7s)2 at 2.41 
ppm belongs to the 1-isomer, and that at 2.47 ppm to the 2-isomer.
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ppm
Fig. 5.18 H-NMR Spectrum of Crystallised N, N-Dimethylbenzotriazol-l-yl- 
methylamine
ppm
Fig. 5.19 H-NMR Spectrum of Recrystallised N, N-Dimethylbenzotriazol-1-
yl-methylamine
227
5,3.4 Synthesis of Deuteriated Trimethylamine
The synlhesis and subsequent transfer of dried labelled triniethylaimne is a key 
step in the synthesis of the desired labelled biocompatible polymer. After deuteriated 
dimethylaniline was obtained, the procedure was adapted to prepare deuteriated 
trimethylamine.
There are two peaks in the ^H-NMR spectrum of deuteriated trimethylamine 
hydrochloride (Fig. 5. 20), one at 2.88 ppm, belonging to the deuteriated product and 
another at 4.78 ppm, coming from the water in the D2O solvent. There is only one 
peak in the spectrum (Fig. 5. 21) of the product.
The results demonstrate that pure deuteriated trimethylamine hydrochloride 
was obtained. That is to say that trimethylaraine was successfrdly synthesised and 
transferred to the pear-shaped flask.
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Fig. 5, 20 H-NMR Spectrum of ^ H-Trimethylamine Hydrochloride
Fig. 5.21 H-NMR (*H Decoupled ) Spectrum of ^ H-Trimethylamine 
Hydrochloride
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5.3,5 Synthesis of Deuteriated HEMA-PC
It was necessary to know whether deuteriated trhnethylamine had been 
synthesised and dissolved in acetonitrüe before the solution was transferred to a flask 
to react with HEMA-phospholane to form HEMA-PC.
The presence of deuteriated trimethylamine in the acetonitrile solution was 
confirmed by the results presented in Fig. 5. 22, the ^H-NMR spectrum of deuteriated 
trimethylamine hydrochloride formed after hydrochloric acid solution (1 ml, 4M) was 
added to 0.5 ml solution of deuteriated trimethylamine/acetonitrile.
Fig. 5. 23 is the ^H-NMR spectrum of HEMA-phospholane, an intermediate 
compound.
Fig. 5. 24 and Fig. 5. 25 were obtained after the recrystaUised deuteriated 
HEMA-PC was analysed by ^H- and ^H-NMR spectroscopy, respectively.
The assignment of the peaks in the H-NMR spectrum of HEMA-PC Fig. 5. 
24) is given in Table 5. 8 .
Table 5 .8  Assignment of peaks in the H NMR spectrum of HEMA-PC 
(Fig. 5. 24)
Proton type 
Chemical 
shift (ppm)
-CHs
1.9
-N(CHs)3
3.2
-CH 2 -
3.6
-CH 2N
4.1
Proton type POCH2 COOCH2 H/C=C
C=C.
H
Chemical 
shift (ppm)
4.3 4.4 5.7 6.2
The NMR spectra show that pure N-methyl deuteriated HEMA-PC was 
obtained using the procedures described.
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Fig. 5, 22 H-NMR ( H Decoupled ) Spectrum of ^ H-Trimethylamine 
Hydrochloride
PUl
ppm
Fig. 5. 23 H NMR Spectrum of HEMA-Fhospholane
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Fig. 5.24 H-NMR Spectrum of Recrystallised H-HEMA-PC
ppm
Fig. 5.25 H-NMR ( H Decoupled ) Spectrum of Recrystallised H-HEMA-
PC
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5.3.6 Synthesis of Deuteriated PmMla
After the procedure for the preparation of unlabelled PtnMl2 had been modified 
to a small scale, the procedure was used to prepare deuteriated PmMlz. The and 
^H-NMR spectra of the deuteriated product are given in Fig. 5. 26 and Fig. 5. 27.
The ^H-NMR spectroscopy assignment of the product is given in 
Table 5. 7. It is obvious that the peaks coming fi:om the olefin hydrogens atoms of the 
methacryloyl group at 5.7 ppm and 6.2 ppm in the H-NMR spectrum of deuteriated 
HEMA-PC Fig. 5. 24) disappear in the ^H-NMR spectrum of deuteriated PmMl2 
(Fig. 5. 26). There is a peak at 3.25 ppm in the ^H-NMR of deuteriated PmMlz 
(Fig. 5. 27), belonging to the - NCH2D(CHs)2 group. All these results indicate that 
deuteriated PmMl2 polymer was satisfactorily synthesised usmg these procedures.
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Fig. 5. 26 ’H-NMR Spectrum of ’H-PmMlj
ppm
Fig. 5, 27 H-KMR ( H Decoupled ) Spectrum of H-PmMlz
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5.3.7 Synthesis of Tritiated PmMli
Fig. 5. 28 and Fig. 5. 29 are the spectra of tritiated HEMA-PC and tritiated 
PmMl2 polymer respectively. Fig. 5. 30 is the result obtained after radio-TLC analysis 
of tritiated PmMli.
After the second precipitation, the specific activity (0.063 pCi/mg) of tritiated 
PmMli was consistent with that obtained after first precipitation of the polymer. These 
results tell us that chemically and radiochemically pure tritiated polymer, PmMl] was 
obtained, but at a very low specific activity. There were several reasons which made 
the specific activity of the tritiated PmMl2 polymer so low.
1. Tritium gas was used at a very early stage of the procedure. From then on, 
there were several steps necessary prior to obtaining the final tritiated product. Each 
stage decreased the specific activity of the product.
2. Lithium tritide and lithium aluminium tritide are moisture-sensitive reagents. 
Water in the solvents and on the surfaces of the glass apparatus decomposes these 
reagents. Althou^ a cautious approach was enq>loyed, for example, using firesh 
anhydrous solvents and reagents, drying the glass apparatus in an oven above 140 °C 
overnight before using, etc., it is impossible to completely keep moisture away from 
the solvents and the glass apparatus.
3. Tritiated trimethylamine has a very low boihng point (about 2.6 °C). It is a 
gas at room temperature. The absorption efficiency by acetonitrile and the efficiency of 
transfer of the trimethylamine/acetonitrile solution were unknown at the conditions 
employed.
4. High specific activity was not necessary for tritiated PmMl2 polymer and 
it was known that in order to get PmMl2 polymer it was essential to use 
recrystallised HEMA-PC. The total yield fi*om trimethylamine to recrystallised HEMA- 
PC was very low (about 6- 10% for both HEMA-PC and deuteriated HEMA-PC).
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Fig. 5. 28 H-NMR Spectrum of Crystallised ^H-HEMA-PC
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ppm
Fig. 5, 29 H-NMR Spectrum of ^ H-PmMlz
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Fig. 5. 30 Radio-TLC Spectrum of ^ H-PmMla
In addition, about 2 grams of reciystabised HEMA-PC was needed to carry out 
the polymerisation procedure and obtain the PmMl2 polymer. So, the tritium gas was 
diluted with hydrogen at the very early beginning and the tritiated trimethylamine was 
diluted with non-labeUed trimethylamine.
5. It was found that after concentration of the HEMA-PC/acetonitrile solution, 
there were 22.6 mCi left in the solution. Supposing all the activity in the solution came 
from tritiated HEMA-PC, the specific activity of the HEMA-PC should be
the activity in the concemtrated solution
W hEMA. + W cCP +  Wtnmdhylisminc +  W hQ
22.6 mCi
9.45g + 8.49g + 3.6g - 0.065*36.5g
= 1.18 mCi= 1.18 pCi/mg
The specific activity of the crystallised HEMA-PC was 0.057 pCi/mg, only 5% of the 
specific activity calculated above. In fact, the specific activity of HEMA-PC diould not 
change after crystallisation. This means that most of the activity in the concentrated 
solution was not firom tritiated HEMA-PC.
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5.3.8 Preliminary Investigations of Deuteriation of 
HEMA-PC and PmMh by Microwave-Assisted 
Method
Fig. 5. 31 - Fig. 5. 46 give the and spectra of the deuteriated
HEMA-PC samples obtained usmg different conditions. The deuteriation results are 
summarised in Table 5. 9.
Table 5. 9 Peak Assignments in the Spectra of Deuteriated HEMA-PC
Sample No. Fig. No. Peak positions (ppm)
01230596 Fig. 5. 32 1.93 (-CHs in HEMA-PC), 3.35 (methanol, solvent), 
4.90 (water), 5.7 and 6.1 (double bond, very small)
02230596 Fig. 5. 34 1.97 (-CHs m HEMA-PC), 3.35 (methanol, solvent), 
4.94 (water)
03230596 Fig. 5. 36 1.94 (-CHs in HEMA-PC), 3.35 (methanol, solvent),
4.94 (water), 5.7 and 6.1 (double bond, small)
01240596 Fig, 5. 38 1.93 (-CHs in HEMA-PC), 3.35 (methanol, solvent), 
4.90 (water), 5.7 and 6.1 (double bond, very small)
02240596 Fig. 5. 40 1.97 (-CHs in HEMA-PC), 3.35 (methanol, solvent), 
4.94 (water), 4.68 (unknown)
03240596 Fig. 5. 42 1.94 (-CHs in HEMA-PC), 3.35 (methanol, solvent),
4.94 (water), 5.7 and 6.1 (double bond, small), 4.68 
(unknown)
03300596 Fig. 5. 44 1.97 (-CHs in HEMA-PC), 3.35 (methanol, solvent), 
4.95 (water), 4.67 (unknown)
04300596 Fig. 5. 46 1.93 (-CHs in HEMA-PC), 3.35 (methanol, solvent)
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Fig. 5. 31 H -m m  Spectrum of ^ H-HEMA-PC (Sample 01230596)
ppm
Fig. 5.32 H-NMR ( H Decoupled ) Spectrum of H-HEMA-PC (Sample 
01230596)
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ppm
Fig. 5. 33 ^H-NMR Spectrum of ^ H-HEMA-PC (Sample 02230596)
ppm
Fig. 5.34 H-NMR ( H Decoupled ) Spectrum of ^ H-HEMA-PC (Sample 
02230596)
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Fig. 5.35 ‘H-NMR Spectrum of ^ H-HEMA-PC (Sample 03230596)
ppm
Fig, 5,36 H-ISMR ( H Decoupled ) Spectrum of H-HEMA-PC (Sample 
03230596)
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Fig. 5. 37 ‘H-NMR Spectrum of ^ H-HEMA-PC (Sample 01240596)
1 ppm
Fig. 5.38 H-NMR ( H Decoupled ) Spectrum of H-HEMA-PC (Sample 
01240596)
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Fig. 5. 39 H-NMR Spectrum of H-HEMA PC (Sample 02240596)
9 8' 7 ' ' "”'~6 ' ' ' ' é ppm
Fig. 5.40 H-NMR ( H Decoupled ) Spectrum of H-HEMA-PC (Sample 
02240596)
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Fig. S. 41 *H-NMR Spectrum of ^ H-HEMA-PC (Sample 03240596)
ppm
Mg. 5. 42 H-NMR ( H Decoupled ) Spectrum of H-HEMA-PC (Sample 
03240596)
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Fig. 5. 43 ^H-NMR Spectrum of ^ -HEM A-PC (Sample 03300596)
ppm
Fig. 5. 44 H-NMR ( H Decoupled ) Spectrum of H-HEMA-PC (Sample 
03300596)
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Fig. 5. 45 H-NMR Spectrum of H-HEMA-PC (Sample 04300596)
ppm
Fig. 5. 46 H-NMR ( H Decoupled ) Spectrum of H-HEMA-PC (Sample 
04300596)
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Table 5. 9 shows that HEMA-PC was labelled at the methyl group
/CHjD O-
" '3
CH,
'CH.
and that the labelling was nearly regiospecific. The percentage incorporation was 
probably lower than 10 % and is only a best estimate as the value could not be 
obtained by the comparison of the ratio of the integration values of the peaks.
When the irr adiation time was increased there was little difference in the degree 
of incorporation (see Fig. 5. 32 and Fig. 5. 38, Fig. 5. 34 and Fig. 5. 40, Fig. 5. 36 
and Fig. 5. 42).
It is known that when Pt02 was used as catalyst rather than Pt, the percentage 
incorporation was lower. HEMA-PC was also deuteiiated at the same position by the 
thermal exchange method using Pt as catalyst.
The ^H-ISIMR spectra of the samples Aow that HEMA-PC did not polymerise 
or decon]pose noticeably under the conditions enoployed.
Fig. 5. 47 - Fig. 5. 50 are the ^H- and ^H-NMR spectra of the HEMA-PC 
samples obtained usmg only very small amount of D2O (50 pi) as isotope source. Table 
5. 10 summarises the deuteriation results.
Table 5.10 Peak Assignments in the Spectr a of Deuteriated HEMA-PC
sample No. Fig. No. peak positions (ppm)
01070696 Fig. 5. 48 1.93 (-CH3 in HEMA-PC), 3.35 (methanol, solvent), 4.69 
(water), 5.68 and 6.14 (double bond, very small)
02070696 Fig. 5. 50 1.93 (-CH3 in HEMA-PC), 3.35 (methanol, solvent), 4.93 
(water)
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Table 5. 10 shows that the HEMA-PC was labelled at the methyl group when 
the amount of D2O was reduced. The relative peak area at 1.93 ppm in the ^H-NMR 
spectra of the sainples (Fig. 5. 48 and Fig. 5. 50) is larger as the amount of D2O used 
was reduced (the sanples analysed with with the same number of scans).
Unlike HEMA-PC, PmMlz was not labelled by the microwave-assisted method.
In summary, HEMA-PC can be nearly specifically deuteriated, nearly 
specifically, at the methyl group when the amount of D2O is very small. If PmMl2 
needs to be tritiated at the methyl position, the microwave-assisted method can be used 
to obtain tritiated HEMA-PC, which can then be polymerised to form tritiated PmMl2.
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Fig. 5. 47 ^H-NMR Spectrum of H-HEMA PC (Sample 01070696)
3 2  1 ppm
Fig. 5. 48 H NMR (^H-Decoupled) Spectrum of H HEMA-PC (Sample 
01070696)
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ppm
Fig. 5. 49 H-NMR Spectrum of H-HEMA-PC (Sample 02070696)
ppm
Fig. 5.50 H-NMR (^H-Decoupled) Spectrum of H-HEMA-PC (Sample 
02070696)
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6.1 Introdnction
Méthylation of organic compounds with reagents such as methyl iodide is a 
convenient method for preparing and labelled products. The
méthylation reaction usually proceeds rapidly and quantitatively. In theory it can 
provide a product containing three deuterium atoms and there are many examples in 
the literature where this has been achieved. It is often very desirable to have 
compounds containing three tritium atoms - compounds of very h i^  specific activity 
are necessary for e.g. radio-immunoassays and receptor binding studies \  There are 
important differences in the preparation of deuteriated and tritiated methylating agents, 
the latter (because of the high levels of radioactivity involved) being much more 
demanding.
Methyl iodide is the most frequently used methylating agent but because of its 
low boding point (43 °C) and high volatility it is difficult to handle in small quantities. 
A potentially more usefiil reagent is methyl tiifhioromethanesulphonate or methyl 
triflate in short. It is less volatde (boiling point 94 °C) and more reactive than methyl 
iodide  ^ and easier to handle. Consequently it may become a more widely used 
methylating agent but before it becomes established there is a need to obtain more 
quantitative i,e. kinetic, data.
Although not widely used in this aspect, an NMR spectrometer can be used to 
measure changes in concentration as a fimction of time. Althou^ the technique can be 
used to measure very fast reactions when it comes to taking spectra as a function of 
time, the limiting factor is the time it takes to record a spectrum. This is of the order of 
1 -2 minutes, thereby limiting it to reactions with half-lives of this order. The need for 
relatively high concentrations is now less as NMR spectrometers of high magnetic field 
e.g. 600 MHz are now avadable. Provided the important signals do not overlap the 
NMR method is a powerful one as it may be possible to identify the intermediates 
formed during the reaction. Furthermore no cahbration procedures are required
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For the general reaction:
A + B - > P  + Q
we have -dA/dt = k[A][B] Equation 6 . 1
and [Ao] - [A] =  [Bo]- [B] Equation 6.2
where [Ao] is the concentration of A  at t = 0, and [A] the concentration at time t; [Bo] the 
concentration of B at t = 0 , and [B] the concentration at time t.
Equation 6 . 1 and Equation 6.2 lead to Equation 6 . 3 and Equation 6 . 4:
 ^ ha = kt Equation 6 . 3[Bo] - [Ao] [Bo] [A]
or
[Bo] - [Ao] [Bo]  ^ (1 - x)
where x is the extent of reactant conversion. So, if the left hand side of Equation 6 . 4 is 
plotted against time, a straight Ime should be obtained, the slope of the line being equal to 
the rate constant, k.
The N-methylation of 4-(p-nitrobenzyl)pyridine was chosen as a model reaction for 
the kinetic methodology studies.
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6.2 Experimental
6.2.1 Méthylation of 4-(p-Nitrobenzyl)pyridine Using 
Methyl Triflate as Methylating Reagent
4-(p-Nitrobenzyl)pyridine (4-PNBP, 54 mg, 0.25 mmole) was dissolved in acetone 
(1 ml) in a small round bottom flask. Then, methyl triflate ( C C I 4 -  C F 3 S O 3 C H 3  solution 
0.5 ml, 0.25 mmole C F 3 S O 3 C H 3 )  was added to the flask. The solution was stirred at
room temperature for two hours. The product was purified by thin layer chromatography 
method (developing solvents ethanol : CCI4  : petroleum ether = 1 : 1 : 2 )  and analysed
using ^H-NMR spectroscopy.
6.2.2 H-NMR Kinetic Study of the N-Methylation of 
4-(p-Nltrobenzyl)pyridine Using Methyl Triflate 
as Methylating Reagent at Low Temperature
The rate of N-methylation of 4-PNBP at room temperature using methyl triflate as 
methylating reagent was too rapid to be monitored using H-NMR spectroscopy when 
CDCI3 was used as solvent. So, the reaction was carried out at a lower temperature.
The temperature of the NMR spectrometer was calibrated with 4% methanol/d4- 
methanol standard sample before the reaction.
To an NMR tube was added 4-PNBP (0.0019 mmole), methyl triflate (0.0024 
mmole) and CDCI3 (0.5 ml). The concentrations of the reagents at the start of the reaction 
were 0.0038M and 0.0048M, respectively. The reaction was followed at 283.2K, 278.2K, 
273.2K, 268.2K, and 263.2K, respectively, by monitoring the change in the ratio of the 
integration of the doublet peak at 8.76 ppm (belonging to the product of the reaction.
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metliyl-4-iiitrobenzylpyridiniumcation) to that of the doublet peak at 8.57 ppm (belonging to 4- 
PNBP).
Let
p = the integration of the doublet peak at 8.76 ppm, 
a = the integration of the doublet peak at 8.57 ppm, 
then the conversion
X  =
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6.3.1
6.3 Results and Discussions
Méthylation of 4-(p-NitrobenzyI)pyridine Using 
Methyl Triflate as Methylating Reagent
Fig. 6 . 1 and Fig. 6 . 2 give the spectra of 4-(p-nitrobenzyl)pyridine and
purified product respectively. It can be seen that the methylated product, 
îthyl-4-niti'obenzylpyridinlumcationhas been obtained successfully. In other words the following 
méthylation reaction has taken place
NO,
CHz
NO,
acetone
N  +
CH,
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Fig. 6 .1  H-NMR Spectrum of 4-(p-Nitrobenzyl)pyridme
ppm
Fig. 6 .2  H-NMR Spectrum of N-Methyl-4-nitrobenzylpyridiniumcation
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6.3.2 H-NMR Kinetic Study of the N-Methylation of 4-(p-Nitrobenzyl)pyridine Using Methyl Triflate 
as Methylating Reagent at Low Temperature
Fig. 6 . 3 was obtained by plotting the extent of reactant conversion(x) versus 
reaction time wben the N-methylation reaction of 4-PNBP was carried out at 283.2K Fig.
6 . 4 was obtained by plotting F(x) versus reaction time, where
F(x) = 10.0048 - 0.0038
^  (0.0048 -  0.0038) + 0.0038 x (1 -  x) 
0.0048 x(l-jc)
A strai^t line can be drawn through the points, with slope = 0.277 
r = 0.997. The rate constant, k is equal to the slope of the line. Hence,
k = 0.277 M" Is-1
Using the same method, Table 6 . 1 was obtained from the results shown in 
Fig. 6 . 3 - Fig. 6 . 12.
Table 6 .1  Rate Constants (k) at Different Temperatures
Reaction temperature °K k(M's") r
283.2 0.277 ±0.003 0.997
278.2 0.177± 0.004 0.990
273.2 0.143± 0.002 0.992
268.2 0.099± 0.001 0.995
263.2 0.071+ 0.001 0.997
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Fig. 6.11 Conversion(x) versus Reaction Time, at 263.2K
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The Arrhenius equation k = A can be used to obtain the activation energy
for the N-methylation reaction of 4-PNBP.
Fig. 6 . 13 was obtained by plotting ln(k) versus 1/T.
c -2 -
- 2.2  -
-2.4 --
- 2.6  -
- 2.8
3.75 3.8 3.853.653.6 3.73,5 3.55
1/T*1000
Fig. 6.13 Relationship between Reaction Rate, k, and Temperature, T
A strai^t line can be obtained through these points, with slope = - 4914.54, r
0.995, hence
- E/R = the slope = - 4914.54
The activation energy E = 4914.54 x 1.987 x 4.18 = 40818,5 J/mole = 40.82
kJ/mole.
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6.4 Further W ork
6.4.1 Synthesis of Isotopically Labelled Methyl
Triflate
Possible routes aie suggested below:
1. Reaction of methanol with trifluoromethanesulphonic anhydride  ^‘
CH3 OH + (CF3S02)20 CF3 SO3 CH3 + CF3 SO3H
Procedure: Trifluoromethanesulphonic anhydride and anhydrous methanol 
are kept at room tenqierature for 15 minutes. The more volatile products are 
transferred to an apparatus for manipulation of volatile compounds and distilled in 
vacuum, to give methyl trifluoromethanesulphonate.
2. Reaction of trifluoromethanesulphonic acid with dimethyl sulphate
CF3SO3H +2( CH3)2S04 2CF3SO3CH3 + H2SO4
Procedure: Trifluoromethanesulphonic acid is added to dimethyl sulphate 
followed by ef&cient stirring at 0°C for 30 minutes, then at room temperature for 
two hours, before distillation under nitrogen to give methyl 
trifluoromethanesulphonate.
3. Reaction of silver trifluoromethanesulphonate with methyl iodide
CF3 S0 3 Ag + CH3 I ^  CF3 SO3 CH3  + Agi
Procedure: Methyl iodide is added with stirring to silver 
trifluoromethanesulphonate dissolved in carbon tetrachloride or benzene, at room 
ten^erature. Precipitation of silver iodide occurred immediately and the reaction is
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complete after two hours. The volatile products are distilled in vacuum from the silver 
iodide produced, then redistilled to give methyl trifluoromethanesulphonate.
6.4.2 Conclusion
This preliminary study has ^own that ^H-NMR spectroscopy can be an extremely 
useful method for measuring the kinetics of méthylation reactions and that it can also be 
used to follow the rates of deuteriation/tritiation of selected substrates. Ways in which 
deuteiiated/tritiated methyl triflate can be prepared have also been suggested.
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